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Osteoarthritis (OA) is a degenerative joint disease and is the most prevalent joint disorder with 
increasing impact worldwide, currently affecting approximately 300 million people globally [1, 
2]. Several risk factors for OA have been identified, including ageing, obesity, gender, genetic 
predisposition and joint trauma [3]. However, OA pathophysiology is multifactorial and its 
etiology remains unknown. Due to the expected rise in life expectancy and body weight in 
western countries, the incidence of OA is predicted to keep rising in coming years putting a large 
strain on health care and costs [1, 3]. OA can affect any joint, but is mostly observed in the knee, 
hands, hip and spine, causing symptoms such as severe pain, stiffness and loss of joint function 
[4, 5]. It is already regarded as one of the ten most disabling diseases in developed countries 
and symptoms are often accompanied with severe functional impairment [6]. Unfortunately, 
current treatment options do not modify disease outcome, and are mainly focused on life-style 
adjustments, pain relief, or joint-replacement surgery at end-stage of the disease [1, 7]. 
The main pathophysiological hallmarks of OA are considered to be the degeneration of articular 
cartilage, sclerosis of subchondral bone, inflammation and fibrosis in the synovial membrane 
and formation of bone-like structures (osteophytes) at joint margins [8]. All these changes 
contribute to disease progression, and for this reason OA is currently viewed as a disease of 
the whole joint. However, degeneration of articular cartilage is still considered to be the most 
important characteristic of OA. Articular cartilage has very poor intrinsic repair capacity, leading 
to progressive and irreversible cartilage degeneration after injury. It is therefore crucial to target 
cartilage damage in early stages to prevent further progression. In recent years it has been 
increasingly recognized that synovial inflammation actively contributes to cartilage degeneration 
and OA progression. Approximately 50% of the OA patients show signs of synovial inflammation 
and this significantly correlates with cartilage damage and pain [9-14]. Although the actual cause 
of synovitis in OA is unknown, cells in the synovium can be triggered by endogenous danger 
signals derived from damaged tissue, such as cartilage matrix fragments or alarmins [15-18]. In 
response, the OA synovium produces several inflammatory mediators, such as pro-inflammatory 
cytokines, alarmins and chemokines, which directly contribute to the initiation and progression of 
articular cartilage degeneration [9, 19, 20]. The interaction between local cartilage damage and 
the synovium leads to a state of low-grade, chronic joint inflammation, and ultimately results in 
disease progression and clinical OA development [21, 22]. An improved understanding of how 
inflammation contributes to the onset and progression of cartilage damage in OA could therefore 
enable the development of future targeted therapies. 
CHAPTER 1
12
CHANGES IN ARTICULAR CARTILAGE
Articular cartilage is a highly specialized connective tissue which facilitates joint function by 
providing a smooth, lubricated surface and reducing the frictional coefficient [23]. The unique 
structural organization of the cartilage matrix is crucial for its biomechanical properties. 
Chondrocytes are responsible for maintenance of the extracellular matrix (ECM), which contains 
a complex network of collagen type II and proteoglycans such as aggrecan [24, 25]. Collagen 
type II proteins provide structure and strength to articular cartilage, while water-attracting 
proteoglycans serve as lubricants that help withstand high compressive forces. To maintain a 
healthy cartilage ECM, chondrocytes regulate essential anabolic processes like the production 
of ECM components and the ECM-cross linking enzymes that strengthen the matrix structure 
[23, 26]. On the other hand, they also control catabolic processes, such as the production of 
matrix degrading enzymes, which mediate healthy remodeling of the cartilage matrix. 
However, during OA, the delicate balance between anabolic and catabolic processes shifts 
towards catabolism, resulting in breakdown of the cartilage matrix (schematic overview 
in Fig. 1). Increased production and activation of cartilage degrading enzymes like matrix 
metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motifs 
(ADAMTSs) have been recognized as a key event in the initiation and progression of cartilage 
degeneration in OA [27-29]. Of the MMP and ADAMTS families, especially MMP-3, MMP-9 and 
MMP-13 have been implicated in collagen degradation, and ADAMTS-4, ADAMTS-5, MMP-3 and 
MMP-13 in aggrecan breakdown [30, 31]. Remarkably, also anabolic activities of chondrocytes 
are increased in the initial phase of OA, indicated by chondrocyte proliferation clusters and 
increased proteoglycan production [27, 29, 32]. However, this is not sufficient to restore the 
ECM balance, and could be regarded as an inadequate attempt to maintain cartilage integrity 
[29]. Moreover, at this stage chondrocyte clusters are observed and chondrocytes differentiate 
towards a hypertrophic-like state which resembles the phenotype of growth plate chondrocytes. 
Hypertrophic chondrocytes are characterized by expression of hypertrophic markers such as 
MMP-13 and Collagen type X, and contribute to matrix instability and degeneration [33, 34]. 
Altogether, this shows that chondrocyte homeostasis is severely disturbed in OA and may lie at 
the root of OA-related cartilage degeneration.
Although many factors control chondrocyte function, two groups of signaling molecules are 
recognized as key regulators of important anabolic and catabolic processes. First, growth 
factors have been identified as important regulators of several essential chondrocyte functions 
like metabolism, differentiation, proliferation, and ECM production and degradation [35, 36]. The 
transforming growth factor-β (TGF-β) family is an especially important group of growth factors 
in cartilage, as it controls chondrocyte homeostasis on all these levels and has important anti-
inflammatory and anti-hypertrophic properties [37, 38]. Secondly, pro-inflammatory cytokines 
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have been identified as important regulators of mainly catabolic processes in cartilage. For 
example, they stimulate chondrocytes to produce and activate matrix degrading enzymes or 
inhibit synthesis of ECM molecules thereby contributing to cartilage degeneration [39-47]. 
The pro-inflammatory cytokine interleukin-6 (IL-6) is highly increased in OA synovial fluid and 
directly modulates chondrocyte function e.g. via induction of matrix-degrading enzymes [42, 48]. 
However, the role of IL-6 in cartilage and OA development has not received much attention so far. 
It is evident that TGF-β and IL-6 both play important roles in regulating cartilage homeostasis and 
degeneration, but a link between these two factors in cartilage remains to be identified. In this 
thesis, we focus on interactions between the protective growth factor TGF-β and the detrimental 
cytokine IL-6 in chondrocytes. Therefore, we first elaborate on the role of TGF-β signaling in 
cartilage homeostasis, and thereafter discuss the contribution of IL-6 to the development of 
cartilage degeneration and OA.  
 
Figure 1. Cartilage degeneration in osteoarthritis. Schematic overview of healthy cartilage and synovium 
(left). Anabolic mediators, such as TGF-β, maintain cartilage homeostasis by repressing hypertrophic 
differentiation and regulating matrix synthesis. On the right, osteoarthritic cartilage and synovium is depicted 
which shows the main pathological changes of the disease. The balance between anabolic and catabolic 
processes shifts towards catabolic breakdown of the cartilage matrix by degenerative mediators such as 
MMPs. The synovial membrane is activated and releases pro-inflammatory cytokines and matrix degrading 
enzymes. Moreover, altered TGF-β signaling results in hypertrophic differentiation of articular chondrocytes. 
TGF-β: transforming growth factor-β, MMPs: matrix metalloproteinases. 


































TGF-β SIGNALING IN HEALTHY AND AGEING CARTILAGE 
The growth factor TGF-β is essential for the formation and maintenance of healthy articular 
cartilage [49, 50]. It has a central role in cartilage homeostasis, and disruption of TGF-β 
signaling has been implicated in OA development. TGF-β signaling induces receptor-mediated 
phosphorylation of intracellular mediators called Smad proteins, which translocate to the 
nucleus and activate target gene expression [51]. TGF-β has the ability to induce two intracellular 
signaling pathways leading to Smad2/3 or Smad1/5/9 activation. Which pathway is activated 
is determined by TGF-β concentration, TGF-β receptor expression, and the expression of co-
receptors [52, 53]. Lower concentrations of TGF-β mainly activate Smad2/3 signaling, while 
activation of Smad/1/5/9 signaling is increased at higher concentrations [54, 55]. Moreover, 
activation of the TGF-β type I receptor ALK5 stimulates Smad2/3 signaling in cartilage, while 
activation of ALK1 promotes the Smad1/5/9 signaling route [55, 56]. On a functional level, both 
pathways have profoundly different effects and even have been shown to antagonize each 
other [53, 57]. Signaling via the Smad2/3 route protects cartilage against the development of 
chondrocyte hypertrophy and blocks the production of catabolic enzymes [37, 52]. Indeed, 
mice with loss of Smad3 function develop degenerative OA-like joint disease, with progressive 
cartilage damage, osteophyte formation and increased expression of collagen type X [58]. In 
contrast, signaling via the Smad1/5/9 route promotes chondrocyte hypertrophic differentiation, 
and is associated with MMP-13 expression [53, 59, 60]. Besides its role in regulating chondrocyte 
hypertrophy, TGF-β controls matrix maintenance and production. On one hand, TGF-β regulates 
the synthesis of matrix components like proteoglycans and collagen type II [61-63]. On the 
other hand TGF-β blocks the expression of catabolic mediators, for instance by inducing 
metalloproteinase inhibitor expression thereby preventing matrix degeneration [64, 65]. TGF-β 
also has an important anti-inflammatory function in cartilage, as it can actively block the effects 
of pro-inflammatory cytokines [52]. However, during ageing or osteoarthritis TGF-β signaling is 
altered which contributes to disrupted cartilage homeostasis. 
Ageing is strongly associated with OA development, and changes in ageing articular cartilage 
have been extensively investigated [66]. Ageing affects TGF-β signaling in multiple ways, which 
has been postulated to be a potential cause for age-related OA development. Our lab has 
previously shown that TGF-β signaling via Smad3 is decreased in murine and bovine cartilage with 
age, which was associated with increased cartilage degeneration and reduced repair capacity 
[67-70]. Moreover, expression of TGF-β itself, as well as chondrocyte responsiveness towards 
TGF-β decreases markedly with age [68, 71]. Possibly, this reduction in TGF-β/Smad3 signaling 
is caused by age-related changes in TGF-β receptor expression. Our lab has demonstrated that 
ALK5 expression decreases in ageing bovine cartilage [68], and that there is a shift towards ALK1 
signaling in ageing mice which correlates with OA development [53]. Also in OA, TGF-β signaling 
in cartilage is altered in several ways [38, 72]. First, levels of active TGF-β are increased in OA 
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due to inflammation, cartilage degradation and high levels of proteases [38, 73, 74]. Secondly, 
TGF-β signaling shifts from protective p-Smad2/3 signaling towards detrimental p-Smad1/5/9 
signaling in chondrocytes [53, 72]. This can potentially be explained by the higher TGF-β levels 
and/or by increased expression of ALK1 versus ALK5 in OA cartilage [53]. Finally, the increased 
presence of inflammatory cytokines in OA contributes to altered TGF-β signaling via inhibition of 
protective Smad2/3 signaling [75, 76]. A better understanding of why TGF-β signaling is altered 
in ageing or osteoarthritic cartilage, e.g. by investigating the interplay between inflammation 
and TGF-β signaling in chondrocytes, will help to separate protective and detrimental effects of 
TGF-β. This will ultimately lead to the development of therapeutic approaches that halt or prevent 
cartilage damage in OA. 
INTERLEUKIN-6 IN OA 
The cytokine IL-6 is a multifunctional cytokine with broad-ranging effects in tissue homeostasis 
and defense by regulating central processes like hematopoiesis and the acute phase response 
[77]. Increased expression of IL-6 has been implicated in the pathophysiology of several 
diseases, such as rheumatoid arthritis and Castleman’s disease [77, 78], and might also 
play a role in OA. The IL-6 signaling pathway is activated by binding of IL-6 to the membrane-
bound IL-6 receptor (IL-6R). Hereafter, the IL-6/IL-6R forms a complex with the signal transducer 
glycoprotein 130 (gp130), which results in activation of the Janus kinases/signal transducers 
and activators of transcription (JAK/STAT) pathway [79, 80]. The regulatory protein suppressor 
of cytokine signaling 3 (SOCS3) has been identified as a primary inhibitor of the IL-6 pathway, 
and is essential to control the duration and biological response of IL-6 signaling [81, 82]. SOCS3 
restricts IL-6 signaling by binding to gp130 and inhibiting JAK-kinase activity. The IL-6R itself has 
no signal transduction capacity and is differentially expressed in various tissues. Chondrocytes 
generally have low IL-6R expression [83, 84], while IL-6R expression is high in certain cell types 
like monocytes, hepatocytes, and particular leukocyte subsets [85]. Chondrocyte sensitivity to 
IL-6 may be enhanced during OA, due to changes in mIL-6R expression levels by hormones 
cytokines and epigenetic factors [85]. In contrast to the IL-6R, gp130 is ubiquitously expressed 
throughout the body [85, 86]. Interestingly, a soluble variant of IL-6R (sIL-6R) exists, which 
forms a complex with IL-6 and can then bind to any gp130-expressing cell. This process is 
termed trans signaling and greatly broadens the scope of IL-6 responsiveness [87, 88]. sIL-6R 
is produced by shedding of membrane-bound IL-6R receptor or alternative splicing [89, 90]. 
Signaling via membrane-anchored IL-6R (mIL-6R) is termed classic signaling and has been 
linked to homeostatic processes (schematic overview in Fig. 2). In contrast, IL-6 trans-signaling 
mainly regulates pro-inflammatory events and is implicated in numerous chronic diseases and 
























Figure 2. A schematic overview of the IL-6 signaling routes. Classic IL-6 signaling involves cells 
expressing both membrane (m)IL-6R and gp130; free IL-6 binds to mIL-6R, forming a complex with gp130. 
IL-6 trans-signaling is activated by pre-formed complexes of IL-6 and soluble IL-6R (IL-6/sIL-6R) and requires 
only gp130 expression on target cells. After IL-6 binds to the IL-6R, complex formation with gp130 initiates 
phosphorylation of JAKs resulting in activation of STAT3-, PI3K- and Ras-Raf-MEK-ERK signaling. gp130: 
glycoprotein 130; IL-6: interleukin-6; IL-6R: IL-6 receptor. JAK: janus kinase; MAPK: mitogen-activated protein 
kinase; PI3K: phosphoinositide 3-kinase.
 
Levels of IL-6 and sIL-6R are increased in serum and synovial fluid of OA patients compared 
to healthy individuals [91, 92], and circulating IL-6 levels have been associated with OA 
development [93, 94]. Moreover, there are several indications that IL-6 directly contributes to 
cartilage degradation in OA [42, 48, 95]. IL-6 enhances the expression of MMP-3 and -13 in 
bovine chondrocytes, as well as the expression of ADAMTS-4 and -5 [48]. Moreover, intra-articular 
injection of IL-6 in murine knee joints results in cartilage damage and increased production of 
MMP-3 and -13 [42]. In line with this, therapeutically blocking IL-6 or its downstream mediator 
STAT3 during experimental OA rescues cartilage damage and osteophyte formation [95]. 
However, also protective effects of IL-6 have been described such as modest stimulation of 
proteoglycan synthesis and induction of tissue inhibitors of metalloproteinases [96-98]. These 
discrepancies may be explained by functional differences in IL-6 classic versus trans signaling 
routes as will be explained in chapter five of this thesis. Altogether, this shows that IL-6 has 
detrimental effects in cartilage and contributes to cartilage degeneration in OA. 
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INTERPLAY BETWEEN INFLAMMATION AND TGF-β SIGNALING IN 
CARTILAGE
As mentioned, TGF-β has important anti-inflammatory effects in cartilage. Especially interactions 
between TGF-β signaling and the pro-inflammatory cytokines IL-1β and TNF-α have been studied 
[99-101]. Our lab has previously shown that TGF-β potently counteracts 38% of the genes 
regulated by pro-inflammatory cytokine IL-1β in chondrocytes [99]. We also showed that intra-
articular injection of TGF-β in mice resulted in protection against IL-1β-induced proteoglycan 
degeneration [101]. Moreover, it has been reported that TGF-β can protect cartilage against 
TNF-α-induced collagen breakdown in bovine articular cartilage [100]. How this works is not fully 
elucidated yet, but several mechanisms have been suggested. For example, TGF-β decreases 
IL-1 receptor (IL-1R1) expression in rabbit chondrocytes thereby limiting IL-1β signaling [102, 
103]. Moreover, TGF-β can activate expression of IL-1 receptor antagonist (IL-1RA) in monocytes, 
leading to inhibition of IL-1β signaling [104]. Additionally, competition between NF-κβ, the 
intracellular mediator of IL-1β signaling pathway, and SMAD3 for co-transcription factors has 
been described as a possible mechanism in endothelial cells [105]. This anti-inflammatory 
function of TGF-β is lost upon ageing, demonstrated by a reduced ability of TGF-β to counteract 
IL-1β-mediated inhibition of proteoglycan synthesis and IL-1β-induced nitric oxide production 
[70].
Vice versa, inflammation itself can also affect TGF-β signaling. For example, IL-1β decreases 
TGF-β receptor II expression on both mRNA and protein level in human articular chondrocytes 
resulting in inhibition of TGF-β-induced gene expression [75]. Reduction of TGF-β receptor II 
expression was also observed in mechanically compressed bovine cartilage after stimulated 
with conditioned medium obtained from in vitro cultured OA human synovial biopsies [106]. 
Moreover, both IL-1β and TNF-α have been shown to disturb TGF-β signaling in chondrocytes by 
modulating activation of the intracellular mediators Smad2/3, which prevented TGF-β-mediated 
collagen type II and aggrecan expression [76]. This can possibly be explained by IL-1β-mediated 
induction of inhibitory Smad7, which ultimately decreases Smad2/3 activation levels and TGF-β 
downstream gene expression [107]. However, both TNF-α and IL-1β have been described to 
reduce SMAD3/4 DNA-binding activity in human OA chondrocytes, independent of SMAD7 [76].
CROSSTALK BETWEEN THE TGF-β AND IL-6 SIGNALING PATHWAYS
Remarkably, interactions between TGF-β and IL-6 signaling have not been studied so far 
in cartilage. In other tissues, several mechanisms of interaction between the TGF-β and IL-6 
signaling pathway have been reported [108-111], however, it differs per cell type whether TGF-β 
and IL-6 show synergistic or antagonistic effects. In T-cells, for example, TGF-β synergizes with 
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IL-6 by promoting the degradation of FOXP3 to modulate the activity of regulatory T-cells [109]. 
Furthermore, IL-6 and TGF-β synergize to stimulate Th17 differentiation via several mechanisms 
[112]. The combination of TGF-β and IL-6 stimulates the expression of transcription factors 
RORγt and RORα which mediate differentiation of the Th17 cell lineage [113, 114]. Moreover, 
TGF-β  suppresses expression of SOCS3 in T-cells,  resulting in enhanced STAT3 activation 
which is required for Th17 differentiation [110]. In contrast, in intestinal epithelial cells TGF-β 
was shown to suppress IL-6 signaling via Smad2-mediated inhibition of STAT1 and STAT3 
phosphorylation which may be protective in the context of inflammatory bowel disease [108]. Also 
in macrophages, antagonism between the IL-6 pathway and TGF-β pathway has been described 
[115]. Here it was shown that the increased SOCS3 expression in macrophages antagonizes 
TGF-β signaling via direct inhibition of Smad3 [115]. Also during joint inflammation, SOCS3 is 
highly expressed in both the synovium and articular cartilage [116]. As TGF-β signaling is crucial 
for cartilage homeostasis, increased SOCS3 expression in articular cartilage expression may 
lead to disturbed TGF-β signaling as observed in OA.  However, interactions between SOCS3 
and TGF-β signaling have not yet been investigated in articular cartilage. Crosstalk between 
SOCS3 as negative regulator of the IL-6 signaling pathway, and TGF-β signaling has been 
reported in several other studies. Loss of SOCS3 in T-helper cells results in hyperproduction of 
TGF-β [117], and loss of SOCS3 in the liver promotes fibrosis by enhancing TGF-β production 
[118]. Besides cell type, possibly also the (patho)physiological context determines the outcome 
of TGF-β and IL-6 crosstalk, such as during tumorigenesis. Signaling molecules Smad3 and 
STAT3 can engage in direct physical interaction [119-122], which has antagonistic effects during 
the early phase of tumorigenesis but synergistic effects during late-phase progression [123]. 
Altogether, these studies indicate potential crosstalk between the TGF-β and IL-6 signaling 
pathway, which is not yet explored in chondrocytes. Because of the detrimental role of IL-6 in 
cartilage degeneration [42, 48, 95] and the protective role of TGF-β [37, 52, 69] in cartilage 
homeostasis, potential interplay between these pathways may have important implications for 
cartilage homeostasis and OA development. 
AIM AND OUTLINE OF THIS THESIS
In this thesis, we investigated the interplay between components of the IL-6 and TGF-β signaling 
pathway in articular cartilage and explored implications thereof in ageing and OA. In the first two 
chapters (chapter 2 and 3) we studied two potential mechanisms of interplay between the IL-6 
and TGF-β signaling pathway, as illustrated in Figure 3. In the chapters thereafter (chapter 4 and 
5), we explore the implications of our findings in the context of ageing and OA. 
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Figure 3: Schematic representation of potential interplay (indicated in red) between the TGF-β and IL-6 signaling 
pathways as studied in chapter 2 and 3 of this thesis
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Figure 3. Schematic representation of potential interplay (indicated in red) between the TGF-β and IL-6 
signaling pathways as studied in chapter 2 and 3 of this thesis.
First, in chapter two we investigated whether SOCS3, as important regulator of the IL-6 signaling 
pathway, interferes with protective TGF-β/Smad3 signaling in articular cartilage. To investigate 
this, we studied the effect of adenoviral overexpression of SOCS3 on different components of 
the TGF-β signaling pathway in human articular chondrocytes. To reach high expression levels, a 
human chondrocyte cell line (G6 chondrocytes) was used for adenoviral studies. We investigated 
the effect of SOCS3 on TGF-β receptor expression, as well as functional TGF-β signaling such 
as TGF-β-induced transcriptional activity, p-Smad activation, and activation of target gene 
expression. As OA-related inflammation can strongly impair TGF-β-dependent cartilage repair, 
we additionally investigated whether SOCS3 interferes with TGF-β-mediated cartilage formation. 
To study cartilage formation, we used bone-marrow derived MSCs transduced with a SOCS3 
adenovirus cultured in a three-dimensional pellet culture model. Cartilage formation was 
determined in the pellets by histological analysis and quantification of proteoglycan content. 
Based on our findings, we discuss whether therapeutic targeting of SOCS3 in inflammatory OA 
could help prevent disrupted TGF-β signaling in chondrocytes or help improve TGF-β-dependent 
cartilage repair processes.
Regulation of IL-6 signaling by TGF-β has been reported in various cell types [108-111]. 
However, it remains unknown if TGF-β also modulates IL-6 signaling in cartilage, which could 
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be important to control detrimental IL-6 effects. Therefore, we investigated in chapter three 
whether TGF-β regulates IL-6 signaling in articular chondrocytes. To be able to study different 
IL-6 signaling pathway components in a standardized manner a human chondrocyte cell line 
(G6 chondrocytes) was used. In addition, main findings were verified in freshly isolated primary 
human OA chondrocytes. We first determined if TGF-β regulates IL-6 expression itself and thereby 
affects autocrine IL-6 signaling via p-STAT3. This was studied in the human G6 chondrocyte cell 
line, and validated in freshly isolated primary human OA chondrocytes. To investigate if TGF-β 
also regulates exogenous IL-6 signaling, we performed co-stimulation experiments with TGF-β 
and recombinant IL-6. Subsequently, we analyzed IL-6-mediated induction of p-STAT3 and target 
gene expression with and without the presence of TGF-β. To identify potential mechanisms via 
which TGF-β may regulate IL-6 signaling in chondrocytes, we determined the effect of TGF-β 
on IL-6R expression in both G6 and primary chondrocytes. Interestingly, we uncovered that 
TGF-β regulates IL-6R expression in chondrocytes, which is an entirely new concept and has 
not been reported until now. Via this unique mechanism TGF-β can regulate IL-6 signaling in 
cartilage, which could be crucial to restrict pro-inflammatory IL-6 effects and preserve cartilage 
homeostasis. 
After we established that TGF-β regulates IL-6 signaling in cartilage, we hypothesized that 
ageing might affect this regulation due to the altered TGF-β signaling that our lab previously 
found in ageing cartilage [53, 67, 68, 101]. Therefore, in chapter four, we investigated if TGF-
β-mediated regulation of IL-6R was indeed lost in aged cartilage, and whether this subsequently 
results in increased IL-6 signaling. To study this, we used cartilage obtained from bovine 
metacarpophalangeal (MCP) joints, which can easily be obtained from cows of a wide age-
range. Macroscopic selection of healthy bovine cartilage allows for the separation of ageing and 
OA which is difficult in murine or human cartilage where OA is often concomitant [68]. As many 
changes develop in the cartilage extracellular matrix with advancing age we used freshly isolated 
cartilage explants, and not isolated chondrocytes, in this study [124]. As hypothesized, we 
identified considerable age-related changes in IL-6R expression in flash-frozen bovine articular 
cartilage. Therefore, we studied whether the response to IL-6 stimulation was different in young 
versus aged cartilage by analyzing activation of p-STAT3 and OA-related degenerative markers. 
Finally, we explored whether TGF-β-mediated regulation of IL-6R expression and signaling was 
lost in bovine cartilage with advancing age. As IL-6 has a detrimental role in cartilage, loss of 
TGF-β-mediated dampening of IL-6 signaling with advancing age might be important in age-
related OA development.
In chapter three and four we established an important role of TGF-β in restricting IL-6 signaling 
in articular cartilage, which might be lost during ageing or inflammation. This pointed to IL-6 as a 
potential therapeutic target in OA. Although IL-6 is present in high levels in OA patients and has 
a pivotal role in OA development, it has not been a primary target of interest so far. In chapter 
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five we review current evidence regarding the role of IL-6 in OA pathophysiology, and discuss 
potential therapeutic approaches to target the IL-6 signaling pathway in OA. We provide a novel 
point of view by focusing on the unique ability of IL-6 to signal via a classic- and trans-signaling 
route. Based on this interesting standpoint, we discuss the opposing effects of these signaling 
routes in local joint tissues as well as experimental OA mouse models. Moreover, we evaluate 
currently available IL-6 targeted therapies and discuss whether a better focus on these different 
IL-6 signaling routes might lead to better therapeutic strategies for future OA treatment.  
In chapter six, we summarized and discussed the results as described in this thesis, and 
elaborate on potential implications for cartilage degeneration and OA treatment. 
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Inflammation in osteoarthritis (OA) contributes to disrupted cartilage homeostasis, for instance 
by dysregulating protective TGF-β signaling. Previously, it was shown that the cytokine-inducible 
protein suppressor of cytokine signaling 3 (SOCS3) inhibits TGF-β signaling in macrophages. 
Here, we investigated if inflammation-induced SOCS3 is able to disturb TGF-β signaling in 
articular chondrocytes and/or TGF-β-mediated cartilage formation and thereby could contribute 
to damage in OA.
 
Design
The impact of OA-related inflammation (IL-1β, IL-6 or OA synovium-conditioned medium) on 
TGF-β transcriptional activity and SOCS3 gene and protein expression was determined in 
articular chondrocyte cell lines (G6, H4). Moreover, increased SOCS3 levels were achieved using 
adenoviral overexpression in human G6- and bovine chondrocytes, whereafter TGF-β signaling 
was analyzed by measuring Smad3 transcriptional activity, C-terminal Smad-phosphorylation, 
and Smad3-dependent gene expression. The effect of SOCS3 on cartilage formation was 
studied using lentiviral overexpression during a three-dimensional MSC-based culture model to 
mimic chondrogenesis.
Results
In articular chondrocytes, OA-related inflammatory mediators inhibited TGF-β transcriptional 
activity, and simultaneously increased SOCS3 expression. However, adenoviral overexpression 
of SOCS3 itself did not alter TGF-β transcriptional activity, C-terminal activation, nor nuclear 
translocation of p-Smad3 in articular chondrocytes. Moreover, relative activation of protective 
ALK5-Smad2/3 versus deleterious ALK1-Smad1/5/9 signaling was not altered by SOCS3 
overexpression either. In line with this, increased SOCS3 levels did not affect activation of 
TGF-β responsive genes like SERPINE1 and SMAD7. Interestingly, overexpression of SOCS3 did 
strongly impair TGF-β-dependent MSC-based cartilage formation, resulting in reduced pellet 
sizes and sGAG content.
Conclusions
In contrast to earlier findings in macrophages, our results show that SOCS3 does not alter 
TGF-β signaling in articular chondrocytes on the level of receptor expression, p-Smad activation 
or TGF-β transcriptional activity. Strikingly, SOCS3 did strongly impair MSC-based cartilage 
formation, suggesting that inflammation-induced SOCS3 might impair cartilage repair in OA. 
However, given our findings in chondrocytes, this effect is most likely independent of SOCS3 
directly affecting TGF-β signaling. 




Progressive degeneration of articular cartilage is the main characteristic of osteoarthritis (OA). 
Although cartilage degeneration was considered as a simple wear and tear process in the past, 
nowadays it is known that the whole joint is involved and that inflammation significantly contributes 
to OA pathogenesis [125, 126]. Inflammation of the synovial membrane is observed in ~50% of 
OA patients and several studies showed a positive correlation between synovial inflammation 
and cartilage damage [9, 10]. The activated synovium releases inflammatory mediators such 
as interleukin(IL)-1β, tumor necrosis factor-α (TNF-α) and IL-6, which stimulate the production 
of cartilage matrix degrading enzymes [127, 128]. Increased production of cartilage degrading 
enzymes results in degeneration of essential cartilage matrix molecules like aggrecan and 
collagen type II, leading to structural cartilage loss. As cartilage has very limited intrinsic repair 
capacity, current research focuses on techniques to prevent cartilage degeneration at an early 
stage or to repair degenerated cartilage tissue. 
Unfortunately, the inflammatory micro-environment in OA is a major disturbing factor for cartilage 
homeostasis and repair. Inflammatory mediators in the OA joint dysregulate chondrocyte 
homeostasis and aggravate cartilage degeneration e.g. via activation of cartilage degrading 
enzymes [129]. In addition, OA-related inflammation can impair cartilage repair processes, such 
as MSC-based repair strategies currently applied in the clinic [130-133]. We previously showed 
that inflammatory mediators secreted by OA synovium strongly inhibit cartilage formation by 
human mesenchymal stem cells (MSCs) [134, 135]. Moreover, synovial fluid obtained from 
knee trauma patients inhibited in vitro chondrogenic redifferentiation of human chondrocytes 
[136, 137], and synovial fluid of OA and RA patients impaired chondrogenic differentiation of 
human subchondral progenitor cells [138]. However, the exact mechanism of how OA-related 
inflammation disrupts cartilage maintenance and repair is unclear. 
A potential mechanism how inflammation disturbs cartilage homeostasis is via inhibition 
of transforming growth factor-β (TGF-β) signaling. TGF-β is an essential factor for cartilage 
homeostasis, and has multiple functions in cartilage [139]. In chondrocytes, TGF-β can signal via 
two different receptors, namely activin-like kinase (ALK)5 and ALK1, which results in activation of 
different intracellular signaling routes [53, 140]. Signaling via ALK5 leads to Smad2/3 recruitment 
and phosphorylation and mediates protective processes. Lack of intracellular TGF-β signaling 
via Smad3 results in chondrocyte hypertrophy and progressive, OA-like cartilage degeneration 
[58, 141]. In contrast, signaling via ALK1 results in phosphorylation of the Smad1/5/9 complex. 
The latter has been associated with deleterious processes such as the development of 
chondrocyte hypertrophy [37]. We previously showed that increased ALK1/ALK5 receptor ratio 
was associated with ageing and OA cartilage [53], suggesting that a tight balance between these 
signaling pathways is essential for healthy cartilage. Importantly, TGF-β stimulates production of 
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essential cartilage extracellular matrix (ECM) molecules like collagen type II and proteoglycans 
both in vitro and in vivo [61-63]. Intra-articular injection of TGF-β into murine knee joints, for 
example, significantly increases proteoglycan synthesis in articular cartilage [61]. Moreover, 
TGF-β potently stimulates chondrogenic differentiation of human MSCs, thereby promoting the 
formation of new cartilage [142, 143]. Together, this shows that TGF-β signaling is crucial for 
cartilage maintenance as well as cartilage formation.
In OA, TGF-β signaling is disturbed which contributes to the development of cartilage degeneration 
[37, 38]. This is possibly caused by the increased presence of inflammatory cytokines, such as 
IL-1β and IL-6, which can dysregulate TGF-β signaling in articular chondrocytes [75, 76, 106]. 
For example, IL-1β decreases TGF-β receptor II expression in articular chondrocytes resulting 
in inhibition of TGF-β-induced gene expression [75]. In addition, IL-1β has been reported to 
inhibit Smad2/3 signaling in chondrocytes via increasing expression of inhibitory Smad7 [75]. 
Moreover, IL-6 has been reported to inhibit TGF-β signaling in intestinal epithelial cells [108]. 
These inflammatory mediators activate distinct intracellular signaling routes, like the Nuclear 
Factor kappa-light-chain-enhancer of activated B cells (NF-κβ) or Janus kinase (JAK)/ signal 
transducer and activator of transcription (STAT) signaling pathways [80, 144], and may affect 
TGF-β signaling via different mechanisms. However, one common factor is rapidly induced upon 
the presence of various pro-inflammatory cytokines, which is the regulatory protein suppressor 
of cytokine signaling 3 (SOCS3) [145, 146]. SOCS3 is a negative regulator of cytokine signaling, 
thereby usually preventing, but in some cases aggravating disease [147]. SOCS3 generally 
functions as a negative regulator of the JAK/STAT signaling pathway, by binding to the activated 
cytokine receptor or directly inhibiting JAK kinase activity, both resulting in restriction of STAT3 
activation [147]. Moreover, SOCS3 can inhibit inflammatory IL-1β signaling by preventing TRAF-6 
ubiquitination, thereby limiting activation of TAK1 [148]. 
Indeed, during joint inflammation, SOCS3 is highly expressed in both synovium and cartilage 
[116]. We previously showed that SOCS3 expression is increased in OA chondrocytes and 
correlates with the expression of multiple matrix-degrading enzymes [149]. However, what causes 
this correlation is unclear. Interestingly, there are indications that SOCS3 can alter the TGF-β 
signaling pathway. Deletion of SOCS3 in T-helper cells or liver tissue resulted in hyperproduction 
of TGF-β and TGF-β-induced fibrosis in mice [117, 118]. In addition, SOCS3 impairs TGF-β 
signaling in macrophages by binding to Smad3 and inhibiting its nuclear transportation and 
transcriptional activity [115]. Together this indicates a potential deleterious effect of SOCS3 on 
TGF-β function and signaling in cartilage. Therefore, we investigated whether inflammation-
induced SOCS3 dysregulates TGF-β signaling in articular chondrocytes and/or TGF-β-mediated 
cartilage formation. 





Chondrocyte cell lines (H4 or G6 chondrocytes) were cultured in Dulbecco’s Modified Eagle 
Medium: Nutrient Mixture F-12 (DMEM/F-12,Gibco) with 5% fetal calf serum (FCS, Thermo 
Scientific), supplemented with 100 mg/l pyruvate (Gibco), 100 U/ml penicillin and 100 mg/ml 
streptomycin in standard culture conditions (5% CO2 (v/v), 37 °C, 95% humidity). Murine H4 
chondrocytes were derived from articular hip cartilage from C57BL/6 mice [150]. Human G6 
chondrocytes were derived from femoral head cartilage of an anonymous OA donor, transduced 
with a temperature-dependent SV40 oncogene resulting in cell proliferation at 32°C, but not 
at 37°C [149]. G6 chondrocytes were cultured at 32°C for cell expansion, and experiments 
were performed at 37°C. Primary bovine chondrocytes were obtained from articular cartilage 
of bovine metacarpophalangeal joints (MCP). Cartilage slices were digested overnight with 1.5 
mg/ml collagenase B (Roche Diagnostics) in DMEM/F12 to obtain a single cell suspension. 
Chondrocytes were centrifuged at 1,500 rpm for 10 min, washed with saline and resuspended in 
complete medium (consisting of the same components as the chondrocyte cell line medium but 
with 10% FCS). Bovine chondrocytes were plated at a density of 8 x 104 cells/cm2 and cultured 
for 1 week in standard conditions [5% CO2 (v/v), 37 °C, 95% humidity] to assure cell attachment. 
Before start of experiments, bovine chondrocytes and chondrocyte cell lines were serum-starved 
overnight in FCS-free medium. For SOCS3-overexpressing studies G6- or primary bovine 
chondrocytes were transduced for 2 h with adenoviruses overexpressing active murine SOCS3 
(AdSOCS3) or luciferase as negative control (AdLuc) with a multiplicity of infection (MOI) of 10 
(G6 chondrocytes) or 200 (primary bovine chondrocytes). The SOCS3 adenoviral vector was 
constructed as described previously [146]. Here after, chondrocytes were cultured for a period of 
48 h to ensure increased adenoviral-mediated protein expression before start of experiments. For 
stimulation experiments, chondrocytes were stimulated with rhTGF-β1 (Biolegend), rhIL-1β (R&D 
Systems), rhIL-6 (Biolegend) or OA synovium-conditioned medium (OAS-cm) for time periods 
and dosages indicated in figure legends. OAS-cm represents a pool of conditioned medium 
from seven different OA patients, produced as described previously [135]. Briefly, synovium 
obtained from OA patients undergoing total hip replacement was collected and cultured for 24h 
in DMEM with 0.1% BSA (0.3 g tissue/mL). Hereafter, supernatant was collected, debris was 
removed by centrifugation, and conditioned medium was stored at -20°C until further use.
Chondrogenic differentiation of MSCs
Human fetal bone-marrow derived MSCs (purchased from ScienCell Research Laboratories) 
were expanded for two weeks in Mesenchymal Stem Cell Growth Medium (MSCGM, Lonza) 
supplemented with 1% penicillin-streptomycin-glutamine (Gibco). MSCs were cultured at 37 °C 
with 5% CO2 and 95% humidity until four passages, where after cells were stored in liquid N2 
until later use. For virus experiments, MSCs were transduced for 24 h with SOCS3 (LV-SOCS3) 
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or luciferase (LV-Luc) lentivirus with a concentration of 200 ng/1.0 x105 cells in MSCGM medium 
containing protamine sulfate (100 μg/ml; Sigma-Aldrich). The SOCS3 human transgene was 
inserted into lentiviral vector and lentivirus was packaged as described previously [151]. After 
virus transduction, medium was removed, cells were washed with saline and expanded for 
two days. To start chondrogenic differentiation, MSCs were centrifuged at 300 g for 8 min in 
polystyrene V-bottom tubes (Greiner Bio-One) to obtain high-cell density pellets (200.000 cells/
pellet). MSC-pellets were cultured for one week in 500 μl chondrogenic medium, containing 
Dulbecco’s modified Eagle’s medium (DMEM; Gibco) supplemented with 1% penicillin-
streptomycin-glutamine (Gibco), insulin (6.25 μg/mL), transferrin (6.25 μg/mL), sodium selenite 
(6.25 ng/mL), proline (0.4 mg/mL), sodium pyruvate (1 mg/mL), linoleic acid (5.35 μg/mL), 
ascorbic acid (50 μg/mL), dexamethasone (10−7 M), and bovine serum albumin (1 mg/mL; all 
from Sigma-Aldrich). In addition, rhTGF-β1 (10 ng/ml) and rhBMP-2 (20 ng/ml) were added 
to chondrogenic medium, and freshly added during refreshment of complete chondrogenic 
medium (three times per week). 
Histological staining and measurement of GAG content in MSC pellets
For measurements of glycosaminoglycan (GAG) content, individual pellets were digested 
overnight using 0.1% (w/v) papain (Sigma-Aldrich) in digestion buffer (200 mM NaPO4, 100 mM 
NaAc, 5 mM cysteine-HCl, 10 mM EDTA at pH 6.4) at 60 °C. Hereafter, sulfated GAG content was 
measured in 40 μl of papain-digested sample by addition of 200 μl of dimethylmethylene blue 
(DMB) solution (0.05 mM DMB, 41 mM NaCl, 45 mM glycine, at pH 3.0) following the Farndale 
assay [152]. Absorbance was measured at 595 nm using the iMark-Reader (Bio-Rad). For 
histological staining, pellets were fixed in 4% formalin overnight, dehydrated and embedded in 
paraffin. Hereafter, tissue sections of 5 μm were prepared. To visualize sulfated GAGs, sections 
were stained with aqueous Safranin-O and counterstained with aqueous Fast Green (0.1%, 
Brunschwig Chemie). Pellet size was evaluated by eye on a macroscopical level. 
Protein isolation and western blot
Chondrocytes were lysed using lysis buffer (Cell Signaling) containing protease inhibitor 
cocktail (PIC, complete, Roche Diagnostics). Cell lysates were sonicated on ice for 10 cycles 
of 30 seconds sonication using a Bioruptor (Diagenode) as described previously [153]. Protein 
concentration was normalized between samples using a bicinchoninic acid assay (BCA, Thermo 
Scientific). Proteins were separated with a 10% reducing bis-acrylamide SDS-PAGE gel and 
transferred to a 0.45 μm pore nitrocellulose membrane (Life Sciences) via wet transfer (Towbin 
buffer, 2 h, 275 mA at 4 °C). Membranes were incubated overnight at 4 °C with primary antibodies 
directed against SOCS3 (polyclonal rabbit antibody, #2923S, 1:1000, Cell Signaling), p-STAT3 
(polyclonal rabbit antibody, #9131, 1:1000, Cell Signaling), p-Smad3 (monoclonal rabbit antibody, 
#C25A9, 1:000, Cell Signaling), p-Smad1/5/9 (polyclonal rabbit antibody, #9511, 1:000, Cell 
Signaling), MBD3 (monoclonal mouse antibody, 10281, 1:1000, IBL), β-actin (monoclonal rabbit 
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antibody, #4970, 13E5, 1:1000, Cell Signaling) or GAPDH (mouse monoclonal antibody, 1G5, 
1:10,000 Sigma Aldrich). After overnight incubation, membranes were incubated for 1 h with 
polyclonal Goat anti-Rabbit coupled to horseradish peroxidase (1:1500, Dako) at RT. Enhanced 
chemiluminescence (ECL) was used to visualize proteins with ECL prime kit (GE Healthcare) and 
ImageQuant LAS4000 (Leica) according to manufacturer’s instructions. 
Enrichment of nuclear and cytoplasmic fractions
To investigate p-Smad3 nuclear translocation, nuclear and cytoplasmic protein fractions were 
enriched as described previously [154]. Harvested chondrocytes were incubated for 10 min 
on ice in buffer A: 10 Mm HEPES (Sigma-Aldrich), 10 mM KCl (Merck), 0.5 mM DTT (Sigma-
Aldrich), 1.5 mM MgCl2 (Merck), 0.05% NP40 (BDH), pH 7.9 supplemented with 2.5 mM sodium 
pyrophosphate, 1mM β-glycerophosphate, 1 mM Na3VO4 (all from Sigma-Aldrich) and PIC 
(Roche Diagnostics). Protein lysates were centrifuged at 400 g for 10 min at 4 °C in a tabletop 
centrifuge (Eppendorf). Supernatant was collected (cytoplasmic fraction) and stored. Remaining 
pellet (nuclear fraction) was washed in buffer A, spun down and resuspended in buffer B (5 mM 
HEPES, 0.5 mM DTT, 0.2 mM EDTA (Merck), 300 mM NaCl, 1.5 mM MgCl2, 26% glycerol (v/v, 
Merck), pH 7.9) supplemented with phosphatase and protease inhibitors. Nuclear fractions were 
transferred to a Dounce homogenizer and nuclei were lysed using a glass type B (tight) pestle 
(Sigma-Aldrich). Nuclear fraction was incubated for 1 h at 4 °C on a roller bench, centrifuged at 
3,200 g for 20 min at 4 °C, where after supernatant (nuclear fraction) was collected and stored. 
Before western blotting, nuclear and cytoplasmic fractions were sonicated according to normal 
protocol (described in western blot section) and protein concentration was determined with BCA 
measurement. MBD3 and β-actin were used as respective (loading) controls for nuclear and 
cytoplasmic fraction enrichment. 
TGF-β transcriptional reporter luciferase assays
TGF-β transcriptional activity was determined using luciferase reporter assays. The effect of OA-
related inflammation on TGF-β transcriptional activity was investigated using the pNL1.2-SBE 
luciferase reporter assay in G6 chondrocytes. This reporter assay consists of a SMAD binding 
element (SBE) driven by a minimal promoter including a TATA-box (bold) (Genecust) [155]. 
The SBE-DNA fragments contains three palindromic SMAD3 binding elements (underlined): 
5’AGTATGTCTAGACTGAAGTATGTCTAGACTGAAGTATGTCTAGACTGACTCGAGGATATCAA
GATCTGGCCTCGGCGGCCTAGATGAGACACTAGAGGGTATATAATGGAAGCTCGACTT 
CCAG-3’. Promoter sequences were cloned into the pNL1.2 reporter vector as follows. First, the 
SBE-fragment was digested with KpnI/HindIII restriction enzymes (NEB)-and ligated with T4 Ligase 
(NEB) into the KpnI/HindIII-digested pNL1.2 vector (Promega). Hereafter, correct orientation was 
confirmed with restriction analysis. To obtain plasmid DNA, TOP10-transformed competent cells 
were propagated and plasmid DNA was extracted using a Plasmid Maxi Kit (Qiagen) according 
to manufacturer’s protocol. Construct sequences were validated by Sanger sequencing. G6 
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chondrocytes were seeded in a cell density of 8 x 104 cells/cm2 and transfected with the pNL1.2-SBE 
luciferase reporter plasmid using Lipofectamine 2000 Transfection Reagent (Invitrogen) according 
to manufacturer’s protocol. The effect of SOCS3 on TGF-β transcriptional activity was determined 
by co-transduction of G6 chondrocytes with the CAGA12-luciferase reporter adenovirus (26), 
combined with the SOCS3 adenovirus (both MOI 5). To determine luciferase activity of reporter 
assays, G6 chondrocytes were lysed using reporter assay lysis buffer (Promega) and luciferase 
activity was measured after addition of Bright Glo TM substrate (CAGA-Luc) or Nano Glo (pNL1.2-
SBE) (both from Promega) using a luminometer (Clariostar, BMG).
RNA isolation and quantitative polymerase chain reaction (PCR) analysis
Total messenger RNA was extracted from chondrocytes using TRIzol reagent (Sigma Aldrich) 
following manufacturer’s protocol. After isolation, RNA was dissolved in ultra-pure water and 
concentration and purity was measured using a NanoDrop photospectrometer (Thermo 
Scientific). Hereafter, a maximum of 1 μg of mRNA was treated with 1 Unit DNAse (Life 
Technologies) for 15 min at RT to remove possible genomic DNA, followed by an inactivation 
step with 1 μL 25 mM EDTA (Life Technologies) at 65°C for 10 min. An equal amount of RNA 
was reverse transcribed to complementary DNA using 1.9 μL ultrapure water, 2.4 μl 10x DNAse 
buffer, 2.0 μl 0.1M dithiothreitol, 0.8 μl 25mM dNTP, 0.4 μg oligo dT primer, 200U M-MLV reverse 
transcriptase (Life Technologies) and 0.5 μl 40 U/ml RNAsin (Promega). Reverse transcription 
protocol was as follows: 5 min at 25°C, 60 min at 39°C, and 5 min at 95°C using a thermos-
cycler. Gene expression was measured using SYBR Green Master Mix (Applied Biosystems) 
and 0.25 mM primers (Biolego, see Table 1) using a StepOnePlus real-time PCR system (Applied 
Biosystems). Amplification protocol: 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 
min at 60°C. Melting curves were analyzed to confirm product specificity. To calculate the relative 
gene expression (−ΔCt), the average of two reference genes was used: hGAPDH and hRPS27A 
for G6 chondrocytes and bGAPDH and bRPS14 for bovine chondrocytes. 
Statistical analysis
Quantitative data were expressed as curve or column scatter with displayed mean ± standard 
deviation (SD). Mean represents either mean of multiple experiments, or mean of technical 
replicates as indicated in Figure legends. Before each analysis, Gaussian distribution was tested 
using the D’Agostino-Pearson Omnibus K2 test. Differences in sGAG content of MSC-pellets 
were tested using one-way analysis of variance (ANOVA) with Bonferroni post-correction to 
correct for multiple comparisons. The effect of inflammatory mediators or SOCS3 overexpression 
on TGF-β transcriptional activity was determined with Kruskal Wallis analysis, followed by the 
Dunn’s Multiple Comparison Test. Gene expression was analyzed with Kruskal Wallis and Dunn’s 
post-test (differences in ALK expression) or with One-Way ANOVA followed by Bonferroni’s post-
test (differences in TGF-β-mediated induction of immediate early genes) or Dunnett’s post-test 
(effect of inflammation on hSOCS3 expression). Statistical analyses were performed using 
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GraphPad Prism version 5.03 (GraphPad Software) on the absolute measured values. P-values 
<0.05 were considered significant. 
Table 1. Template and sequence of the primers used in this study.



















OA-related inflammation induces SOCS3 expression and inhibits TGF-β transcriptional 
activity in articular chondrocytes 
The cytokine-inducible protein SOCS3 has been identified as a potential inhibitor of TGF-β/
Smad3 signaling in macrophages [115], but whether SOCS3 impairs protective TGF-β signaling 
in articular chondrocytes is yet unknown. As SOCS3 is a regulator of inflammation in cells of 
the immune system [147], we first established whether inflammatory factors modulate SOCS3 
gene and protein expression in articular chondrocytes. Stimulation with rhIL-1β, rhIL-6 or OAS-cm 
for 6 h strikingly increased gene expression of hSOCS3 in G6 chondrocytes with 6.5-fold (2.7 
ΔCt), 2.0-fold (1.0 ΔCt), and 6.1-fold (2.6 ΔCt) respectively (Fig. 1A). In contrast with the effect 
of inflammatory mediators, we found no evidence that hSOCS3 gene expression was affected 
by stimulation with rhTGF-β. Western blot confirmed that IL-1β also increased SOCS3 protein 
expression in articular chondrocytes, while TGF-β had no effect (Fig. 1B). A combination of these 
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Figure 1. OA-related inflammatory factors increase SOCS3 expression and simultaneously inhibit 
TGF-β transcriptional activity in articular chondrocytes. (A) G6 chondrocytes were stimulated in 
duplicate or triplicate with rhIL-6 (25 ng/ml), rhIL-1β (1.0 ng/ml), OAS-cm (2.5%) or rhTGF-β (1.0 ng/ml) 
for 6 h, where after hSOCS3 gene expression was analyzed using qPCR. Data are expressed as mean ± 
SD of technical replicates. (B) H4 chondrocytes were stimulated with rhIL-1β (1.0, 10.0 ng/ml) or rhTGF-β 
(1.0, 10.0 ng/ml) to study the effect on SOCS3 protein expression as determined by western blot. (C) To 
study interaction between OA-related inflammation and functional TGF-β signaling, G6 chondrocytes were 
transfected with a TGF-β transcriptional reporter assay construct (SBE-pNL1.2 luciferase reporter). After 
transfection, G6 chondrocytes were pre-incubated overnight with rhIL-6 (25 ng/ml), rhIL-1β (1.0 ng/ml) or 
OAS-cm (0.5%) and thereafter stimulated with increasing concentrations of rhTGF-β for 5 h. Data represents 
mean ± SD of three technical replicates. (D) Luciferase activity relative to experimental condition stimulated 
with rhTGF-β (0.1 ng/ml), as set at 100%. Data represents mean ± SD of two independent experiments 
performed in duplicate or triplicate. * = P < 0.05, ** = P < 0.01, *** = P < 0.001 as measured by one-way 
ANOVA (A) or Kruskall Wallis test (D) both followed by Dunn’s multiple comparison test. 
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established that OA-related inflammation increases SOCS3 expression in articular chondrocytes, 
we investigated if these inflammatory mediators inhibit TGF-β signaling at the same time. To study 
TGF-β signaling, we used a luciferase reporter assay with SMAD-binding elements. Luciferase 
activity was strongly induced in a dose-dependent fashion in G6 chondrocytes, with a maximum 
of ~8.5-fold induction at 0.1 ng/ml of rhTGF-β (Fig. 1C). Interestingly, TGF-β-induced luciferase 
activity was counteracted by pre-incubation with the pro-inflammatory mediators IL-1β, IL-6 and 
OAS-cm (Fig. 1C). More specifically, transcriptional activity induced by 0.1 ng/ml of TGF-β was 
significantly inhibited by IL-1β with approximately 80%, while a downward trend was observed 
in response to OAS-cm (~30%) and IL-6 (~20%)(Fig. 1D). Since these inflammatory mediators 
highly increase SOCS3 expression at the same time, and SOCS3 was previously shown to 
inhibit TGF-β/Smad3 signaling in other cell types, it seemed plausible that inflammation-induced 
SOCS3 has a central role in reducing TGF-β signaling in this setting. 
Overexpression of SOCS3 does not alter TGF-β transcriptional activity or C-terminal 
phosphorylation of Smad3
To determine whether SOCS3 could be pivotal in the inhibitory effect of inflammatory mediators 
on TGF-β function, increased SOCS3 expression was mimicked using adenoviral overexpression. 
In order to study TGF-β transcriptional activity, G6 chondrocytes were simultaneously transduced 
with the CAGA12-luciferase adenovirus in combination with a SOCS3- or control adenovirus. As 
expected, stimulation with rhTGF-β strongly induced luciferase activity with a maximum of ~18-fold 
(Fig. 2A). However, overexpression of SOCS3 did not significantly affect TGF-β-induced luciferase 
production compared to control conditions. This lack of effect was not due to unsuccessful 
overexpression, since SOCS3 protein levels were highly increased in G6 chondrocytes after 
transduction visualized with western blot (Fig. 2B). Moreover, endogenous p-STAT3 was clearly 
suppressed by SOCS3 overexpression, confirming transgene activity (Fig. 2B). Previously, it was 
shown that SOCS3 can directly inhibit Smad3 phosphorylation [115]. Therefore, we investigated 
if SOCS3 might inhibit TGF-β signaling on a more upstream level by studying C-terminal 
phosphorylation of Smad3 at several time points after TGF-β stimulation using western blot. 
However, SOCS3 overexpression did not distinctly alter p-Smad3 levels at baseline or after TGF-β 
stimulation (Fig. 2C). Of note, we observed a small reduction in p-Smad3 levels at 2 h after TGF-β 
stimulation in SOCS3 overexpression conditions compared to control virus. However, this effect 
was not consistent and not detectable at other time points. As it was previously shown that SOCS3 
can inhibit nuclear translocation of Smad3 in macrophages [115], we additionally studied p-Smad3 
levels in nuclear and cytoplasmic protein fractions of SOCS3-transduced G6 chondrocytes. Levels 
of p-Smad3 were detected in both cytoplasmic and nuclear fractions, and were clearly induced 
in nuclear fractions after 1 h stimulation with rhTGF-β (Fig. 2D). However, we observed no effect 
of SOCS3 overexpression on p-Smad3 nuclear translocation in control or TGF-β stimulated 
conditions. Together, these results indicate that increasing SOCS3 does not affect TGF-β/Smad3 

























































































































































Figure 2. Overexpression of SOCS3 does not affect TGF-β transcriptional activity, C-terminal 
phosphorylation or nuclear activation of Smad3. To study the effect of SOCS3 on TGF-β signaling, G6 
chondrocytes were transduced with SOCS3- or control adenovirus (luciferase (Luc) or empty backbone 
(Del)), or left untreated (control). At 48 h after transduction, G6 chondrocytes were stimulated with rhTGF-β 
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and several read-out parameters were analyzed. (A) Transcriptional activity in SOCS3- versus control 
conditions was determined by adenoviral transduction with CAGA12-luc construct. G6 chondrocytes were 
stimulated with increasing concentrations of rhTGF-β for 16 h and luciferase activity was determined. Data 
is expressed relative to medium control and presented as mean ± SD of four technical replicates and 
is representative of three independent experiments. (B) SOCS3 protein expression 48h after adenoviral 
transduction with SOCS3- or luciferase adenovirus as determined by western blot. Additionally, p-STAT3 
levels were analyzed to verify transgene activity. (C) C-terminal phosphorylation of Smad3 was analyzed in 
SOCS3 overexpression- and control conditions at several time points (0, 5, 15, 30, 60, 120, 240 min) after 
stimulation with 1.0 ng/ml of rhTGF-β using western blot. (D) Nuclear translocation of p-Smad3 was analyzed 
after 1h of rhTGF-β (1 ng/ml) stimulation by enrichment of nuclear and cytoplasmic protein fractions. β-actin 
was used as loading control for cytoplasmic fraction and MBD3 for the nuclear fraction. Statistical differences 
in CAGA-12 luc assay were tested using the Kruskall Wallis test followed by Dunn’s multiple comparison test. 
SOCS3 does not change expression levels of TGF-β receptors ALK1 and ALK5 or 
activation of Smad2/3 and Smad1/5/9 signaling pathways
TGF-β can activate two different type I receptors in chondrocytes, named ALK5 and ALK1, which 
both activate a different intracellular Smad signaling route [53]. Therefore, a possible alternative 
mechanism how SOCS3 may alter TGF-β signaling could be via modulation of the balance 
between ALK1 and ALK5 receptors. However, gene expression of hALK5 and hALK1 was not 
affected by overexpression of SOCS3 in G6 chondrocytes (Fig. 3A). Also in primary bovine 
chondrocytes, SOCS3 overexpression did not affect bALK5 or bALK1 expression, confirming 
that this absence of effect was not due to the choice of cell source (Supplementary Fig. 1A). As 
SOCS3 may influence Smad signaling downstream of the receptors, we also determined TGF-
β-mediated activation of p-Smad2/3 versus p-Smad1/5/9 signaling pathway in G6- and bovine 
chondrocytes. Increased phosphorylation of both pathways was clearly visible after 1 h of TGF-β 
stimulation in articular chondrocytes. Nonetheless, TGF-β-induced phosphorylation of Smad2/3 
and Smad1/5/9 was not affected by SOCS3 overexpression in both G6- and primary bovine 
chondrocytes (Fig. 3B, Supplementary Fig. 1B). These results indicate that the balance in ALK5-

























































































Figure 3. ALK1 and ALK5 expression and signaling is not affected by SOCS3 overexpression. To 
study the effect of SOCS3 on TGF-β receptor expression and signaling, G6 chondrocytes were transduced 
with SOCS3- or luciferase adenovirus, or left untreated (control). (A) Gene expression of hALK1 and 
hALK5 receptors was analyzed 48 h after virus transduction using qPCR. Data represents mean of three 
independent experiments, in which each point represents the mean of three technical replicates. (B) 
C-terminal phosphorylation of Smad3 or Smad1/5/9 was analyzed with western blot in G6 chondrocytes at 
1 h after rhTGF-β stimulation (1.0 ng/ml). Statistical differences in hALK1 and hALK5 expression were tested 
with Kruskall Wallis followed by Dunn’s multiple comparison test.
TGF-β-dependent target gene expression is not altered by enhanced SOCS3 in 
articular chondrocytes 
To study the effect of SOCS3 on TGF-β-mediated transcription in a more physiological setting, 
we analyzed expression patterns of Smad3-dependent target genes hSERPINE1, hJUNB, 
hSMAD7 and hID-1 in G6 chondrocytes [156-160]. Stimulation with 1 ng/ml of rhTGF-β markedly 
increased gene expression of hSERPINE1 (4.6-fold, 2.2 ΔCt) , hJUNB (5.6-fold, 2.5 ΔCt), 
hSMAD7 (5.6-fold, 2.5 ΔCt) and hID-1 (2.5-fold,1.3 ΔCt) within 2 h after stimulation (Fig. 4). 
Adenoviral overexpression of SOCS3 strongly increased hSOCS3 gene expression with ~2000-
fold (11.3 ΔCt) compared to the luciferase control (Supplementary Fig. 2A). However, SOCS3 
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overexpression did not significantly change TGF-β-mediated induction of hSERPINE1, hJUNB, 
hSMAD7 or hID-1 in G6 chondrocytes (Fig. 4). Also in primary bovine chondrocytes, increased 
SOCS3 did not modify TGF-β-dependent expression of these target genes as measured at 2 h, 
8 h and 24 h after stimulation (Supplementary Fig. 2B). Together, this indicates that increased 














































































































Figure 4. Adenoviral overexpression of SOCS3 does not alter TGF-β-mediated induction of Smad3-
dependent genes. To study the effect of SOCS3 on TGF-β-induced expression of Smad3-dependent genes, 
G6 chondrocytes were transduced with SOCS3- or luciferase adenovirus, or left untreated (no virus control). 
After 48 h, G6 chondrocytes were stimulated with rhTGF-β for 2 h and expression of hSERPINE1, hJUNB, 
hSMAD7, and hID1 was analyzed with qPCR. Data represents mean of three independent experiments, in 
which each point represents the mean of three technical replicates. Differences in TGF-β-mediated induction 
of hSERPINE1, hJUNB, hSMAD7 and hID1 were tested with one-way ANOVA and Bonferroni post-hoc test. 
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Enhanced SOCS3 expression impairs TGF-β-dependent MSC-based cartilage 
formation
We have previously shown that an inflammatory OA-like microenvironment strongly reduces 
TGF-β-dependent cartilage formation of MSC pellets [134, 135]. To study whether inflammation-
induced SOCS3 might be involved in this inhibitory effect, we first determined whether OA-
related inflammation increases SOCS3 expression in MSCs. Indeed, protein expression of 
SOCS3 was induced by OAS-cm treatment in chondrogenic MSC-pellets, especially after 
96h incubation (Fig. 5A). To study the role of SOCS3 in TGF-β-dependent cartilage formation, 
MSCs were transduced with either SOCS3- or luciferase lentivirus, and cartilage formation was 
stimulated by 3D-pellet formation and addition of chondrogenic medium supplemented with 
rhTGF-β (10 ng/ml) and rhBMP-2 (20 ng/ml) (Fig. 5B). Overexpression of SOCS3 on western blot 
was confirmed after 1 week of culture (Fig 5C). Moreover, SOCS3 overexpression resulted in 
inhibition of endogenous p-STAT3 levels, which demonstrates adequate transgene activity (Fig. 
5C). Interestingly, MSC-pellet size was strongly reduced by SOCS3 overexpression after 7 days 
of chondrogenic differentiation (Fig. 5D). Moreover, intensity of Safranin-O staining was reduced 
in SOCS3-overexpressing pellets, indicating decreased sulphated GAGs content. Indeed, 
exact measurement of sGAG-content showed a significant reduction of ~50% in sGAG content 
of SOCS3-pellets compared to luciferase control (Fig. 5E). Similar to the results obtained in 
chondrocytes, SOCS3 overexpression did not affect p-Smad3 levels in MSC-pellets compared 
to luciferase control in the presence of TGF-β (Fig. 5F). Altogether, this shows that increased 
SOCS3 expression inhibits MSC-based cartilage formation. 




























































Figure 5. Lentiviral overexpression of SOCS3 inhibits MSC-based cartilage formation. (A) 
Endogenous protein expression of SOCS3 protein in MSC-pellets after 7 days of chondrogenic differentiation 
as determined by western blot. Pellets were stimulated with medium only or OAS-cm (2.5%) for a period 
of 24 h or 96 h. (B) Overview of experimental design. MSCs were transduced with SOCS3 or luciferase 
lentivirus and hereafter cultured in chondrogenic medium containing rhTGF-β (10 ng/ml). After 7 days pellets 
were harvested for histological analysis and sGAG measurement. (C) Protein levels of SOCS3 and p-STAT3 
as determined by western blot in MSCs at 1 week after lentiviral transduction with SOCS3- or luciferase 
lentivirus. (D) Histological staining of MSC-pellets at day 7 of chondrogenic differentiation, transduced with 
SOCS3- or luciferase lentivirus. Intensity of safranin-O staining indicates proteoglycan content of MSC-
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pellets. Representative pictures are shown of three pellets per condition. (E) Quantification of sGAG content 
of MSC pellets at day 7 after differentiation in MSCs with no virus (Ctrl), or transduced with SOCS3- or 
luciferase lentivirus. Data represents mean of three independent experiments, in which each point is the 
mean of three pellets. (F) C-terminal phosphorylation of Smad3 determined by western blot in MSCs at 1 
week after lentiviral transduction with SOCS3- or luciferase lentivirus. ** = P < 0.01 as measured by one-way 
ANOVA with Bonferonni post-hoc test. 
DISCUSSION
The inflammatory micro-environment in the OA joint impairs TGF-β signaling in chondrocytes 
as well as TGF-β-dependent cartilage repair processes, which may be regulated via the central 
cytokine-inducible protein SOCS3. In this study, we show that OA-related inflammatory factors 
indeed increase SOCS3 expression in articular chondrocytes, and simultaneously inhibit 
TGF-β transcriptional activity. However, inflammation-mediated inhibition of TGF-β signaling in 
chondrocytes is not mediated via SOCS3, as we found no evidence that SOCS3 alters TGF-β 
receptor expression, Smad phosphorylation and nuclear translocation, or TGF-β-mediated 
transcription. Finally, we demonstrate that SOCS3 overexpression strongly inhibits MSC-based 
cartilage formation, resulting in decreased pellet size and sGAG content. Based on our findings 
in chondrocytes, it is likely that this is independent of SOCS3 directly affecting TGF-β signaling.
To study the effect of OA-related inflammation on hSOCS3 expression in articular chondrocytes, 
we stimulated chondrocytes with IL-6, IL-1β or OAS-cm. IL-6 is a common inducer of SOCS3, 
and IL-6 levels are highly increased in OA synovial fluid [161-163]. IL-1β is a pro-inflammatory 
cytokine present in OA synovial fluid, which can directly inhibit proteoglycan synthesis, increase 
expression of matrix degenerative mediators, and regulate SOCS3 expression [134, 146, 149, 
164, 165]. Additionally, conditioned medium derived from OA-synovial biopsies (OAS-cm) was 
used, which reflects the complex inflammatory microenvironment present in an OA joint. Our 
results showed that IL-6, IL-1β and OAS-cm all induced hSOCS3 expression after 5 h, and these 
effects were most prominent after IL-1β or OAS-cm stimulation. This is in line with our previous 
findings that IL-1β potently increases SOCS3 gene and protein expression in both H4 and G6 
chondrocytes, although IL-6 and OAS-cm were not included in these studies [146, 149]. Possibly, 
IL-6 causes higher induction of SOCS3 at earlier time points, as computational modeling shows 
that IL-6 stimulation can result in rapid and transient activation of SOCS3 [166]. Moreover, our 
results showed that the inflammatory mediators IL-1β, IL-6 and OAS-cm, besides increasing 
SOCS3 expression, also inhibit TGF-β transcriptional activity in articular chondrocytes. Together, 
this initially suggested that inflammation-induced SOCS3 might have been a central mediator in 
inflammation-mediated inhibition of TGF-β signaling in cartilage. However, our data did not show 
that SOCS3 inhibits TGF-β signaling in articular chondrocytes. 
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In articular cartilage, multiple functions of SOCS3 have been reported, both protective as well as 
deleterious. For instance, a key role for SOCS3 in controlling chondrocyte cytokine responses 
during joint inflammation has been demonstrated [84]. In cartilage explants where SOCS3 
was deleted (SOCS3-/-), stimulation with the inflammatory cytokine IL-6 resulted in increased 
expression of catabolic mediators and enhanced cartilage degradation. Moreover, intra-articular 
injection of inflammatory mediators such as IL-6 in cartilage specific SOCS3-/- mice aggravated 
cartilage damage and inflammation [84]. This suggests that SOCS3 has a beneficial role in 
chondrocytes, by restricting pro-inflammatory cytokine signaling and thereby the development 
of cartilage damage. On the other hand, deleterious functions of SOCS3 in chondrocytes have 
also been reported. We previously showed that SOCS3 inhibits insulin growth factor-1 (IGF-
1) signaling in chondrocytes, via the reduction of insulin receptor substrate-1 phosphorylation 
[146]. As IGF-1 is an essential stimulator of proteoglycan synthesis in cartilage [167, 168], 
SOCS3 may cause non-responsiveness to IGF-1 via this mechanism, leading to a reduced 
anabolic capacity in chondrocytes. In addition, SOCS3 can inhibit TGF-β signaling in 
macrophages via direct inhibition of Smad3 phosphorylation and nuclear translocation [115]. 
Therefore, we initially anticipated this could reflect a new detrimental role for SOCS3 in cartilage, 
via the inhibition of protective TGF-β signaling in chondrocytes. However, increasing SOCS3 
levels using viral overexpression did not affect TGF-β-induced transcriptional activity, C-terminal 
phosphorylation- or nuclear translocation of Smad3 in human or bovine articular chondrocytes. 
This finding is opposed to the observations of Liu et al., who showed that TGF-β directly binds 
Smad3 and inhibits Smad3 activation and nuclear translocation to control Toll like receptor 4 
(TLR4) signaling in macrophages [115]. In contrast to our approach, they studied the role of 
endogenously expressed SOCS3 using small interfering (si)RNA-based silencing of SOCS3. 
However, in our experience siRNA-transfection is difficult to employ in chondrocytes as they 
secrete matrix macromolecules during culture resulting in low transfection efficiency [169, 170], 
which is why we used a viral overexpression strategy instead. Moreover, we studied the effect of 
SOCS3 on several aspects of the TGF-β signaling pathway, and found no effect on expression 
of TGF-β receptors ALK5/ALK1, respective activation of p-Smad2/3 and p-Smad1/5/9 signaling 
or TGF-β-dependent expression of Smad3-dependent genes. Together with the lack of effect 
on Smad3 phosphorylation and nuclear translocation, these results show that SOCS3 does not 
impair TGF-β signaling in articular chondrocytes. Possibly, the effect of SOCS3 on TGF-β/Smad3 
signaling is cell type-dependent, and may be present in other cell types such as macrophages 
[115]. 
Interestingly, overexpression of SOCS3 did strongly inhibit chondrogenic differentiation of MSCs. 
As the presence of inflammatory mediators is a known limiting factor of MSC-based cartilage 
repair, it is possible that inflammation-induced SOCS3 hampers cartilage repair strategies 
in OA patients. Although TGF-β is a crucial factor for our chondrogenic differentiation model 
[171], we convincingly showed that SOCS3 did not inhibit TGF-β signaling in chondrocytes. 
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We therefore suggest that the inhibitory effect of SOCS3 on MSC-based cartilage formation 
is mediated via direct inhibition of the IGF-1 pathway. IGF-1 is crucial for the synthesis of 
essential matrix components during chondrogenesis [167, 168], and it was previously shown 
that SOCS3 inhibits IGF-1 signaling in chondrocytes [146]. Alternatively, SOCS-3 may impair 
cartilage formation via inhibition of its natural target STAT3. Activation of STAT3 signaling strongly 
stimulates chondrogenic differentiation and increases matrix production [172]. Moreover, IL-6/
STAT3 signaling has been shown to stimulate cartilage regeneration [96]. Inhibition of SOCS3 
in MSCs may ultimately improve cartilage repair in an inflammatory OA joint. But first, we need 
to make sure that targeting of SOCS3 during cartilage formation is only beneficial, and does not 
result in uncontrolled cytokine signaling in inflammatory conditions [147]. 
In conclusion, we show that OA-related inflammatory factors increase SOCS3 expression in 
articular chondrocytes. However, SOCS3 does not cause inflammation-mediated inhibition 
of TGF-β signaling in chondrocytes, as we found no evidence that SOCS3 inhibits TGF-β 
signaling on the level of receptor expression, p-Smad activation or TGF-β transcriptional activity. 
Strikingly, SOCS3 did strongly impair MSC-based cartilage formation. Based on our findings in 
chondrocytes, the effect of SOCS3 on cartilage formation is likely not caused by direct inhibition 
of TGF-β signaling, but works via a different mechanism. Thus, inflammation-induced SOCS3 
may play a role in impaired MSC-based cartilage repair processes, which identifies SOCS3 as a 
potential target to improve chondrogenesis in the OA joint. 
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Supplementary Figure 1. Overexpression of SOCS3 in primary bovine chondrocytes does not 
affect ALK1/ALK5 expression or activation of p-Smad2/3 versus p-Smad1/5/9 signaling. To study 
the effect of SOCS3 on TGF-β signaling, primary bovine chondrocytes were transduced with SOCS3- or 
luciferase adenovirus, or left untreated (control). (A) Gene expression of bALK1 and bALK5 receptors 
was analyzed 48 h after virus transduction using qPCR. Data represents mean ± SD of three technical 
replicates from one experiment (B) C-terminal phosphorylation of Smad2/3 or Smad1/5/9 was analyzed with 
western blot in primary bovine chondrocytes at 1 h after rhTGF-β stimulation (1.0 ng/ml). (C) SOCS3 protein 
expression in primary bovine chondrocytes as determined by Western blot. SOCS3 protein increased after 
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viral transduction with increasing multiplicity of infection (MOI) of SOCS3 adenovirus. Statistical differences in 
bALK1 and bALK5 expression were tested with Kruskall Wallis followed by Dunn’s multiple comparison test. 
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Supplementary Figure 2. Overexpression of SOCS3 in primary bovine chondrocytes does not 
affect TGF-β-induced expression of Smad3-dependent genes. (A) To study the effect of SOCS3 on 
TGF-β-induced expression of Smad3-dependent genes, primary bovine chondrocytes were transduced with 
SOCS3- or luciferase adenovirus, or left untreated (no virus control). (B) After 48 h, bovine chondrocytes 
were stimulated with rhTGF-β for 2 h, 8h and 24 h and expression of bSERPINE1, bJUNB, bSMAD7, and bID1 
was analyzed with qPCR. Data represents mean ± SD of three technical replicates from one experiment. 
Differences in TGF-β-mediated induction of bSERPINE1, bJUNB, bSMAD7 and bID1 were tested with 
Kruskall Wallis followed by Dunn’s multiple comparison test.
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Transforming growth factor-β (TGF-β) is an important homeostatic regulator of cartilage. In 
contrast, interleukin-6 (IL-6) is a pro-inflammatory cytokine implicated in cartilage degeneration. 
Cross-talk between TGF-β and IL-6 is reported in tissues other than articular cartilage. Here, we 
investigated regulation of IL-6 signaling by TGF-β in articular chondrocytes. 
Design
Human primary chondrocytes and the human G6 chondrocyte cell line were stimulated with 
TGF-β1 or interleukin-1β (IL-1β). Expression of IL-6 and IL-6 receptor (IL-6R) was determined on 
mRNA and protein level. TGF-β regulation of IL-6 signaling via phospho-STAT3 (p-STAT3) was 
determined using Western blot, in presence of inhibitors for IL-6R, and Janus kinase (JAK)- and 
activin receptor-like kinase (ALK)5 activity. Furthermore, induction of STAT3-responsive genes 
was used as a read-out for IL-6-induced gene expression. 
Results
TGF-β1 increased IL-6 mRNA and protein expression in both G6 and primary chondrocytes. 
Moreover, TGF-β1 stimulation clearly induced p-STAT3, which was abolished by inhibition of 
either IL-6R, JAK- or ALK5 kinase activity. However, TGF-β1 did not increase expression of 
the STAT3-responsive gene SOCS3 and pre-treatment with TGF-β1 even inhibited induction 
of p-STAT3 and SOCS3 by rhIL-6. Interestingly, TGF-β1 potently decreased IL-6R expression. 
In contrast, IL-1β did increase IL-6 levels, but did not affect IL-6R expression. Finally, addition 
of recombinant IL-6R abolished the inhibitory effect of TGF-β1 on IL-6-induced p-STAT3 and 
downstream SOCS3, BCL3, SAA1 and MMP1 expression. 
Conclusions
In this study we show that TGF-β decreases IL-6R expression, thereby dampening IL-6 signaling 
in chondrocytes. This reveals a novel effect of TGF-β, possibly important to restrict pro-
inflammatory IL-6 effects to preserve cartilage homeostasis. 




The main function of chondrocytes is to maintain cartilage homeostasis, which is a balance 
between cartilage matrix synthesis and degradation. This balance is tightly regulated by soluble 
anabolic and catabolic factors. During osteoarthritis (OA), the balance shifts towards catabolic 
processes, leading to cartilage damage. In OA cartilage, chondrocytes display a catabolic 
phenotype and produce matrix degrading enzymes such as matrix metalloproteinase (MMP)-13, 
leading to destruction of surrounding cartilage matrix [1-3]. It is unclear why OA chondrocytes 
display this catabolic phenotype, but both increased levels of catabolic mediators and a changed 
response to anabolic factors are thought to contribute to this process. 
Transforming growth factor-β (TGF-β) is a crucial factor for the formation and maintenance 
of healthy articular cartilage [4, 5]. Knock-out studies investigating loss of the TGF-β type II 
receptor or intracellular signaling mediator Smad3 in mice show the rapid development of severe 
cartilage damage [6, 7]. Furthermore, TGF-β signaling is involved in protection against cartilage 
destruction, by counteracting the effects of catabolic, pro-inflammatory cytokines [8]. We have 
previously shown that TGF-β can effectively counteract pro-inflammatory IL-1β signaling and 
thereby prevent IL-1β induced cartilage destruction [9, 10]. However, we have also shown that 
in OA, TGF-β protective effects in cartilage are impaired, which may be caused by a decrease 
in expression of TGF-β type I receptor activin receptor like-kinase (ALK)5 which signals via the 
protective Smad2/3 pathway [11, 12]. This loss in responsiveness to TGF-β potentially contributes 
to the imbalance in cartilage homeostasis observed in OA. 
Interleukin-6 (IL-6) is considered to be a catabolic factor for chondrocytes because several 
studies show a role for IL-6 in cartilage degradation [13-15]. IL-6 is present in increased levels 
in serum and synovial fluid of OA patients compared to unaffected individuals, and circulating 
IL-6 levels are even considered to be predictive for OA development [16, 17]. In vitro, IL-6 
enhances the expression of MMP-3 and -13 in bovine chondrocytes, as well as the expression of 
a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) 4 and -5 [13]. Also 
in mice, intra-articular injection of IL-6 results in cartilage damage and increased production of 
MMP-3 and -13 [14]. Moreover, therapeutically blocking IL-6 or its downstream mediator STAT3 
during experimental OA evidently rescues cartilage damage and osteophyte formation [15]. 
Interestingly, regulation of IL-6 signaling by TGF-β has been reported in various cell types 
[18-21]. For example, TGF-β blocks IL-6-mediated phosphorylation of intracellular mediators 
STAT1 and STAT3 in intestinal epithelial cells, as well as the induction of ICAM expression [18]. 
Furthermore, TGF-β can induce the expression of suppressor of cytokine signaling (SOCS)3, a 
negative regulator of the IL-6 pathway, in macrophage/osteoclast precursors, but not in T-cells 
[20, 22]. In contrast, TGF-β synergizes with IL-6 in T-cells by promoting the degradation of FOXP3 
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[19]. This shows that TGF-β regulation of IL-6 signaling is context- and cell type dependent. 
Although it is evident that TGF-β and IL-6 play important roles in regulating cartilage homeostasis 
and degeneration, a link between these two factors in chondrocytes remains to be identified. 
Therefore, the goal of this study was to investigate potential regulation of IL-6 signaling by TGF-β 




Primary human chondrocytes were isolated from macroscopically intact cartilage obtained 
after surgery from seven anonymized OA patients undergoing total knee or hip arthroplasty 
(Radboud University Medical Center, Nijmegen, the Netherlands). Patients were informed about 
the anonymized use of this material for research and were able to refuse. According to Dutch 
law, informed consent is therefore not necessary.
Primary cell culture
To obtain chondrocytes, cartilage explants were digested overnight in 1.5 mg/ml Collagenase 
B (Roche Diagnostics) in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/
F12, Gibco). Chondrocytes were seeded in a density of 1x105 cells/cm2 in 6-well plates (Cellstar; 
Greiner Bio-one International) for protein experiments, or in 24-wells plates (Cellstar; Greiner Bio-
one International) for gene expression experiments. Chondrocytes were cultured in monolayer 
for one week prior to experiments in DMEM/F12 supplemented with 10% fetal calf serum (FCS; 
Thermo Scientific), 100 mg/l pyruvate (Gibco), 100 U/ml penicillin and 100 mg/ml streptomycin 
in standard conditions [5% CO2 (v/v), 37 °C, 95% humidity]. Chondrocytes were serum-starved 
overnight in DMEM/F12 medium without FCS before start of the experiment. 
Chondrocyte cell line culture
Human G6 chondrocytes are adult articular chondrocytes derived from femoral head cartilage 
of an anonymous OA donor, transduced with a temperature-dependent SV40 large oncogene 
[23]. Consequently, the G6 chondrocytes proliferate at 32°C, but not at 37°C. G6 chondrocytes 
were cultured at 32°C under the same conditions as primary chondrocytes, except with 5% FCS. 
Two days before experiments were performed, G6 chondrocytes were cultured at 37°C to stop 
proliferation and serum-starved overnight in DMEM/F12 medium supplemented with 0.5% FCS. 
Culture with cytokines or pharmacological inhibitors
Serum starved primary chondrocytes and G6 chondrocytes were stimulated with rhTGF-β1 
(Biolegend), rhIL-1β (R&D systems), rhIL-6 (Biolegend), rhIL-6R (Biolegend) or a combination of 
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these proteins, for time periods and dosages indicated in figure legends. In experiments where 
inhibitors were used, dimethylsulfoxide (DMSO) (0.05% (v/v)) was used as vehicle control. To 
inhibit ALK5 kinase activity, SB-505124 (Sigma Aldrich) [24] was used in a concentration of 5 
μM. For inhibition of Janus kinases (JAKs), the pan-JAK inhibitor Tofacitinib (LC Laboratories) 
was used in a concentration of 1 μM. A humanized anti-IL-6R monoclonal antibody (Tocilizumab, 
RoActemra, Roche) was used to block IL-6 signaling at 1 μg/ml. Chondrocytes were pre-
incubated with the inhibitors 1 h prior to addition of rhTGF-β1. 
Protein measurement using Luminex technology
Luminex multianalyte technology on the Bio-Plex 200 system (Bio-Rad) in combination with 
multiplex cytokine kit (Bio-Rad) was used to study levels of IL-6 in 50 ml of chondrocyte 
culture supernatants after rhTGF-β1 stimulation. Samples below detection limit (0.40 pg/ml) 
were set at lowest measurable concentration to perform statistical analysis. 
Protein isolation and Western blot
Chondrocytes were lysed using lysis buffer (Cell Signaling) containing protease inhibitor cocktail 
(Roche Diagnostics). Cell lysates were sonicated on ice using a Bioruptor (Diagenode) [25]. 
Protein concentration was normalized between samples using a bicinchoninic acid assay 
(Thermo Scientific). Samples were boiled for 10 min at 95°C in Laemmli Sample buffer (1% SDS 
and 100mM Tris, pH 9.5). Proteins were separated on a 10% reducing bis-acrylamide SDS-PAGE 
gel, and transferred to a 0.45 μm pore nitrocellulose membrane using wet transfer (Towbin buffer, 
2h, 275 mA at 4°C). Non-specific antibody binding was blocked for 1 h with 5% non-fat dry milk 
(Campina) to detect IL-6R, β-actin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 
blocked in 5% bovine albumin serum to detect phosho-STAT3 (p-STAT3) or phospho-Smad2/3 
(p-Smad2/3), in TBS-T (15 mM Tris-HCl, pH 7.4, 0.1% Tween). Membranes were incubated 
overnight at 4°C with primary antibodies directed against IL-6R (polyclonal rabbit antibody, 
128008, 1:1000, Abcam) , p-STAT3 (polyclonal rabbit antibody, #9131, 1:1000, Cell Signaling), 
or p-Smad2/3 (polyclonal rabbit antibody, #3101, 1:1000, Cell Signaling) and afterwards labeled 
for 1 h with polyclonal Goat anti-Rabbit or Rabbit anti-Mouse coupled to horseradish peroxidase 
(1:1500, Dako) at RT. Enhanced chemiluminescence (ECL) was used to visualize proteins with 
ECL prime kit (GE Healthcare) and ImageQuant LAS4000 (Leica). GAPDH was used as loading 
control (mouse monoclonal antibody, 1G5, 1:10,000 Sigma Aldrich). ImageJ was used for 
quantification of the signal. 
RNA isolation and quantitative real-time PCR
RNA was isolated using Tri-reagent (Sigma-Aldrich) following manufacturer’s protocol. RNA 
concentrations were determined using a NanoDrop photospectrometer (Thermo Scientific). 
Thereafter, a maximum of 1 μg RNA was dissolved in ultrapure water and treated with 1 μl 
of DNAse (Life Technologies) for 15 min at room temperature to remove possible genomic 
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DNA, followed by incubation at 65°C with 1 μl EDTA (Life Technologies). Samples were reverse 
transcribed into complementary DNA (cDNA) using 1.9 μl ultrapure water, 2.4 μl 10x DNase 
buffer, 2.0 μl 0.1 M dithiothreitol, 0.8 μl 25 mM dNTPs, 0.4 μg oligo dT primer, 1 μl 200 U/ml MMLv-
reverse transcriptase (Life Technologies) and 0.5 μl 40U/ml RNAsin (Promega) and incubated for 
5 min at 25 °C, 60 min at 39 °C, and 5 min at 95 °C using a thermo-cycler. Gene expression was 
measured using SYBR Green Master Mix (Applied Biosystems) and 0.25 mM primers (see Table 
1) (Biolegio) with a StepOnePlus real-time PCR system (Applied Biosystems). The amplification 
protocol was 10 min at 95 °C, followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C. Melting 
curves were analyzed to confirm product specificity. To calculate the relative gene expression, 
the average of the reference genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 
ribosomal protein S27A (RPS27A) was used. 
Table 1. Template and sequence of the primers used in this study.










Quantitative data of gene expression analysis was expressed as column scatter or grouped 
category graphs and display mean values of separate experiments (G6 chondrocytes) or donors 
(primary chondrocytes) with corresponding 95% confidence interval (CI). Significance was tested 
using displayed means with repeated measures ANOVA followed by Dunnett’s or Bonferroni post-
test (see figure legends). Differences in IL-6 protein levels after rhTGF-β1 stimulation were tested 
using an unpaired two-tailed t-test. For each analysis, Gaussian distribution was tested using the 
D’Agostino-Pearson Omnibus K2 test. P < 0.05 was considered significant. All analyses were 
performed using Graph Pad Prism version 5.03 (GraphPad Software, La Jolla, CA).
 




TGF-β1 rapidly induces IL-6 in human chondrocytes 
To examine if TGF-β1 can regulate IL-6 expression, G6 chondrocytes were stimulated with 1.0 
ng/ml of TGF-β1. TGF-β1 significantly induced IL6 mRNA expression after 2 h, 4 h and 6 h by 
respectively 21-, 38- and 112-fold (4.4, 5.3, 6.8 ΔCt) (Fig. 1A). To validate these results, we 
performed the same experiment in freshly isolated primary chondrocytes of four different donors. 
Although variation between donors was observed, TGF-β1 induced a significant increase in IL6 
expression of on average 32-fold (5.0 ΔCt) at 4 h and 74-fold (6.2 ΔCt) at 6 h (Fig. 1B). Similar 
induction of IL6 expression was observed when 0.1 ng/ml of rhTGF-β1 was used, corresponding 
to TGF-β levels found in synovial fluid of healthy donors (Supplementary Fig. 1A) [26], We further 
confirmed these results on protein level, and observed a significant 20-fold increase in IL-6 
production after TGF-β1 stimulation of G6 chondrocytes (Fig. 1C). 
TGF-β1 induces phosphorylation of STAT3 via IL-6 receptor signaling
To investigate if TGF-β1-induced IL-6 leads to autocrine signaling, we investigated the pattern 
of p-STAT3, an IL-6R downstream signaling protein. TGF-β1 stimulation of G6 chondrocytes 
induced a clear increase in p-STAT3 at 2 h and 4 h (Fig. 2A). In contrast, total levels of STAT3 
protein were not changed by stimulation with rhTGF-β1. When we studied the p-STAT3 pattern 
in primary chondrocytes from different donors, we found that p-STAT3 was consistently 
upregulated by TGF-β1 at 2 h and 4 h in all donors. In two out of four donors, we observed 
a minor increase at 5-15 min, but this was not consistent throughout experiments. Because 
G6 chondrocytes and primary chondrocytes showed similar patterns of p-STAT3 induction by 
TGF-β1, we used G6 chondrocytes for further inhibitor studies. To test if TGF-β1-induced p-STAT3 
was IL-6R dependent, we stimulated G6 chondrocytes with TGF-β1 in presence of the IL-6R 
blocking antibody tocilizumab. As expected, induction of p-STAT3 by TGF-β1 was completely 
prevented by blockade of the IL-6R suggesting IL-6 dependency (Fig. 2B). To further explore 
which signaling proteins are responsible for induction of IL-6 and p-STAT3 via TGF-β1 we used 
small molecule inhibitors. Inhibition of TGF-β receptor (ALK5) kinase activity with SB-505124 
inhibited both induction of p-Smad2/3 and p-STAT3 at all time points after TGF-β1 stimulation 
(Fig. 2C). Furthermore, addition of the pan-JAK inhibitor tofacitinib completely prevented 
induction of p-STAT3 by TGF-β1 and even decreased baseline levels (Fig. 2D). This effect was 
not due to inhibition of the TGF-β signaling pathway, as the increase in p-Smad2/3 by TGF-β1 
was not inhibited by tofacitinib. Altogether, this shows that TGF-β1-induced p-STAT3 depends on 












































































































Figure 1. TGF-β1 stimulation of human chondrocytes rapidly induces IL-6. The human G6 chondrocyte 
cell line and primary human chondrocytes of four donors were stimulated in triplo with 1.0 ng/ml of rhTGF-β1 
for 2, 4 and 6 hours to study TGF-β1-induced IL6 gene expression using qPCR. (A) For G6 chondrocytes, 
the mean of three separate experimental repeats is shown with corresponding 95% confidence interval (CI). 
(B) For primary chondrocytes, the mean of four donors is shown with corresponding 95% CI, and individual 
donors are plotted showing mean ± SD of technical replicates (C) G6 chondrocytes were stimulated with 
1.0 ng/ml of rhTGF-β1 for 24 hours, after which the concentration of IL-6 in the supernatant was measured 
using Luminex technology. The means of three separate experiments are shown with corresponding 95% CI. 
* = P < 0.05; ** = P < 0.01, *** = P < 0.001 as measured by repeated measures ANOVA with Dunnett’s 
post-test (A, B) or unpaired two-tailed t-test (C).
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Figure 2. TGF-β1 stimulation leads to STAT3 phosphorylation, dependent on the IL-6R, as well as 
ALK5- and JAK-kinase activity. (A) The human G6 chondrocyte cell line and primary human chondrocytes 
of three donors were stimulated with 1.0 ng/ml of rhTGF-β1 for 5, 15, or 30 min and 1, 2, and 4 h, to study 
TGF-β1-induced STAT3 phosphorylation with Western Blot. (B) Tocilizumab (anti-IL-6R antibody) was used to 
investigate if TGF-β1-induced STAT3 phosphorylation was dependent on IL-6R signaling. G6 chondrocytes 
were pre-incubated with 1 μg/ml of Tocilizumab for 1 h, and afterwards stimulated with 1 ng/ml of rhTGF-β1 
for 4 h. Small molecule inhibitors for (C) TGF-β receptor kinase activity (SB-505124, 5 μM) and (D) JAK-
kinase activity (Tofacitanib, 1 μM) were used to investigate if TGF-β1-induced STAT3 phosphorylation was 
dependent on ALK5- or JAK kinase activity respectively. G6 chondrocytes were pre-incubated with inhibitors 
or vehicle for 1 h, and stimulated with 1 ng/ml of rhTGF-β1 for indicated time points. Western Blots shown are 
representative of at least three independent experiments. Toc: Tocilizumab; Med: medium; US: unstimulated. 
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TGF-β1 blocks IL-6-mediated gene expression of SOCS3 and limits STAT3 
phosphorylation 
We showed that TGF-β1 induces IL-6 signal transduction via activation of its downstream 
mediator STAT3. To investigate if the observed STAT3 phosphorylation results in gene 
transcription, mRNA expression of the well-known STAT3 target gene SOCS3 was measured, 
which itself is an important negative regulator of IL-6 signaling [27]. Because SOCS3 expression 
is immediately induced after p-STAT3 induction [28], we investigated the effect of TGF-β1 on 
SOCS3 expression at 6 h, shortly after TGF-β1 induction of p-STAT3 (2-4 h). Surprisingly, we 
did not find any evidence of an increase in SOCS3 mRNA expression by TGF-β1 (Fig. 3A). Also 
addition of tocilizumab, which blocks TGF-β1-induced IL-6 signaling, did not significantly change 
SOCS3 expression. In contrast, stimulation of G6 chondrocytes with 10 ng/ml of recombinant 
IL-6 did lead to a significant increase in SOCS3 expression of 3.0-fold (1.6 ΔCt), confirming that 
SOCS3 is an IL-6/STAT3 target gene in our experimental setting (Fig. 3A). Thus, stimulation with 
IL-6 alone increased SOCS3 expression, but stimulation with TGF-β1 did not, while this ultimately 
also leads to IL-6 production. This suggests that TGF-β1 blocks IL-6-induced regulation of 
SOCS3 expression. To further prove that TGF-β1 indeed inhibits IL-6 effects, we investigated 
if TGF-β1 could also block the effects of recombinant IL-6. We performed pre-treatment with 
TGF-β1 for a 6 h period, mimicking the setting where cells are first exposed to TGF-β1 and 
afterwards to IL-6. Interestingly, activation of STAT3 after rhIL-6 exposure was inhibited by TGF-β1 
pre-treatment, but p-STAT3 levels were not fully reduced to baseline level (Fig. 3B). Furthermore, 
TGF-β1 pre-treatment completely prevented rhIL-6-induced SOCS3 expression (Fig. 3C). These 
data demonstrate that TGF-β1 inhibits the IL-6 response in chondrocytes, despite upregulating 
IL-6 itself. 
TGF-β1 potently decreases IL-6 receptor levels in articular chondrocytes
Next, we studied the effects of TGF-β1 on the IL-6R, a potential mechanism via which TGF-β 
could regulate IL-6 intracellular signaling. Interestingly, we observed that TGF-β1 stimulation 
led to a striking decrease in IL6R expression in G6 chondrocytes after 4 h (13-fold, 3.7 ΔCt) 
and 6 h (8-fold, 3.0 ΔCt) (Fig. 4A). This effect of TGF-β1 also held true in primary chondrocytes 
derived from different donors, showing that the effect of TGF-β on IL6R expression is not donor 
specific. In primary chondrocytes, TGF-β1 significantly decreased IL6R expression after both 
4 h and 6 h with an average of 2.75-fold (1.5 ΔCt) and 3.2-fold (1.7 ΔCt) respectively (Fig. 4B). 
In addition, 0.1 ng/ml of rhTGF-β1, a concentration reflecting TGF-β levels in synovial fluid of 
healthy donors [26], decreased IL6R expression to the same extent (Supplementary Fig. 1B).
To investigate if other factors stimulating IL-6 production can also regulate IL6R expression, 
we included stimulation with the pro-inflammatory cytokine IL-1β, a known inducer of IL-6. As 
expected, IL-1β did strongly elevate IL6 expression by 1024-fold (10.0 ΔCt) after 4-6 h, even to a 
higher extent than TGF-β1 (Fig. 4C). Interestingly, in contrast to TGF-β1, IL-1β did not significantly 
change the expression of IL6R in G6 chondrocytes. This suggests that IL-6 itself is not involved in 
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regulation of IL6R expression. Also on protein level, we observed significantly lower IL-6R levels 
after 24 h of TGF-β1 stimulation of G6 chondrocytes, while IL1β even increased IL-6R levels (Fig. 
4D). These data show that TGF-β1 decreases IL-6R expression, which could explain why TGF-β1 


































































Figure 3. TGF-β1 blocks IL-6 mediated gene expression of SOCS3 and limits STAT3 phosphorylation. 
(A) To investigate the downstream effects of TGF-β1-induced IL-6 signaling, G6 chondrocytes were pre-
incubated with 1 μg/ml of Tocilizumab to block IL-6R signaling, and stimulated with TGF-β1 for 6 h. Expression 
level of the STAT3 target gene SOCS3 was measured as a read-out for IL-6-mediated gene expression. (B, 
C) To study the effect of TGF-β1 on signaling of exogenous rhIL-6, human G6 chondrocytes were pre-
stimulated with or without 1.0 ng/ml of rhTGF-β1 for 6 hours, and afterwards stimulated with rhIL-6 (10 ng/
ml). The IL-6 response was measured by induction of STAT3 phosphorylation after 30 min (B) or induction of 
SOCS3 mRNA after 6 h (C). For Western Blot is representative of three independent experiments. For gene 
expression results, the means of three or four separate experimental repeates are plotted with corresponding 
± 95% CI. * = P < 0.05; ** = P < 0.01, *** = P < 0.001 as measured by repeated measurements ANOVA 

































































































































































































Figure 4. TGF-β1 potently decreases IL-6 receptor levels in both G6 and primary chondrocytes. 
To investigate the effect of TGF-β1 on expression of the IL6R, G6 chondrocytes and primary human 
chondrocytes of four donors were stimulated in triplicate with 1.0 ng/ml of rhTGF-β1 for 2, 4 or 6 hours. (A) 
For G6 chondrocytes, the mean of three separate experimental repeats is shown with corresponding 95% CI. 
(B) For primary chondrocytes, the mean of four donors is shown with corresponding 95% CI, and individual 
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donors are plotted showing mean ± SD of technical replicates. (C) G6 chondrocytes were stimulated with 
1.0 ng/ml of rhTGF-β1 or 1.0 ng/ml of rhIL-1β for 2, 4 or 6 hours to study effects on IL6 and IL6R expression. 
Mean of four separate experimental repeats is shown with corresponding 95% CI. (D) G6 chondrocytes were 
stimulated with 1.0 ng/ml of rhTGF-β1 or 1.0 ng/ml of rhIL-1β for 6 h and 24 h to determine effects on IL-6R 
protein expression using Western Blot. Western blots are representative of four independent experiments. 
Quantification of the Western Blot was performed by Image J. Quantitative values of IL-6R protein intensity 
were first corrected for GAPDH values, and then plotted as fold change (%) compared to US samples. * 
= P < 0.05; ** = P < 0.01, *** = P < 0.001 as measured by one-way ANOVA with Dunnett’s (A, B, C)or 
Bonferroni (D) post-test. US: unstimulated. 
TGF-β1 blocks the IL-6 response by decreasing IL-6 receptor levels 
To determine the consequences of TGF-β1-mediated down regulation of IL-6R expression, we 
investigated if TGF-β1-mediated inhibition of IL-6 signaling was dependent on reduced IL-6R 
levels. We performed pre-treatment with TGF-β1 for a 6 h period, to ensure that IL-6R levels were 
decreased before stimulation with rhIL-6. In addition, we rescued IL-6R levels using a soluble 
form of the IL-6R. Strikingly, levels of p-STAT3 were dose-dependently increased after adding 
soluble IL-6R, showing that TGF-β1 inhibition of rhIL-6-induced p-STAT3 is dependent on the IL-
6R (Fig. 5A). On gene expression level, the addition of rhIL-6R also restored induction of SOCS3 
expression by rhIL-6 in the presence of TGF-β1 (Fig. 5B). Moreover, the expression of additional 
IL-6-responsive genes, MMP1, BCL3 and SAA1, was comparably regulated. Pre-treatment 
with rhTGF-β1 clearly inhibited the induction of these genes by rhIL-6, which was abolished by 
addition of rhIL-6R. Altogether, this indicates that TGF-β1 dampens IL-6 effects on chondrocytes 






















































































































































































































Figure 5. TGF-β1-mediated inhibition of IL-6 signaling is dependent on decreased IL-6R levels. To 
study the effect of TGF-β1 on IL-6 signaling with or without recombinant IL-6R, human G6 chondrocytes were 
pre-stimulated with 1.0 ng/ml of rhTGF-β1 for 6 h, and afterwards stimulated with rhIL-6 (10 ng/ml) alone or 
in combination with rhIL-6R (1, 10 and 100 ng/ml). The IL-6 response was measured by induction of p-STAT3 
after 30min of IL-6 stimulation (A) or induction of SOCS3, MMP1, BCL3 and SAA1 expression after 6 h (B). 
Western blots are representative of three independent experiments. For gene expression studies, the means 
of four separate experimental repeates are plotted with corresponding ± 95% CI. * = P < 0.05; ** = P < 
0.01, *** = P < 0.001 as measured by repeated measures ANOVA with with Bonferroni’s post-test. 














TGF-β-induced IL-6 binds to IL-6R
TGF-β decreases
 IL-6R expression
TGF-β induces IL-6 
production
Gene expression
Figure 6. Schematic overview of TGF-β1-mediated regulation of IL-6 signaling in chondrocytes. 
TGF-β1 induces the release of IL-6 in human articular chondrocytes. Released IL-6 binds in an autocrine 
manner to membrane-bound IL-6 receptor on chondrocytes and leads to phosphorylation of the intracellular 
signaling mediator STAT3. Simultaneously, TGF-β1 decreases IL-6 receptor expression on chondrocytes, 
resulting in limited STAT3 phosphorylation and inhibition of STAT3-responsive target genes. 
DISCUSSION
In this study we identified TGF-β as a key regulator of the IL-6 signaling pathway in articular 
chondrocytes. We show that articular chondrocytes can produce IL-6 in response to TGF-β1, but 
that downstream signaling is limited. We show that this inhibition is facilitated by down regulation 
of the IL-6R by TGF-β1, a unique mechanism which had never been reported until now. 
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IL-6 is a pleiotropic cytokine that has an essential role in regulating immune response and 
defense [29]. In OA, levels of IL-6 are enhanced in serum and the synovial fluid and correlate 
with disease progression [16, 17]. Within the joint, both synoviocytes and chondrocytes can 
produce IL-6 and several inflammatory factors are known to increase IL-6 production [30-32]. 
We show that also stimulation with TGF-β1, a homeostatic regulator of cartilage, leads to IL-6 
production in chondrocytes. Only Guerner et al. previously studied regulation of IL-6 production 
in chondrocytes in response to both catabolic and anabolic factors. They reported that TGF-β, 
but not epidermal-, insulin-, or platelet derived-growth factor, increased the production of IL-6 by 
chondrocytes [33]. This observation was surprising, because TGF-β is perceived as a homeostatic 
regulator of cartilage [8]. In contrast, IL-6 is mainly recognized as a catabolic mediator that 
activates MMPs and ADAMTSs enzymes, contributing to cartilage degradation [14, 15, 34, 35]. 
Interestingly, we discovered that IL-6 induced by TGF-β1 did not lead to downstream induction 
of the STAT3 target gene SOCS3. Furthermore, TGF-β1 blocked the effects of recombinant IL-6, 
by limiting STAT3 phosphorylation and blocking induction of SOCS3. Together, this suggests that 
the presence of TGF-β can block downstream IL-6 signaling and thereby protect chondrocytes 
from the catabolic effects of IL-6. 
Inhibition of IL-6 signaling by TGF-β had not yet been reported in articular chondrocytes. Also 
in other cell types only few studies investigated inhibitory effects of TGF-β on IL-6 signaling. In 
T-cells it has been shown that TGF-β inhibits IL-6-induced SOCS3 expression, thereby promoting 
Th17 development [20]. However, TGF-β did not reduce IL-6-mediated p-STAT3, in contrast to 
our results. This implies that in T-cells there might be specific inhibition of SOCS3, and not a 
general inhibition of IL-6 effects. In intestinal epithelial cells, TGF-β inhibits IL-6 signaling in a 
similar manner as we observed in chondrocytes [18]. Pre-treatment with TGF-β inhibited IL-6-
mediated induction of both p-STAT1 and p-STAT3, as well as IL-6-induced gene expression of 
ICAM [18]. Until now it was unclear via which mechanism TGF-β blocked IL-6 signaling.
In this study, we demonstrate that TGF-β1 can block IL-6 signaling via decreasing IL-6R levels. 
Because cartilage contains large amounts of inactive TGF-β, which can be activated upon 
loading, TGF-β-mediated down regulation of IL-6R could be involved in homeostatic regulation 
of cartilage [4, 11]. This is an entirely new concept, as there is no literature reporting that TGF-β 
decreases IL-6R levels in cartilage. This effect of TGF-β might be independent of IL-6, as we 
showed that IL-1β increased IL-6 production but did not affect IL-6R expression. In literature, 
inflammatory factors such as LPS and IL-1β are mainly known to increase IL6R expression 
[36, 37]. However, this seems to be cell type specific as IL-1β decreases IL6R expression in 
monocytes, but increases its levels in hepatocytes [38]. Therefore, it is possible that TGF-β 
effects on IL-6R expression could be specific for cartilage and TGF-β differently affects the IL-6 
signaling pathway in other tissues or cell types. Interestingly, multiple studies report that IL6R 
expression is directly regulated by various miRNA’s (miR-34a, miR-218, miR-590-5p) [39-41]. 
TGF-β DAMPENS IL-6 SIGNALING IN CHONDROCYTES VIA IL-6R SUPPRESSION
77
3
Several of these miRNA’s have been linked to the TGF-β signaling pathway, and direct regulation 
of miR-34a by TGF-β has been described [40]. Follow-up studies are needed to show that TGF-β 
suppression of IL-6R expression is caused by TGF-β-induced miRNAs.
Besides regulation of IL-6R expression, it is possible that TGF-β blocks other mediators of IL-6 
signaling downstream of the receptor as well. Interaction at the level of downstream mediators 
Smad3 and STAT3 has been extensively reported [42, 43]. These studies demonstrate that 
complex formation between Smad3 and STAT3 can lead to either inhibition of TGF-β signaling 
or synergy with STAT3 signaling cytokines, dependent on cell type or context [44]. Complex 
formation between Smad3 and STAT3 has not been studied in chondrocytes until now, but it 
is possible that these complexes are formed within our experimental setting and contribute 
to regulation of IL-6 signaling by TGF-β. However, we showed that TGF-β-mediated down 
regulation of IL-6R expression was the rate limiting factor, as rescuing IL-6R levels with soluble 
IL-6R abolished the inhibitory effect of TGF-β on IL-6 signaling. 
Next to a human chondrocyte cell line, we used human primary chondrocytes derived from 
macroscopically intact cartilage of OA patients in this study to investigate if our hypothesis held 
true in freshly isolated chondrocytes from different donors. Between the different individuals we 
observed diversity in the magnitude of TGF-β effect size, more specifically in the regulation of IL-6 
and IL-6R mRNA expression by TGF-β1. Moreover, we observed rapid p-STAT3 activation (5-15 
min) in two donors. Direct activation of STAT3 was previously detected in hepatic stellate cells, 
but not in normal hepatocytes, indicating that this pathway is strongly cell-context dependent 
[45]. In this study, early p-STAT3 activation was caused by direct binding of JAK3 to TGF-βRI. It is 
therefore possible that the basal levels of TGF-β receptors (ALK5 vs ALK1), determines the early 
p-STAT3 peak in our setting [12]. However, this can also be caused by different factors, such as 
gender, age, disease severity or OA phenotype, which we were unable to study due to the use of 
anonymized material. It would be interesting for future research to establish whether rapid STAT3 
activation represents a specific patient group.
Next to membrane-bound IL-6R present on the cell membrane, also a soluble form of the IL-6R 
exists. Soluble IL-6R results from shedding of membrane-bound IL-6R or from differential splicing 
of IL-6R mRNA and can form a complex with IL-6 and IL-6 receptor β (gp130), bypassing the need 
of membrane-bound IL-6R [46, 47]. Interestingly, endogenous soluble IL-6R can be detected in 
synovial fluid of OA patients and contributes to enhanced activation of chondrocytes by IL-6 
[48-50]. This process, called trans-signaling, has been shown to negatively affect cartilage. For 
example, the IL-6/IL-6R complex can decrease transcription of the matrix components aggrecan 
and collagen type II in chondrocytes [34, 35]. This implies that in OA, the presence of soluble IL-
6R may bypass the need of membrane bound IL-6R, which would abolish the protective effects 
of TGF-β on membrane bound IL-6R levels similar to our experiments where we add exogenous 
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rhIL-6R (Fig. 5). We propose that the presence of soluble IL-6R bypasses protective TGF-β 
effects, rendering cartilage sensitive again for catabolic IL-6 trans-signaling. These implications 
would highlight soluble IL-6R as an important target for therapies directed against IL-6. 
In conclusion, we show that TGF-β1 dampens IL-6 signaling in chondrocytes, despite upregulating 
IL-6 levels. Moreover, we demonstrate that TGF-β1 inhibits IL-6 effects via down regulation of 
the IL-6R. This reveals a novel, protective effect of TGF-β potentially contributing to cartilage 
homeostasis. We suggest that when this protective effect is lost, due to the presence of soluble 
IL-6R during inflammation, cartilage is more sensitive to catabolic IL-6 signaling. This sheds light 
on the protective role of TGF-β in cartilage homeostasis and OA development. 



















































































































Supplementary Figure 1. Physiological levels of rhTGF-β1 (0.1 ng/ml) affect IL-6 and IL-6R 
expression in human articular chondrocytes. To investigate the effect of physiological levels of TGF-β1 
on expression of IL-6 (A) and IL6R (B), primary human chondrocytes of three donors were stimulated in 
triplicate with 0.1 ng/ml of rhTGF-β1 for 2, 4 or 6 hours. The mean of three donors is shown with corresponding 
95% CI, and individual donors are plotted showing mean ± SD of technical replicates.
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Osteoarthritis (OA) development is strongly associated with ageing, possibly due to age-related 
changes in transforming growth factor-β (TGF-β) signaling in cartilage. Recently, we showed 
that TGF-β suppresses interleukin (IL)-6 receptor (IL-6R) expression in chondrocytes. As IL-6 is 
involved in cartilage degeneration, we hypothesized that age-related loss of TGF-β signaling 
results in increased IL-6R expression and signaling in ageing cartilage. 
Design
Bovine articular cartilage was collected and immediately processed to study age-related 
changes in IL-6R expression using qPCR and IHC (age-range: 0.5-14 years). Moreover, cartilage 
from young and aged cows was stimulated with rhIL-6 and/or rhTGF-β1 to measure IL-6-induced 
p-STAT3 using Western blot. Expression of STAT3-responsive genes was analyzed using qPCR. 
Results
Expression of IL-6 receptor (bIL-6R) significantly increased in cartilage upon ageing (slope: 0.32, 
95%CI: 0.20-0.45), while expression of glycoprotein 130 (bGP130) was unaffected. Cartilage 
stimulation with IL-6 showed increased induction of p-STAT3 upon ageing (slope: 0.14, 95%CI: 
0.08-0.20). Furthermore, IL-6-mediated induction of STAT3-responsive genes like bSOCS3 and 
bMMP3 was increased in aged compared to young cartilage. Interestingly, the ability of TGF-β 
to suppress bIL6R expression in young cartilage was lost upon ageing (slope: 0.21, 95%CI: 
0.13-0.30). Concurrently, an age-related loss in TGF-β-mediated suppression of IL-6-induced 
p-STAT3 and bSOCS3 expression was observed.
Conclusions
Ageing results in enhanced IL-6R expression and subsequent IL-6-induced p-STAT3 signaling 
in articular cartilage. This is likely caused by age-related loss of protective TGF-β signaling, 
resulting in loss of TGF-β-mediated IL-6R suppression. Because of the detrimental role of IL-6 in 
cartilage, this mechanism may be involved in age-related OA development. 




Osteoarthritis (OA) development is strongly associated with ageing, but this relationship 
is incompletely understood. It has become apparent that age-related changes in the 
musculoskeletal system contribute to OA development, together with other factors such as joint 
injury, genetic alterations and obesity [1]. Age-related changes in articular cartilage have been 
studied in particular, identifying major changes in chondrocyte phenotype. Ageing is associated 
with a decreased ability of chondrocytes to produce matrix proteins, while their production of 
pro-inflammatory and catabolic mediators is increased [2]. This can partly be explained by an 
age-related reduction in chondrocyte responsiveness to crucial anabolic growth factors such 
as insulin-like growth factor-1 (IGF-1) and transforming growth factor-β (TGF-β) [3, 4]. We have 
previously shown that TGF-β-family signaling is decreased in murine and bovine cartilage with 
ageing, consequently affecting matrix repair and degeneration [4-6]. Moreover, we showed that 
TGF-β counteracts IL-1β-mediated nitric oxide production and suppression of proteoglycan 
synthesis in young but not in old mice [7]. These observations suggest that age-related loss of 
TGF-β function not only has implications for anabolic properties of chondrocytes, but possibly 
also for protection against pro-inflammatory stimuli. 
The pro-inflammatory cytokine interleukin-6 (IL-6) is involved in the pathophysiology of several 
age-related diseases such as osteoporosis and Alzheimer’s disease [8, 9]. IL-6 binds to the IL-6 
receptor α subunit (IL-6R), followed by complex formation with signal transducer glycoprotein 130 
(GP130) [10]. Besides IL-6 signaling, GP130 is involved in signal transduction of several other 
IL-6 family cytokines such as oncostatin M (OSM), IL-11, IL-27 and leukemia inhibitory factor (LIF) 
[11]. After assembly of the IL-6 receptor complex, associated Janus kinases (JAKs) are activated 
intracellularly, which in turn recruit and activate signaling mediators such as signal transducers 
and activator of transcription (STAT)3 [12]. IL-6 has a pivotal role in OA pathophysiology and 
cartilage degeneration, mostly via the induction of pro-inflammatory mediators and extracellular 
matrix degrading enzymes. In articular chondrocytes, IL-6 induces expression of matrix 
metalloproteinases (e.g. MMP-3 and MMP-13), as well as disintegrin and metalloproteinase with 
thrombospondin motifs (e.g. ADAMTS-4 and ADAMTS-5) [13-15]. Moreover, blockade of either 
IL-6 or its receptor in experimental OA models significantly protects against cartilage degradation 
[13, 16]. Systemic levels of IL-6 increase with normal ageing [17, 18], and are associated with 
OA development [19-21]. However, it is unclear whether there is a causal relation between IL-6 
and age-related OA development. We previously showed that TGF-β is a potent inhibitor of IL-6 
effects in chondrocytes, via decreasing IL-6R expression [22]. This protective mechanism might 
be disturbed in ageing cartilage, due to age-related loss of TGF-β signaling. In this study, we 
investigated if TGF-β-mediated suppression of IL-6R is lost in aged cartilage, and whether this 
subsequently results in increased IL-6 signaling. This could be a potential mechanism via which 




Sample collection and stimulation
Bovine articular cartilage explants were harvested from metacarpophalangeal (MCP) joints of 86 
individual cows with different ages. These donors were divided along the different experiments 
(Fig. 1, Fig. 2, Fig. 3, Fig. 4, Supplemental Figures), where each cow was considered as an 
independent donor. For experiments in which a broad age-range was studied, cartilage from 
cows aged 6 months up to 14 years old was included. Moreover, two age groups were defined 
to study young versus old cartilage. To exclude the effects of skeletal immaturity before the 
age of 3 years, cows aged 3-5 years were defined as young. Cows of approximately 10 years 
old (9-12 years) were defined as aged, as it was previously shown that cartilage of 10-year old 
cows shows well-known characteristics of ageing [6]. Cow legs were obtained within 3 h post 
mortem from a local abattoir, after which joints were immediately opened in a sterile environment 
to expose cartilage surface. Joints were examined for macroscopical signs of OA, and only 
cows with an intact cartilage surface were included. One joint per cow was used in this study. 
Full thickness cartilage explants were harvested from four condyles of the MCP joint using a 3 
mm biopsy punch (Kai Medical). Cartilage explants from each individual cow were pooled and 
randomized to exclude bias due to sampling location. Per sample, four randomized explants 
from the same cow were used. For experiments in which isolated bovine chondrocytes were 
used (Supplemental Fig. 2), cartilage was digested overnight using Collagenase B (1.5 mg/
ml, Roche Diagnostics) in DMEM/F12 medium (Gibco). Cartilage explants were shortly rinsed 
in saline and either flash-frozen in liquid nitrogen and stored at -80°C until later use, or cultured 
overnight in a 24-well plate (Cellstar; Greiner Bio-one International) in Dulbecco’s Modified 
Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12 (Gibco)) without serum, supplemented with 
100 mg/l pyruvate (Gibco), 100 U/ml penicillin and 100 mg/ml streptomycin in standard culture 
conditions (5% CO2 (v/v), 37 °C, 95% humidity). After overnight serum starvation, explants were 
stimulated with rhBMP-9 (R&D Systems), rhIL-6 (Biolegend) and/or rhTGF-β1 (Biolegend) for time 
periods and dosages as indicated in figure legends. To reflect physiological levels of TGF-β1 in 
bovine cartilage, 1 ng/ml of rhTGF-β1 was used [23]. For RNA and protein studies, two samples 
(biological replicates) were included per experimental condition, each consisting of four explants 
from the same cow. For inhibitor studies, cartilage explants were pre-incubated with the ALK5 
kinase inhibitor SB-505124 (5.0 μM, Sigma Aldrich) or TAK1 kinase inhibitor (5Z)-7-Oxozeaenol 
(0.5 μM, Tocris Bioscience) for 1 h before stimulation with rhTGF-β1. DMSO was used as vehicle 
control.
RNA isolation and quantitative real-time PCR
Cartilage explants were homogenized using a Mikro-dismembrator (1 min, 1500 rpm, Braun 
Biotech International). Total RNA was subsequently isolated with a RNeasy Fibrous Tissue 
Mini Kit (Qiagen) according to manufacturer’s protocol. Thereafter, 8 μl sample was treated 
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with 1 μl of DNAse (Life Technologies) for 15 min at room temperature (RT) to remove possible 
genomic DNA, followed by inactivation of DNAse by incubation at 65°C with 1 μl 25 mM EDTA 
(Life Technologies). RNA was reverse transcribed into cDNA with single step RT reaction as 
previously described [22]. Gene expression was measured using SYBR green mastermix 
(Applied Biosystems) and validated primers (Biolegio; Table 1) using a StepOnePlus real-time 
PCR system (Applied Biosystems). The following amplification protocol was used: 10 min at 95 
°C, 40 cycles of 15 s at 95 °C and 1 min at 60 °C. Melting curves were performed to confirm gene 
specific amplification. Data was expressed as relative gene expression corrected for the average 
of two reference genes (bGAPDH, bRPS14) depicted as −ΔCt, or corrected for reference genes 
and unstimulated control depicted as ΔΔCt. To determine the fold change in gene expression, 
log base 2 of ΔΔCt was calculated (2-∆∆CT). 
Protein isolation and detection
Cartilage explants were homogenized using a Mikro-dismembrator (1 min, 1500 rpm, Braun 
Biotech International). Samples were dissolved in 800 μl ice cold radioimmunoprecipitation 
assay (RIPA) buffer, with added 1 mM Na3VO4 and protease inhibitor cocktail (Complete, Roche) 
and incubated for 1 h on a roller bench at 4 °C. Samples were centrifuged for 3 min at 13,500 × 
g at 4 °C, where after the pellet was discarded and supernatant was boiled for 10 min at 95 °C. 
Proteins were separated using a 10% reducing bis-acrylamide SDS-PAGE gel, and transferred 
to a 0.45 μm pore nitrocellulose membrane (Life Sciences) using wet transfer (Towbin buffer, 2 h, 
275 mA at 4 °C). Non-specific protein binding was blocked for 1 h with 5% bovine albumin serum 
to detect phosphorylated-STAT3 (p-STAT3) or with 5% non-fat dry milk (Campina) to detect 
GAPDH, dissolved in TBS-T (15 mM Tris-HCl, pH 7.4, 0.1% Tween). Membranes were incubated 
overnight at 4 °C with primary antibodies directed against p-STAT3 (polyclonal rabbit antibody, 
#9131, 1:1000, Cell Signaling) or GAPDH (mouse monoclonal antibody, 1G5, 1:10,000 Sigma 
Aldrich). After overnight incubation, membranes were incubated for 1 h with polyclonal Goat anti-
Rabbit or Rabbit anti-Mouse coupled to horseradish peroxidase (1:1500, Dako) at RT. Enhanced 
chemiluminescence (ECL) was used to visualize proteins with ECL prime kit (GE Healthcare) and 
ImageQuant LAS4000 (Leica). Finally, blots were quantified using ImageJ.
Immunohistochemical analysis
For histological analysis, four explants per individual cow were harvested (5 young and 5 aged 
cows). Directly after isolation cartilage explants were fixed in 4% phosphate-buffered formalin (pH 
7.0) for 16 h. Subsequently, samples were dehydrated using an automated tissue-processing 
apparatus (Thermo Scientific Excelsior AS) and embedded in paraffin. Sections of 4 μm were cut 
and mounted on Superfrost plus glass slides (Thermo Scientific). Sections were deparaffinized 
and washed with PBS. Endogenous peroxidase activity was blocked using 1% hydrogen 
peroxidase in methanol for 30 min at RT. Antigen-retrieval was performed using citrate buffer (0.1 
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in 3% FCS/ 3% normal goat serum in PBS for 1 h at RT. Sections were incubated overnight at 
4 °C with primary antibody directed against IL-6R in blocking solution (Abcam, ab128008, 0.2 
μg/ml). A rabbit IgG isotype antibody (0.2 μg/ml, Dako) was used as a negative control. After 
staining with primary antibodies, a biotin-streptavidin detection system was used according 
to the manufacturer’s protocol (Vector Laboratories). Antibody complexes were visualized 
with diaminobenzidine and counterstained with hematoxylin for 30 sec to visualize total cells. 
The number of positive cells was determined in a given threshold using ImageJ analysis, and 
expressed relative to total cell number. Per individual cow, four cartilage explants were stained 
for IL-6R protein, and pictures (100 x magnification) were taken from each individual explant for 
image analysis In each explant, the number of positive cells and total cells was counted using 
the cell counter plugin of ImageJ. For statistical analysis, the mean value per individual cow was 
used.   
Statistical analysis
Quantitative data of individual cows of age range 0.5-14 years is plotted with a solid line 
representing the best fit regression analysis and 95% confidence interval (CI) as a dotted line 
(Fig. 1A, Fig. 2B, Fig. 4A, B). Quantitative data of young versus aged cows were expressed as a 
grouped column scatter of multiple biological replicates with displayed mean ± 95% CI. Before 
each analysis, Gaussian distribution was tested using the D’Agostino-Pearson Omnibus K2 test. 
The difference in IL-6R protein level between young and aged cows was tested using an unpaired 
two-tailed t-test (Fig. 1C). Differences in expression of IL-6 responsive genes were analyzed by 
comparing IL-6-stimulated conditions versus medium control (repeated measurements ANOVA), 
and by comparing young versus aged cows (normal ANOVA) both followed by Bonferroni’s 
post-test to take multiple comparisons into account (Fig. 2C, Fig. 3). The effect of TGF-β on IL-
6-mediated induction of p-STAT3 and bSOCS3 in young and aged cows was equally analyzed 
(Fig. 4D, E). P < 0.05 was considered significant. All analyses were performed using Graph Pad 
Prism version 5.03 (GraphPad Software).
RESULTS
Expression of IL-6 receptor increases with age in bovine articular cartilage 
Previously, it was demonstrated that bovine cartilage ranging 9 months - 10 years old shows 
well-known characteristics of normal ageing, such as thinning of the cartilage surface, reduced 
chondrocyte numbers, and decreased expression of matrix components such as collagen type 
2 and aggrecan [6, 24]. Therefore, we collected 30 bovine donors of a similar age-range to study 
age-related changes in IL-6 receptor expression. On gene expression, bovine IL6R (bIL6R) levels 
increased with advancing age as determined with regression analysis (slope: 0.32, 95%CI: 0.20 



































































































Figure 1. Age-related changes in interleukin-6 receptor expression in bovine cartilage. (A) Relative 
gene expression of bovine interleukin-6 receptor (bIL-6R) and glycoprotein 130 (bGP130) as determined by 
qPCR in ageing bovine cartilage. Cartilage was collected from 30 different cows ranging from 6 months -14 
years old and directly frozen in liquid N2 followed by RNA isolation and qPCR. Regression analysis (solid 
line) is depicted with corresponding confidence interval (dotted line). (B) Immunohistochemistry staining 
of IL-6R in young cartilage (3-5 years old) versus aged cartilage (9-12 years old). Cartilage was directly 
processed after collection. Pictures are representative of five cows per age group. Scale bars = 100 µm. (C) 
Quantification of percentage of cells positively stained for IL-6R in cartilage of young and aged cows. Using 
a fixed threshold in ImageJ, number of positive cells and total cells was counted in sections of four different 
cartilage explants per cow. Mean of four sections was calculated and plotted for five animals per age group. 
** = P < 0.01 as measured by unpaired two-tailed t-test.
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of bGP130 (slope: 0.01, 95%CI: -0.03 - 0.23). To validate the age-related changes in bIL6R gene 
expression on protein level we performed immunohistochemical staining for IL-6R in young and 
aged cartilage. IL-6R was clearly detectable in bovine articular cartilage, with staining throughout 
the superficial, middle and deep zone of the cartilage (Fig. 1B). In contrast, no staining was 
observed when an isotype control antibody was used (Supplementary Fig. 1). In line with our 
observations on gene expression, the percentage of chondrocytes positively stained for IL-6R 
was increased in aged cartilage compared to young cartilage (17.70% increase, 95%CI: 8.65 - 
26.76)(Fig. 1C). 
Ageing increases IL-6 mediated phosphorylation of STAT3 and induction of SOCS3 
expression 
Next, we determined if the observed age-related increase in IL-6R expression translated to 
enhanced activation of intracellular signaling. To study this, we stimulated cartilage explants ex 
vivo with rhIL-6 (100 ng/ml) for 30 min and measured activation of the main IL-6R downstream 
signaling protein STAT3 [12]. Stimulation with rhIL-6 resulted in a clear induction of p-STAT3 in 
bovine cartilage, which was markedly increased with advancing age (slope: 0.14, 95%CI: 0.08 
- 0.20, n = 17) (Fig. 2A, B). In addition, we studied gene expression of the rapidly activated 
STAT3-target gene SOCS3 in young versus aged cartilage after stimulation with a high (100 ng/
ml) or suboptimal (25 ng/ml) dose of rhIL-6. Dose of rhIL-6 was determined with a dose-response 
study in bovine chondrocytes (Supplemental Fig. 2). Expression of bSOCS3 was increased by 
both concentrations of rhIL-6 compared to control medium, and reached maximum induction at 
1 h after stimulation (Fig. 2C, D). Strikingly, induction of bSOCS3 expression was higher in aged 
compared to young cartilage, but only in response to a suboptimal dose of rhIL-6 (2.3-fold, 1.2 
ΔCt [95%CI: 0.52 - 1.91]). Stimulation with a high dose of rhIL-6 resulted in comparable induction 
of bSOCS3 in young and aged cartilage (~4.9-fold, ~2.3 ΔCt [95%CI: 1.40 - 2.90]). Baseline 
expression values of bSOCS3 and a more extensive time course analysis (1 h - 2 h - 4 h) are 
shown in (Fig. 2D), illustrating inter-individual variation in expression kinetics. Collectively, these 
data clearly show that IL-6-induced intracellular signaling via p-STAT3 and subsequent SOCS3 












































































































































95% CI: 0.08 - 0.20
Figure 2. Aged cartilage shows increased induction of p-STAT3 and SOCS3 expression in response 
to IL-6. (A) To study age-related changes in IL-6 intracellular signaling in cartilage, cartilage explants from 
17 different cows (6 months - 14 years) were stimulated ex vivo with rhIL-6 (100 ng/ml) for 30 min and STAT3 
phosphorylation was visualized using Western blot. Representative image of a young cow (1 year) and old 
cow (10 years) are shown. Quantification of Western blot of all cows is shown in (B). p-STAT3 levels were 
normalized to GAPDH levels and plotted as relative staining compared to control condition. Regression 
analysis (solid line) is depicted with corresponding confidence interval (dotted line). (C, D) To study age-
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related changes in IL-6-mediated gene expression, cartilage from five young cows (3-5 years) and five old 
cows (9-12 years) was stimulated ex vivo with 25 ng/ml or 100 ng/ml of rhIL-6 for 1 h, 2 h, and 4 h. Expression 
of bovine SOCS3 (bSOCS3) was measured using qPCR (C) Expression of bSOCS3 after 1 h of IL-6 
stimulation was corrected for reference genes (bGAPDH, bRPS14) and expressed relatively to unstimulated 
control (ΔΔCt). Plotted as grouped column scatter with mean ± 95% CI. (D) Relative expression of bSOCS3 
after 1 h, 2 h and 4 h corrected for reference genes (ΔCt). Plotted as symbols with connecting lines (each 
symbol represents mean of technical duplicate of individual cows). ** = P < 0.01 as measured by one-
way ANOVA with Bonferroni’s post-test. # = P < 0.05 compared to medium condition, ## = P < 0.001 
compared to medium control tested with repeated measurements one-way ANOVA with Bonferroni’s post-
test. US: unstimulated
Aged cartilage shows higher expression of OA-related degenerative markers in 
response to IL-6
To determine the functional consequences of enhanced IL-6 receptor expression and signaling 
in cartilage upon ageing, we next analyzed age-related differences in IL-6 mediated activation 
of catabolic response genes related to cartilage degeneration. In aged cartilage, stimulation 
with rhIL-6 resulted in induction of catabolic mediators bMMP3, cyclo-oxygenase 2 (bPTGS2) 
and vascular endothelial growth factor-A (bVEGFA) compared to medium control after 4 h 
(bPTGS2) or 48 h (bMMP3, bVEGFA) (Fig 3A). Interestingly, we found no evidence for changes in 
expression of these three catabolic mediators in young cartilage in response to rhIL-6 stimulation. 
Comparison of young versus aged cartilage showed that bMMP3 and bVEGFA were increased 
in aged cartilage in response to a high dose of rhIL-6 (100 ng/ml) (2.6-fold /1.4 ΔCt [95%CI: 
0.66 – 2.07] and 1.9-fold / 0.94 ΔCt [95%CI: 0.36 – 1.52] respectively). Induction of bPTGS2 
was also higher in aged compared to young cartilage  in response to a suboptimal dose of 
rhIL-6 (3.0-fold, 1.6 ΔCt [95%CI: 0.28 – 2.95]). In contrast, we could not find any evidence of 
age-related differences in IL-6-induced expression of the anti-catabolic mediator tissue inhibitor 
of metalloproteinases-1 (bTIMP1)(95%CI of difference: -0.01 – 1.17 [25 ng/ml], -0.75 – 0.42 [100 
ng/ml]) after 48 h of stimulation. Supporting our results on gene expression, rhIL-6 stimulation 
also resulted in higher MMP3 protein expression in aged cartilage, but not in young cartilage 
(Fig. 3B). Taken together, this shows that age-related changes in IL-6 signaling result in increased 




















































































































































Figure 3. Ageing results in increased IL-6-induced expression of degenerative mediators in aged 
cartilage. (A) To study age-related changes in IL-6-mediated expression of markers related to cartilage 
degeneration, cartilage from five young cows (3-5 years) and five old cows (9-12 years) was stimulated ex 
vivo with 25 ng/ml or 100 ng/ml of rhIL-6 for 4 h (bPTGS2) and 48 h (bMMP3, bTIMP1, bVEGF-A). Expression 
values were corrected for reference genes (bGAPDH, bRPS14) and expressed relatively to unstimulated 
controls (ΔΔCt). Values were plotted as grouped column scatter with mean ± 95% CI. (B) MMP3 protein 
levels of cartilage explants stimulated with rhIL-6 (100 ng/ml, 24h). Western blot images are representative 
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of two young (both 5 years) and two old cows (9-10 years). * = P < 0.05; ** = P < 0.01, *** = P < 0.001 
as measured by one-way ANOVA with Bonferroni’s post-test. # = P < 0.05 compared to medium condition, 
## = P < 0.001 compared to medium control tested with repeated measurements one-way ANOVA with 
Bonferroni’s post-test. 
Loss of TGF-β function with age results in increased IL-6 receptor expression and 
signaling
Previously, we demonstrated that TGF-β was able to inhibit IL-6 effects in articular chondrocytes 
by suppressing IL-6R levels [22]. Because TGF-β signaling decreases with advancing age in 
articular cartilage [4, 6], we hypothesized that this may be the underlying cause for the age-
related increase in IL-6R levels. To study this, we stimulated cartilage explants ex vivo with 
rhTGF-β1 (1.0 ng/ml) for 24 h and analyzed IL-6R expression and signaling. To confirm that 
TGF-β signaling was indeed decreased with age in our data set, we first measured expression 
of bSERPINE1, a Smad-3 dependent gene which was previously found to be affected in ageing 
cartilage [6, 25]. As expected, aged cartilage responded less to TGF-β than young cartilage, 
resulting in a negative regression coefficient (slope: -0.13, 95%CI: -0.02 to -0.23, n = 24) (Fig. 
4A). To determine whether bIL6R expression was also no longer suppressed by TGF-β upon 
ageing, we depicted TGF-β-mediated suppression of bIL6R expression (Fig. 4B). Indeed, TGF-β 
suppression of bIL6R was reduced in bovine cartilage with advancing age (slope: 0.21, 95%CI: 
0.13 – 0.30, n = 24). Previous studied showed that expression of the TGF-β receptor ALK5 
decreases in articular cartilage with older age [5, 6]. Possibly, this age-related loss in ALK5 
expression causes the reduced ability of TGF-β to suppress bIL6R expression and signaling in 
aged cartilage. To determine whether ALK5 is involved in TGF-β-mediated regulation of bIL6R 
expression, we made use of the ALK5 inhibitor SB-505124. As TGF-β only suppresses bIL6R 
expression in young cartilage (Fig. 4B), cartilage from cows aged 3-5 years was included in 
this experiment. Interestingly, TGF-β-mediated suppression of bIL6R expression was completely 
abolished by the addition of ALK5 inhibitor SB-505124 (Supplementary Fig. 3A). In contrast, we 
observed no effect of the TAK1 inhibitor (5Z)-7-Oxozeaenol, demonstrating that non canonical 
signaling via TAK1 is not involved. Furthermore, we observed no effect of stimulation with high-
affinity ALK1 ligand BMP-9 on bIL6R expression, suggesting that ALK1 signaling does not 
modulate bIL6R expression (Supplementary Fig. 3B). On a functional level, pre-incubation with 
TGF-β (24 h, 1.0 ng/ml) profoundly suppressed IL-6-induced p-STAT3 in young cartilage (52% 
suppression, 1.32 mean difference [95%CI: 0.81 – 1.84), whereas this suppression was markedly 
reduced in aged cartilage (23% suppression, 0.76 mean difference [95%CI: 0.25 – 1.28) (Fig. 
4C, D). Furthermore, pre-incubation with TGF-β suppressed IL-6-mediated induction of bSOCS3 
in young cartilage (2.5-fold decrease, 1.3 ΔCt [95%CI: 0.37 – 2.16), while we found no evidence 
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Figure 4. Age-related loss in TGF-β function to suppress IL-6 receptor expression and signaling. (A, 
B) To study TGF-β effects with ageing, cartilage explants of 24 cows (age-range: 6 months - 14 years) were 
stimulated ex vivo with TGF-β (1 ng/ml) for 24 h. Gene expression of bIL6R and bSERPINE1 was analyzed 
using qPCR, corrected for reference gene expression and plotted relatively to unstimulated explants (ΔΔCt). 
Regression analysis (solid line) is depicted with corresponding confidence interval (dotted line). (C, D, E) To 
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determine the effect of TGF-β on IL-6 signaling in ageing cartilage, cartilage from five young cows (3-5 years) 
and five old cows (9-12 years) was pre-incubated with TGF-β (1 ng/ml) for 24 h, and hereafter stimulated 
with IL-6 (100 ng/ml). The IL-6 response was measured by induction of STAT3 phosphorylation after 30 min 
or induction of bSOCS3 expression after 1 h. (C) Representative image of a young cow (5 years) and old 
cow (11 years) are shown. (D) Quantification of Western blot of all cows is shown. p-STAT3 levels were 
normalized to GAPDH levels and plotted as relative staining compared to control condition. (E) Expression 
of bSOCS3 was corrected for reference genes (bGAPDH, bRPS14) and expressed relatively to unstimulated 
control (ΔΔCt). Plotted as grouped column scatter with mean ± 95% CI. * = P < 0.05; ** = P < 0.01, *** 
= P < 0.001 as measured by one-way ANOVA with Bonferroni’s post-test. US: unstimulated
DISCUSSION
With ageing a number of changes accumulate in cartilage, including age-related alterations 
in chondrocyte signaling. In this study, we investigated age-related changes in IL-6 receptor 
expression and signaling in bovine cartilage as model of healthy cartilage. We report that IL-6R 
expression is markedly increased with age in articular bovine cartilage, resulting in enhanced 
IL-6-induced p-STAT3 signaling and expression of degenerative markers. Moreover, we showed 
mechanistic proof that age-related loss of TGF-β signaling may be the underlying cause for 
enhanced IL-6R expression and signaling in aged bovine cartilage. 
The IL-6 signaling pathway is initiated by binding of IL-6 to the IL-6R, leading to complex formation 
with the signal transducing receptor GP130. Our study shows that expression of IL-6R increases 
in ageing bovine cartilage on both mRNA and protein level. In contrast, gene expression of 
the GP130 receptor, which also functions as a signal transducing receptor for other IL-6 family 
cytokines [11], is not changed in ageing bovine cartilage. This shows that ageing affects IL-6 
signaling, but not necessarily GP130-mediated signaling via other IL-6 family cytokines. 
Systemic IL-6 levels are increased with ageing and changes in IL-6 expression in ageing tissues 
have been extensively investigated [8, 26]. However, not many studies examined differences 
in IL-6R expression or signaling in relation to ageing. We are the first to show that IL-6-induced 
phosphorylation of STAT3 increased in articular cartilage upon ageing. In accordance with our 
observations, p-STAT3 levels were increased in human skeletal muscle biopsies of old compared 
to young donors (23-fold versus 5-fold respectively) 2 h after exercise [27]. Moreover, induction of 
STAT3 target genes (e.g. IL-6, SOCS3) was higher in old compared to young muscle tissue after 
exercise. However, whether IL-6 was the factor responsible for these effects, was not established 
in this study. Moreover, IL-6 can activate brain cells (microglia) in aged but not in adult mice, 
resulting in excessive production of pro-inflammatory cytokines [28]. Possibly, this is mediated 
via increased IL-6R levels in the ageing brain, similar to our observations in articular cartilage. 
However, this could also be mediated by different age-related changes such as increased levels 
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of IL-6 and/or soluble IL-6R in the cerebrospinal fluid. On the contrary, delayed activation of the 
IL-6 signaling pathway has been found in stem cells of older men [29]. This is potentially due to 
higher levels of the negative feedback inhibitor SOCS3 with older age (86% higher compared 
to young donors). We also found higher induction of SOCS3 expression in response to IL-6 in 
aged cartilage, but this induction was not sustained over time and already decreased after 1 
h. Moreover, we found no evidence that SOCS3 gene expression was affected by ageing at 
baseline level in articular cartilage. 
Surprisingly, male IL-6-/- mice developed more severe OA upon ageing [30]. This suggests that 
IL-6 may have protective role in age-related OA development in men, as opposed to our findings 
which suggest a detrimental role for IL-6 in ageing cartilage. These opposing findings can be 
explained in multiple ways. In a knock-out model, it is possible that different cytokines or growth 
factors compensate for the total loss of IL-6 which can bias the effect on cartilage damage 
and OA development. Moreover, complete, non-conditional IL-6 deficient mice were used in 
this study. As IL-6 is a pleiotropic cytokine with diverse functions throughout the body [31], this 
can in turn influence results of IL-6 in articular cartilage due to IL-6 deficiency from birth in e.g. 
bone or muscle tissue. Finally, in ageing mice, no markable inflammation was detected such as 
inflammatory infiltrate, exudate or synovitis, and systemic or local IL-6 levels were not measured 
[30]. During age-related OA development in humans, synovitis is commonly observed and levels 
of inflammatory mediators, amongst which IL-6, are systemically increased [8, 32, 33]. This 
raises the question whether murine ageing fully reflects human age-related OA development, 
and leaves open the possibility that IL-6 function differs in murine versus human ageing cartilage. 
Due to the limited access to healthy human cartilage of different ages, we used bovine material 
as a model to study age-associated changes in healthy cartilage. Although we cannot exclude 
species-specific observations, ageing bovine cartilage displays many characteristics of ageing 
human cartilage [6, 34, 35]. Bovine cartilage can be obtained in a wide age range, and allows for 
examination of the cartilage surface before inclusion. Macroscopic selection of healthy cartilage 
allowed us to separate ageing from OA processes, which is difficult in murine or human cartilage 
where OA is often concomitant [6]. Interestingly, gene expression of catabolic markers bMMP3, 
bPTGS2 and bVEGFA was increased in aged compared to young cartilage after IL-6 stimulation. 
In contrast, we found no evidence that IL-6 affected expression of anti-catabolic mediator TIMP-1, 
which has been reported previously as an IL-6-responsive gene in chondrocytes [36, 37]. 
Because of the detrimental role of MMP-3, COX-2 and VEGF-A in cartilage [13-15, 38, 39], our 
results suggest that enhanced IL-6 signaling in ageing cartilage may contribute to cartilage 
degeneration and OA development. Of note, we hardly found any regulation of bVEGFA 
expression in response to IL-6 in young cartilage, whereas this was observed in aged cartilage. 
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A plausible mediator causing the observed changes in IL-6R expression and signaling in 
aged cartilage could be TGF-β, a growth factor which is crucial for the maintenance of healthy 
articular cartilage [40]. Previously, we found that TGF-β potently suppresses IL-6R expression 
in chondrocytes and thereby inhibits IL-6 effects in chondrocytes [22]. In this study, we showed 
that TGF-β-mediated suppression of IL-6R expression is lost in aged cartilage. We previously 
observed decreased TGF-β signaling upon ageing in both murine and bovine cartilage. For 
instance, expression of TGF-β2 and -3 as well as corresponding TGF-β receptors, decreased 
strongly with age in murine cartilage [4]. Moreover, the number of p-Smad2 positive chondrocytes 
dropped markedly in aged murine cartilage, indicating a reduction in functional TGF-β signaling. 
Also in bovine cartilage, TGF-β-induced p-Smad3 signaling and expression of TGF-β receptors 
was reduced with age, which was most prominent for TGF-β receptor I (ALK5) [6]. This is in 
line with the finding that the ratio between ALK1 versus ALK5 increases with age in murine 
and human cartilage, potentially causing enhanced MMP-13 expression in OA [5]. Our results 
show that TGF-β-mediated IL-6R suppression is dependent on ALK5 kinase activity and is not 
mediated via ALK1 signaling. It is therefore likely that the reduced ability of TGF-β to suppress 
IL-6R in aged cartilage is due to a loss of ALK5 receptor expression with advancing age. It is 
difficult to directly proof that age-related loss of TGF-β function in cartilage causes enhanced IL-
6R expression in vivo. However, our results clearly show that TGF-β loses its ability to suppress 
bIL-6R expression in aged cartilage. Moreover, we demonstrated that TGF-β has a reduced 
ability to suppress IL-6-mediated p-STAT3 signaling and bSOCS3 expression in aged cartilage. 
Therefore, it is highly likely that age-related loss of TGF-β signaling mediates increased IL-6R 
expression and signaling in ageing cartilage. 
In conclusion, we show that IL-6R expression is increased with advancing age in articular bovine 
cartilage, resulting in enhanced IL-6-induced p-STAT3 signaling and expression of degenerative 
mediators such as MMP-3. Moreover, we demonstrate that age-related loss of TGF-β function 
may be the underlying cause for increased IL-6R expression and signaling in aged cartilage. Due 
to the catabolic and pro-inflammatory role of IL-6 in OA development, we suggest that increased 
IL-6R levels with age predispose cartilage to degenerative changes, ultimately contributing to 
age-related OA development. 
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Supplementary Figure 1. Isotype control staining of bovine cartilage. Cartilage from young (n = 
5) and aged (n = 5) cows was directly processed after collection. Sections were stained with anti-IL-6R 
antibody (Fig. 1B) or IgG control (rabbit IgG). Representative pictures of isotype IgG negative control are 
shown per age group (100, 200x magnification). Scale bars = 100 µm.
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Supplementary Figure 2. rhIL-6 dose-dependently increases p-STAT3 levels in bovine chondrocytes. 
To study the dose-response of bovine chondrocytes to rhIL-6 stimulation, bovine chondrocytes of three 
donors were stimulated with various concentrations of rhIL-6 (1.2, 2.7, 11, 33, 100 ng/ml) for 30 min. The 
IL-6 response was measured by induction of STAT3 phosphorylation as determined by Western blot. (A) 
Representative image of donor 2 is shown. (B) Quantification of p-STAT3 levels relative to GAPDH levels is 
shown for all cows. Age donor 1: 8 years, donor 2: 4 years, donor 3: 4 years. 



















































































Supplementary Figure 3. TGF-β-mediated suppression of bIL-6R expression is dependent on 
ALK5 kinase activity. (A) To study the role of TGF-β receptor ALK5 in TGF-β-mediated regulation of bIL6R 
expression, the small molecule inhibitor SB-505124 (5 µM) was used. Moreover, TAK1 dependency was 
studied using the (5Z)-7-Oxozeaenol (0.5 µM). DMSO was used as a vehicle control. Cartilage explants 
were pre-incubated with inhibitors for 1 h, and hereafter stimulated with rhTGF-β1 for a period of 24 h. (B) To 
study the effect of ALK1 signaling on bIL6R expression, cartilage explants were stimulated with high affinity 
ALK1 ligand rhBMP-9 (5 ng/ml) or rhTGF-β (1 ng/ml) for a period of 24 h. (A, B) As TGF-β only suppresses 
bIL6R expression in young cartilage, cartilage explants from young cows (3-5 years) were included (n = 3). 
Expression of bIL6R was analyzed using qPCR. Data is plotted as grouped column scatter with mean ± 
95% CI. * = P < 0.05; ** = P < 0.01, *** = P < 0.001 as measured by one-way ANOVA with Bonferroni’s 
post-test. Ctrl: medium control.
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Joint inflammation is present in the majority of osteoarthritis (OA) patients and pro-inflammatory 
mediators, such as interleukin-6 (IL-6), are actively involved in disease progression. Increased 
levels of IL-6 in serum or synovial fluid from OA patients correlate with disease incidence and 
severity, with IL-6 playing a pivotal role in the development of cartilage pathology e.g. via 
induction of matrix-degrading enzymes. However, IL-6 also increases expression of anti-catabolic 
factors, suggesting a protective role. Until now, this dual role of IL-6 is incompletely understood 
and may be caused by differential effects of IL-6 classic vs trans-signaling. Here, we review 
current evidence regarding the role of IL-6 classic- and trans-signaling in local joint pathology 
of cartilage, synovium and bone. Furthermore, we discuss targeting of IL-6 in experimental OA 
models and provide future perspective for OA treatment by evaluating currently available IL-6 
targeting strategies. 
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Key messages
•     IL-6 signaling is actively involved in OA pathology, identifying IL-6 as a promising therapeutic 
target 
•     Differences between IL-6 classic vs trans-signaling explain the protective and degenerative 
IL-6 effects in joint tissues 
•    Specific targeting of IL-6 trans-signaling could be a superior treatment strategy in OA 




Osteoarthritis (OA) is a degenerative joint disease with increasing incidence due to a rise in life 
expectancy and average body weight in western society [1, 2]. Currently therapies are focused 
on pain-management or eventually joint replacement. OA affects all joint tissues, resulting in 
loss of articular cartilage, ectopic bone formation, subchondral bone sclerosis and synovial 
inflammation [3]. Inflammation is increasingly accepted as a driver of OA pathology, implying 
the synovium and inflammatory cytokines in driving cartilage degeneration [4-6]. For this reason, 
treatment strategies focused on targeting pro-inflammatory cytokines TNF-α and IL-1β in hand 
and knee OA [7-10], which did not result in clinical applications thus far. Therapies targeting 
IL-6 are approved and effective in treating rheumatoid arthritis (RA), juvenile idiopathic arthritis, 
Castleman’s disease, and giant cell arteritis [11]. Also in OA, IL-6 plays a significant role in 
joint pathology, but has not been a primary target of interest as research mostly focused on 
IL-1β and TNF-α. Here, we review the current state of evidence regarding the role of IL-6 in 
OA pathophysiology, and discuss potential therapeutic approaches to target the IL-6 signaling 
pathway in OA. 
UNDERSTANDING THE COMPLEXITY OF THE IL-6 SIGNALING PATHWAY
Intracellular signaling cascades
IL-6 signaling starts by binding of IL-6 to the IL-6 receptor α subunit (IL-6R), followed by 
complex formation with a homodimer of glycoprotein 130 (gp130) [12]. The IL-6R has no signal 
transduction capacity and its expression is limited, e.g. to monocytes, hepatocytes, and certain 
leucocyte subsets [13]. In contrast, the signal-transducing receptor gp130 is ubiquitously 
expressed. Gp130 also functions as a β subunit for other IL-6 family cytokines, like oncostatin-M, 
IL-11, IL-27 and leukemia inhibitory factor [14]. After IL-6 receptor complex formation, the Janus 
kinases/signal transducers and activators of transcription (JAK/STAT) pathway is activated (Fig. 
1), leading to recruitment and activation of STAT1, STAT3, and to a lesser extent STAT5 [15]. 
Besides canonical signaling via JAK/STAT, IL-6 activates non-canonical signaling via mitogen-
activated protein kinase (MAPK) cascade (Ras-Raf-MEK-ERK pathway) and PI3K- protein kinase 
B (PkB)/Akt. IL-6-induced JAK/STAT is tightly controlled by negative feedback regulators, such 
as suppressor of cytokine signaling (SOCS) protein family and protein inhibitors of activated 
STATs (PIAS) [16, 17]. SOCS proteins are directly induced by gp130 cytokines, resulting in a 
negative feedback loop. SOCS3 has been identified as a specific inhibitor of IL-6 signaling and 
directly inhibits JAK-kinase activity [18, 19]. PIAS negative inhibitors are constitutively expressed 












































Figure 1. Overview of IL-6 signaling pathways. After IL-6 binding to the IL-6R, complex formation 
with gp130 initiates phosphorylation of JAKs resulting in activation of STAT3-, PI3K- and Ras-Raf-MEK-
ERK signaling. Activated transcription factors (e.g. STAT3, NF-κβ and NF-IL-6) translocate to the nucleus 
to regulate target gene expression. SOCS and PIAS proteins negatively regulate IL-6-induced JAK-STAT 
signaling by blocking JAK-mediated activation of STAT3 (SOCS3), or by blocking DNA-binding activity of 
STAT3 (PIAS). Abbreviations: IL-6: interleukin-6; gp130: glycoprotein 130; JAK: janus kinase; STAT3: signal 
transducer and activator of transcription 3; PI3K: phosphoinositide 3-kinase; MAPK: mitogen-activated 
protein kinase; NF-κβ: nuclear factor kappa-light-chain-enhancer of activated B cells; NF-IL6: A nuclear 
factor for IL-6 expression; SOCS3: suppressor of cytokine signaling 3; PIAS: protein inhibitors of activated 
STATs. 
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Cytokine interplay and intracellular cross-talk
Interplay between IL-6 signaling pathways and other cytokines exists on multiple levels [14]. For 
example, other cytokines from the IL-6 family, like ciliary neurotrophic factor (CNTF) and IL-30, 
can also bind and activate the IL-6R, although with lower binding affinity compared with the 
CNTF- and IL-30 receptors [20, 21]. Furthermore, interplay between IL-6 and pro-inflammatory 
cytokine signaling, may restrict uncontrolled pro-inflammatory signaling [22]. For instance, IL-1β 
strongly inhibits IL-6-mediated acute phase reaction in the liver by directly inhibiting p38 MAPK-
dependent STAT3 phosphorylation [22, 23]. More specifically, MAPK p38 and the transcription 
factor NF-κβ were identified as crucial regulators of the IL-6 signaling pathway [22]. Also, interplay 
between IL-6 and anti-inflammatory cytokines, such as TGF-β, is present at receptor level and 
at the level of intracellular mediators [24-26]. Crosstalk between STAT3 and Smad3, the main 
intracellular mediator of TGF-β signaling, exists in diverse pathophysiological conditions and 
leads to either synergistic or antagonistic actions depending on cell type and context [26]. 
Modes of IL-6 signaling
IL-6 has the unique ability to initiate signal transduction via different modes of receptor activation. 
Signaling via membrane-anchored IL-6R (mIL-6R) is termed classic signaling and is important 
for the acute-phase response, hematopoiesis, and central homeostatic processes [27](Fig. 
2A). Interestingly, a soluble form of IL-6R (sIL-6R) can be produced by shedding of membrane-
bound receptor or alternative splicing [28, 29]. sIL-6R can bind secreted IL-6, forming a complex 
that increases the half-life of IL-6 [30]. Signaling via sIL6R is called trans-signaling and greatly 
broadens the scope of IL-6 responsiveness, as any gp130-expressing cell can bind and respond 
to the IL-6/sIL-6R complex (Fig. 2B). IL-6 trans-signaling mainly regulates pro-inflammatory 
events and is implicated in numerous chronic diseases and cancers [27, 31]. Trans-signaling 
leads to stronger activation of IL-6 intracellular signaling routes, resulting in enhanced target 
gene expression, but how this works is still unclear [32, 33]. Possibly, restricted expression of 
mIL-6R limits activation of STAT3 via classic signaling, but not trans-signaling due to additional 
presence of sIL-6R [32]. Within our circulation, a soluble form of gp130 (sgp130) acts as a 
natural inhibitor of IL-6 trans-signaling by binding to the IL-6/sIL-6R with high affinity [31, 34-36]. 
Sgp130 therefore specifically inhibits IL-6 trans-signaling and does not affect classic signaling 
or recently discovered IL-6 cluster-signaling. IL-6 cluster-signaling involves membrane IL-6/IL-6R 
complexes on dendritic cells, which activate gp130 receptors on receiving T-cells resulting in the 
generation of pathogenic Th17-cells (Fig. 2C). [37]. Whether IL-6 cluster-signaling is also relevant 

































Figure 2. Modes of IL-6 signaling. (a) Classic IL-6 signaling involves cells expressing both membrane 
(m)IL-6R and gp130; free IL-6 binds to mIL-6R, forming a complex with gp130. (b) IL-6 trans-signaling is 
activated by pre-formed complexes of IL-6 and soluble IL-6R (IL-6/sIL-6R) and requires only gp130 expression 
on target cells. Soluble gp130 (sgp130) acts as a natural inhibitor of trans-signaling by specifically binding 
to IL-6/sIL-6R complexes. (c) IL-6 cluster signaling utilizes gp130 on receiving cells, activated by IL-6/mIL-6R 
complexes on presenting cells (e.g. dendritic cells). Abbreviations: IL-6: interleukin-6; IL-6R: IL-6 receptor; 
gp130: glycoprotein 130
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LOCAL AND SYSTEMIC PERSPECTIVE: LEVELS OF IL-6 AND ITS SOLUBLE 
RECEPTORS IN OA
IL-6 levels relate to OA incidence and pathology
IL-6 was detected in OA synovial fluid (SF) as early as 1988. However, this did not result in 
follow-up studies, as IL-6 levels were lower compared with RA SF and healthy controls were not 
included [38, 39]. Later, it became clear that IL-6 levels were significantly increased in OA SF 
and serum compared with healthy individuals [40-42]. Furthermore, additional studies showed 
a clear relation between systemic IL-6 levels and OA incidence [43-45]. Increased circulating 
levels of IL-6 were predictive for knee OA and cartilage loss in 3 and 15 years in two independent 
follow-up studies [43, 44]. Moreover, a high innate capacity to produce IL-6, in response to 
lipopolysaccharide stimulation, was associated with hand OA development in 90-year old 
individuals [45]. Higher IL-6 levels in OA serum or SF also correlate with disease progression 
or severity of cartilage pathology [42, 46-48]. This suggests that IL-6 levels may reflect cartilage 
damage, which is supported by the fact that SF IL-6 levels are strongly increased in individuals 
with cartilage defects but no macroscopic signs of OA [49, 50]. When local vs systemic levels 
of IL-6 were compared in the same patients, IL-6 concentrations were higher in OA SF (119.8 ± 
193.5 pg/ml) compared with plasma samples (3.1 ± 2.7 pg/ml) [51]. Furthermore, two patient 
subgroups can be identified based on IL-6 levels in OA SF, high producers (2022±526 pg/mL) 
vs average producers (132±19 pg/mL), of which high producers may particularly benefit from 
IL-6 targeted therapy [52].
Local production of IL-6 by joint tissues
It is now recognized that synovial inflammation is important in OA, and synovitis is observed in 
~50% of OA patients [5, 53]. The synovium is an important producer of IL-6 in OA, for instance 
via (activated) synovial fibroblasts or plasma cells in the synovial lining [52, 54-56]. Besides 
the synovium, the infrapatellar fat pad (IFP) is an important source of IL-6. The IFP is the main 
fat tissue within the knee, and actively contributes to OA pathophysiology via production of 
pro-inflammatory mediators and adipokines [57]. Interestingly, the IFP from knee OA patients 
secreted significantly higher levels of IL-6, but not TNF-α and IL-1β, compared with abdominal 
fat tissue from the same patients [58]. Furthermore, IFP-conditioned medium cultured with 
traumatized cartilage explants caused IL-6-dependent glycosaminoglycan release [59]. Also, 
synovial fibroblasts from obese OA patients secreted higher levels of IL-6 compared with normal-
weight patients [60], indicating that IL-6 may be particularly relevant in obesity-derived OA, 
especially as IL-6 plays a central role in cell metabolism [61]. 
Broadening our horizon: levels of soluble IL-6 receptors in OA
The ratio of IL-6 classic- vs trans-signaling is regulated by sIL-6 receptors [62]. Increased levels 
of sIL-6R in OA patients may direct future treatment towards specific inhibition of IL-6 trans-
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signaling, while decreased sgp130 levels could indicate reduced negative feedback capacity. 
Unfortunately, studies investigating soluble IL-6 receptors in OA are scarce. Systemically, no 
differences were detected in sIL-6R levels in serum of healthy donors and OA patients [63], and 
as far as we know there is no study investigating systemic changes in sgp130 in OA. In OA SF 
both sIL-6R and sgp130 are present, but a comparison to healthy individuals is lacking [64-66]. 
Despite high levels of IL-6 production, it remains unclear if the synovium is a source of sIL-6 
receptors in OA. In RA-derived material, cultured SF mononuclear cells produced sIL-6R, but not 
cultured chondrocytes or synovial cells [64]. However, this was not confirmed in OA. A potential 
source of sIL-6R in OA could be the IFP, which was shown to produce both IL-6 and sIL-6R [58], 
possibly resulting in IL-6 trans-signaling. 
DIRECT EFFECTS OF IL-6 ON LOCAL JOINT TISSUES
Cartilage
As cartilage is the main OA affected tissue, previous studies mostly focused on identifying IL-6 
effects in cartilage. However, IL-6 has both catabolic and protective effects in cartilage, which 
is still not completely understood. Early studies focused on IL-6 classic signaling and generally 
found protective effects of IL-6, such as production of tissue inhibitor of metalloproteinases 
(TIMPs) [67, 68]. Furthermore, IL-6 classic signaling slightly stimulated proteoglycan synthesis 
in human OA chondrocytes [49], and did not affect proteoglycan synthesis of human or bovine 
chondrocytes [69, 70]. However, detrimental effects of IL-6 classic signaling in cartilage have 
also been reported. IL-6 inhibited proteoglycan synthesis in human cartilage explants and rabbit 
chondrocytes [71-73]. Moreover, IL-6 suppressed collagen type II neo-synthesis and enhanced 
IL-1β-mediated proteoglycan degeneration in rabbit chondrocytes [73, 74]. Several studies show 
that IL-6 induces metalloproteinase (MMP)-3, MMP-13 and A Disintegrin and Metalloproteinase 
with Thrombospondin motifs (ADAMTS) enzyme expression, which mediate cartilage 
degeneration [75-77]. Besides regulating matrix synthesis and degeneration, IL-6 induces matrix 
mineralization via formation of basic calcium phosphate crystals leading to proteoglycan loss 
[78]. Furthermore, IL-6 disturbs several other chondrocyte functions, resulting in decreased 
proliferation or increased oxidative stress generation [73, 79]. Of note, IL-6 directly induces 
SOCS3 expression, which can lead to insulin-like growth factor 1 desensitization in cartilage [80]. 
However, enhanced SOCS3 may also be protective as it restricts pro-inflammatory signaling in 
chondrocytes [81]. Altogether, this indicates that the definition of IL-6 classic signaling as only 
‘protective’ is probably too simplified. 
Generally, chondrocytes are considered to have low levels of mIL-6R which may limit STAT3 
activation, but strong evidence for this is missing [32, 82]. In murine epiphysial chondrocytes, 
no mIL-6R expression was observed with flow cytometry [82]. In contrast, expression of mIL-6R 
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was observed in four donors of OA human chondrocytes on both mRNA and protein level [25]. 
Chondrocyte sensitivity for classic IL-6 signaling is determined by mIL-6R levels, which can be 
altered by hormones, cytokines and epigenetic factors [13]. The cytokine IL-1β increases mIL-6R 
expression in chondrocytes and hepatocytes [25, 83], which may explain synergistic effects of 
IL-1β and IL-6 in mediating cartilage degradation or collagen breakdown [71, 73, 84]. Cartilage 
injury induced by blunt trauma also potentiated IL-6-mediated expression of catabolic markers 
in bovine cartilage, but the underlying mechanism was not investigated [59, 85]. On the other 
hand, TGF-β decreases mIL-6R expression in chondrocytes, resulting in inhibition of classic IL-6 
signaling [25]. Also mechanical compression of cartilage, which leads to active TGF-β signaling 
[86], inhibited catabolic effects of IL-6 and TNF-α combined [87]. Changes in mIL-6R expression 
in chondrocytes alter their sensitivity towards IL-6 classic signaling and may partly explain 
previous discrepancies regarding IL-6 effects in cartilage. 
With respect to IL-6 trans-signaling in cartilage, functional studies also show contradictive 
results. Most studies conclude that IL-6 trans-signaling is detrimental for cartilage, as it inhibits 
proteoglycan synthesis and stimulates proteoglycan loss [72, 88]. Moreover, sIL-6R was 
required for full activation of JAK1/2 in bovine chondrocytes, resulting in decreased expression 
of matrix components and increased levels of cartilage degrading enzymes [89, 90]. On the 
other hand, soluble IL-6R also augmented production of anti-catabolic TIMPs in chondrocytes 
[67], which suggests that sIL-6R stimulates general IL-6 signaling and not only the catabolic 
response. In conclusion, there is substantial evidence for a direct role of IL-6 in regulating 
chondrocyte function and cartilage metabolism. While most studies report catabolic effects of 
IL-6 on cartilage, protective effects are also found. These discrepancies may be explained by 
functional differences in IL-6 classic vs trans-signaling, or disturbed expression of mIL-6R levels 
on chondrocytes. 
Other joint tissues
As OA is a whole joint disease, direct effects of IL-6 on other joint tissues such as synovium, 
subchondral bone, and muscle tissue are also of interest [3]. Comparable to IL-6 effects in 
cartilage, mainly IL-6 trans-signaling was associated with detrimental effects in synovium. In OA- 
or RA-digested synovium, both IL-6 classic and trans-signaling increase production of TIMP, but 
only trans-signaling induces expression of ADAMTS4 [67, 68, 91, 92]. Moreover, IL-6 trans- but 
not classic signaling caused strong proliferation of RA synovial fibroblasts that could indicate 
a role in synovial hyperplasia or fibrosis [93]. However, in bone this distinction is less clear. 
On the one hand, IL-6 trans-signaling promotes osteoclast formation and consequently bone 
resorption, while classic signaling inhibits osteoclastogenesis [39, 94, 95]. On the other hand 
IL-6 trans-signaling has been shown to promote bone formation [96]. The dual effect of IL-6 
trans-signaling on bone resorption and formation may be explained by variation in levels of 
the pro-osteoclastogenic factor receptor activator of nuclear factor kappa-B ligand (RANKL). 
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While high-levels of RANKL promote osteoclastogenesis, lower RANKL levels result in inhibition 
of osteoclast formation [97]. Finally, IL-6 may be directly involved in the process of OA-related 
muscle degeneration [98, 99]. Indeed, elevated levels of IL-6 are associated with reduced 
muscle endurance in elderly women with knee OA [100]. Moreover, increased levels of IL-6, 
STAT3 and SOCS3 have been detected in muscle tissue of knee OA patients [101]. However, 
IL-6 also mediates important anabolic processes in muscle tissue, such as muscle growth 
and myogenic differentiation [102]. This dual role of IL-6 in muscle tissue might be a result 
of functional differences in IL-6 classic- vs trans-signaling, but this is yet unknown. Thus, IL-6 
classic and trans-signaling can affect joint tissues besides articular cartilage, but their respective 
functional effects and role in OA development remain elusive. 
Evidence for a role of IL-6 in OA pathology: lessons learned from animal studies 
The role of IL-6 in OA pathophysiology has been studied in several experimental OA models and 
mostly show a destructive role for IL-6 (Table 1). Induction of the destabilization of the medial 
meniscus (DMM) model in IL-6-/- mice resulted in marked reduction of cartilage destruction 
compared to wildtype mice [75]. Moreover, expression levels of MMP-3 and MMP-13 were 
significantly decreased in IL-6-/- mice compared to wildtype, indicating that IL-6 induces catabolic 
mediators in OA. This catabolic role of IL-6 was supported by overexpression of HIF-2α in 
wildtype vs IL-6-/- mice, causing OA-like cartilage destruction in wildtype but not IL-6-/- mice. Local 
injection of IL-6 into the knee joint, caused significantly increased cartilage degeneration and 
MMP-3 and -13 expression, revealing direct evidence for deleterious effects of IL-6 in OA [75]. 
Strikingly, despite marked evidence of IL-6 involvement in OA, only one study blocked IL-6 itself. 
Both systemic administration of a neutralizing antibody as well as anti-IL-6 siRNA resulted in 
decreased cartilage lesions and subchondral bone sclerosis in the anterior cruciate ligament 
transaction (ACLT) OA model [103]. Moreover, systemic treatment with an anti-IL-6-receptor 
neutralizing antibody (MR16) in the DMM model ameliorated the extent of cartilage pathology, 
synovial inflammation and osteophyte development [59]. This antibody is similar to Tocilizumab, 
which directly targets the human IL-6R and is clinically effective in several inflammatory diseases 
[11]. Moreover, blocking of the IL-6R using Tocilizumab resulted in cartilage preservation in a 
mouse model of ischemic osteonecrosis and significantly increased bone volume [104]. 
IL-6 is possibly mainly involved in trauma-related OA, as both the DMM and ACLT models reflect 
trauma-induced OA development. Also in humans, local IL-6 levels strongly increase upon 
cartilage trauma and associate with knee OA progression after previous meniscectomy [49, 
50]. Systemic IL-6 levels also increase during natural ageing and are associated with several 
age-related diseases [105, 106]. However, there was no difference in cartilage degradation in 
wildtype or IL-6-/- mice after age-related OA development [107]. Male IL-6-/- mice even developed 
more cartilage damage, ectopic bone formation and subchondral bone sclerosis compared to 
male wildtype mice, while there was no difference in pathology of females. This suggests that 
A ROADMAP TO TARGET INTERLEUKIN-6 IN OSTEOARTHRITIS
119
5
IL-6 has no pathological role in age-related murine OA, and even ameliorates OA pathology in 
male mice. Multiple studies show interplay between IL-6 and sex-hormones such as testosterone 
and estrogen [108-110], but it is unclear how sex hormones affect IL-6 function within the 
joint. Of note, no markable inflammation was detected in these mice including inflammatory 
infiltrate, exudate or synovitis [107]. This raises the question whether murine ageing fully reflects 
human age-related OA development, in which synovitis is commonly observed and levels of 
inflammatory mediators, amongst which IL-6, are systemically increased [5, 53, 105]. Besides 
age-related OA, there was no difference in OA pathology caused by collagenase-induced OA 
(CIA) between wildtype or IL-6-/- mice [107]. Although using conditional IL-6-/- mice, instead of 
constitutive knockouts, would more closely resemble physiological conditions, this suggests that 
other mediators may cause OA pathology in this model. However, to really exclude a role for IL-6 
in CiOA and age-related OA, lack of IL-6 effects should be confirmed by independent studies. 
Functional differences in IL-6 classic vs trans-signaling may explain the contradictive results 
obtained in the different OA models. Unfortunately, all of the employed blocking strategies block 
both the classic- and trans-signaling pathway and current studies do not report sIL-6R levels. 
Specific inhibition of IL-6 trans-signaling in OA models might be extremely helpful to dissect 
detrimental vs protective effects of IL-6 in the future.
Blocking downstream of IL-6: targeting STAT3 in experimental OA
STAT3 is the most specific downstream mediator of the IL-6 signaling pathway, but is not solely 
activated by IL-6. Therefore, STAT3 activation in OA results from synergistic actions of several 
gp130 cytokines [14]. Hypothetically, targeting of STAT3 may be more successful compared with 
blocking IL-6, as other STAT3-activating cytokines also have catabolic and inflammatory effects 
on cartilage [112]. Indeed, repeated administration of a small molecule inhibitor against STAT3 
(Stattic) in the DMM model resulted in stronger protection against cartilage degeneration and 
osteophyte formation compared with blocking IL-6R [59]. This additional effect may result from 
blockade of both IL-6 and OSM signaling via STAT3, based on the role of oncostatin M OSM in 
osteophyte proliferation and synovial inflammation [113, 114]. Inhibition of JAK2/STAT3 signaling 
in the ACLT model using the AG490 inhibitor, also led to considerable protection against cartilage 
degeneration and subchondral bone sclerosis [103]. However, mesoderm-specific deletion of 
STAT3 leads to expansion of growth plate hypertrophic chondrocytes and severe dysregulation 
of endochondral ossification, caused by STAT3-mediated activation of Sox9 in chondrocytes 
[115]. This phenotype is not observed in IL-6-/- animals [116], suggesting that other STAT3-
activating cytokines may cause dysregulation of cartilage and bone development, such as LIF 
which is associated with reduced skeletal growth [117]. Recently, a novel gp130-small molecule 
modulator (RCGD 423) was discovered, which directed gp130 towards proliferative STAT3/c-
Myc signaling, while inhibiting ERK/NF-κβ signaling. Therapeutic administration of the RCGD 
423 compound, leading to STAT3 activation, resulted in reduced cartilage degeneration in a rat 
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Stattic protects against cartilage degeneration [59]. It is possible that the proliferative effect of the 
RCGD423 inhibitor is caused by the strong activation of c-Myc, as LIF-driven c-Myc activation is 
critical for chondrocyte survival and proliferation in fetal cartilage [111]. These opposing results 
indicate that the ultimate result of STAT3 inhibition, beneficial or detrimental, is strongly context-
dependent and determined by the integrated signal of multiple gp130 cytokines. While targeting 
of STAT3 may seem promising in experimental OA, this might prove difficult in OA patients due 
to large differences in severity and incidence of inflammation, and heterogeneity in STAT3-
activating cytokines or growth factors [53]. This makes it difficult to predict the outcome of STAT3 
inhibition in OA and argues for the simpler approach of directly targeting gp130 cytokines, such 
as IL-6, upstream of STAT3. 
UNDER CONSTRUCTION: IL-6 TARGETED THERAPY IN OA 
Currently multiple therapeutic strategies exist to effectively target the IL-6 signaling pathway, 
and are safely applied for the treatment of several inflammatory diseases. For example, the IL-
6R targeting antibody tocilizumab has been approved for treatment of RA, juvenile idiopathic 
arthritis, Castleman’s disease and recently also for giant cell arteritis [62, 118]. Currently, no 
therapies targeting IL-6 signaling are approved for treatment of OA. This may change in the near 
future, as tocilizumab is being tested in a phase 3 randomized controlled trial in patients with 
refractory hand OA (ClinicalTrials.gov NCT02477059). 
Previous studies showed that levels of IL-6 in SF can vary between different joints, which could 
direct future IL-6 targeted therapy towards relevant patient subgroups. For example, levels of IL-6 
were strikingly higher in knee OA SF compared with carpometacarpal joint fluid [119]. Moreover, 
more IL-6 was detected in post-traumatic wrist OA compared with knee OA patients [120]. As 
inflammation is strongly linked to structural damage in hand OA patients [121-123], this patient 
group may be very suitable to study the consequences of blocking pro-inflammatory cytokines, 
such as TNF-α [124] and IL-1β [7] and now IL-6. Besides stratification of patients based on 
joint-location, treatment choice could also be based on OA subtypes. Post-traumatic OA is a 
common form of OA, developing after joint injury (e.g. anterior cruciate ligament or meniscus 
injury) [125]. In these patients, there may be a therapeutic window after injury, in which targeting 
of inflammatory mediators may prevent the development of further damage. During joint injury, 
such as anterior cruciate ligament rupture, levels of IL-6 in SF are highly increased up to 1000-
fold [126, 127], and a sudden increase in IL-6 levels has also been found after focal cartilage 
damage [49, 50]. This suggests that inhibition of IL-6 shortly after joint injury may be a promising 
treatment strategy to prevent the development of post-traumatic OA, however, the optimal 
therapeutic window to prevent further damage is still unknown. 
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Due to the success of tocilizumab, novel IL-6 pathway inhibitors have been developed, such as 
biologics targeting IL-6R (vobarilizumab, satralizumab, sarilumab), IL-6 (siltuximab, olokizumab, 
sirukumab, clazakizumab and MEDI 5117), IL-6 trans-signaling (olamkicept), or small molecule 
inhibitors directed against JAKs or STAT3 [128]. Multiple inhibitors have been developed 
and clinically tested that target JAK-kinases or STAT3 directly [11]. Although some of these 
compounds are clinically effective in RA, such as tofacitinib and baricitinib (pan-JAK inhibitors), 
they have not been tested in OA patients [129]. Yet, there are pre-clinical indications that JAK/
STAT inhibition could be effective in OA. For instance, tofacitinib inhibited cytokine-induced 
proteoglycan loss and restored collagen type II synthesis in bovine cartilage explants [130]. In 
addition, animal studies indicate protective effects of JAK/STAT inhibition in experimental OA 
[59, 103]. However, targeting of JAK/STAT signaling also results in inhibition of multiple cytokines 
including IL-10, IL-4 and IGF-1, which have a beneficial role in joint biology and OA development 
[14, 131, 132]. As OA is a very heterogeneous disease with large differences in severity of 
inflammation and cytokine profile [53], it will be difficult to predict outcome of JAK/STAT inhibition 
in OA patients. Therefore, the simpler approach of targeting one cytokine, like IL-6, might be 
a safer strategy. As several therapeutics have been developed that target IL-6 signaling via a 
different mechanism, the comparison of these treatments will greatly enhance knowledge about 
the role of IL-6 in disease. Tocilizumab, for instance, blocks all IL-6 signaling pathways (classic 
and trans-signaling, and potentially also cluster-signaling [37], because it inhibits IL-6 binding to 
both mIL-6R and sIL-6R (Fig. 3)[133]. In contrast, olamkicept specifically targets the IL-6/sIL-6R 
complex, thereby only inhibiting IL-6 trans-signaling, and not classic signaling. Olamkicept is a 
fusion protein consisting of two soluble human gp130 proteins fused with the Fc region of human 
IgG (sgp130Fc) [128]. Accordingly, olamkicept blocks pro-inflammatory events of IL-6 trans-
signaling, while simultaneously allowing homeostatic effects of IL-6 classic signaling. Olamkicept 
was already successfully used in treating experimental Crohn’s disease and is now in clinical 
trials for inflammatory bowel disease and active ulcerative colitis [11, 134]. Specific inhibition 
of IL-6 trans-signaling could be a preferred future treatment strategy, as several side effects of 
tocilizumab have already been reported that may result from inhibition of IL-6 classic signaling, 
such as impairment of the acute phase response [128]. Olamkicept might also be a promising 
therapy for OA, as several studies demonstrated catabolic and pro-inflammatory effects of IL-6 
trans-signaling in cartilage and synovial tissue [72, 88, 92, 93]. Thus, even if tocilizumab does 
not prove effective in hand OA, specific inhibition of IL-6 trans-signaling may hold additional 
promise. Nonetheless, additional pre-clinical research will first be needed as the relevance of 
IL-6 trans-signaling in experimental OA has not yet been demonstrated.
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Figure 3. Current IL-6 targeting strategies. Anti-IL-6 monoclonal antibodies (e.g. Siltuximab) directly 
target IL-6, thus blocking both classic and IL-6 trans-signaling. IL-6R targeting antibodies (e.g. Tocilizumab) 
block binding of IL-6 to the IL-6R (both mIL-6R as well as sIL-6R), thereby inhibiting IL-6 classic and trans-
signaling pathways. The sgp130Fc fusion protein (e.g. Olamkicept) was developed to specifically target 
IL-6 trans-signaling, and only binds to the IL-6/sIL-6R complex. Sgp130Fc does not bind to membrane IL-6R 
or free IL-6, therefore allowing classic IL-6 signaling to continue. Abbreviations: IL-6: interleukin 6; mIL-6R: 
membrane IL-6 receptor; sIL-6R: soluble IL-6 receptor; sgp130: soluble glycoprotein 130. 
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CONCLUSIONS AND FUTURE PERSPECTIVES
In this review, we focus on the unique ability of IL-6 to signal via the classic- and trans-signaling 
pathway, and discuss the opposing effects of these signaling routes in OA pathophysiology and 
treatment. Levels of IL-6 are increased in SF and serum of OA patients, and relate to disease 
incidence and pathology. In contrast, regulation of sIL-6R in OA, which controls activation of 
IL-6 trans-signaling, has been overlooked until now and warrants further research. In local joint 
tissues such as cartilage, synovium and bone, IL-6 classic signaling results mainly in protective 
effects, while trans-signaling leads to pro-inflammatory and catabolic effects. However, it is 
highly likely that local regulation of IL-6R levels also determines IL-6 outcome to a great extent. 
Current evidence of IL-6 blockade in experimental OA shows that therapeutic targeting of the 
IL-6 pathway could be a promising treatment strategy to reduce cartilage damage, synovial 
inflammation and subchondral bone pathology in OA patients. Moreover, we propose that 
specific blockade of IL-6 trans-signaling could be a superior treatment strategy, which may result 
in inhibition of deleterious IL-6 effects in OA, while maintaining protective IL-6 signaling via the 
classic pathway.
SEARCH STRATEGY
Articles were selected using the PubMed search engine. To select articles regarding IL-6 in OA, we 
used following search terms present in title or abstract [tiab]: “interleukin-6” in combination with 
search terms covering the topics in this review including “osteoarthritis”, “cartilage”, “synovium”, 
“bone”, “muscle”, “infrapatellar fat pad” and “therapy”. Relevant synonyms were included using 
MeSH terms. Title and abstract of articles were screened for relevant topics as listed in this 
review. Non-English articles, and articles in which IL-6 was only used as a marker of inflammation 
were excluded. In addition, reference lists of cited articles and articles in our personal databases 
were screened for eligibility. Search includes articles published up to January 2020. 
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Cartilage degeneration in OA is caused by disbalance between anabolic and catabolic processes, 
which for a large part is regulated by signaling proteins such as pro-inflammatory cytokines 
and growth factors. In healthy cartilage, the protective growth factor TGF-β maintains cartilage 
homeostasis and has important anti-hypertrophic and anti-inflammatory properties. However, 
pro-inflammatory cytokines can interfere with TGF-β signaling, contributing to disrupted cartilage 
homeostasis and eventually cartilage degeneration. Levels of the pro-inflammatory cytokine 
IL-6 are increased in OA, and directly contribute to cartilage degeneration e.g. via increasing 
expression of matrix degenerative enzymes. Yet, it remains to be elucidated whether IL-6 affects 
TGF-β signaling in chondrocytes, or vice versa. In this thesis, we set out to unravel the interplay 
between components of the IL-6 and TGF-β signaling pathway in articular cartilage and determine 
whether this could play a role in ageing and OA. 
Inflammation-induced SOCS3 does not alter TGF-β signaling in chondrocytes but 
hampers cartilage formation in a three-dimensional MSC pellet culture model
First, we focused on interplay between TGF-β signaling and SOCS3, a protein that is rapidly 
induced by inflammation and functions as an important negative regulator of the IL-6 signaling 
pathway [1, 2]. Previously, it was shown that SOCS3 disrupts TGF-β signaling in macrophages, 
via direct inhibition of the TGF-β signaling molecule Smad3 [3]. Inflammation in OA is known 
to disrupt TGF-β signaling in chondrocytes and additionally inhibits TGF-β-mediated cartilage 
repair. As SOCS3 is a pivotal regulator of inflammation, we investigated whether SOCS3 could 
be a key player in inflammation-induced obstruction of cartilage homeostasis via inhibition 
of TGF-β signaling. In contrast to our initial hypothesis and earlier findings in macrophages, 
our results in chapter two showed that SOCS3 did not alter TGF-β signaling in articular 
chondrocytes. We thoroughly investigated multiple aspects of the TGF-β signaling pathway, and 
did not find an effect of SOCS3 on TGF-β receptor expression, activation or nuclear translocation 
of Smad3, or TGF-β-mediated transcriptional activity in chondrocytes. Possibly, the effect of 
SOCS3 on TGF-β/Smad3 signaling is cell type-dependent, and may be present in other cell 
types such as macrophages [3]. Interestingly, SOCS3 did strongly impair MSC-based cartilage 
formation, a process which is also dependent on TGF-β. More specifically, overexpression of 
SOCS3 resulted in reduced pellet size and sGAG content. However, p-Smad3 levels in SOCS3-
overexpressing MSCs were not different compared to luciferase control. Therefore, and based 
on our observations in chondrocytes, it is likely that SOCS3-dependent inhibition of MSC-based 
cartilage formation is mediated via a different mechanism which is independent of TGF-β. Both 
IGF-1 and STAT3 signaling pathways have been shown to stimulate cartilage formation [4-7], and 
are known targets of SOCS3 [8, 9]. Thus, SOCS3-mediated inhibition of MSC-based cartilage 
formation may therefore be caused by inhibition of IGF-1 or STAT3 signaling, which could be an 
interesting hypothesis for follow-up studies. Despite the lack of impact in mature chondrocytes, 
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based on our findings we suggest that targeting of SOCS3 in an inflammatory OA joint may 
improve MSC-based cartilage repair strategies. However, SOCS3 may also have an important 
protective role in the OA joint, as a key role for SOCS3 in controlling cytokine responses during 
(joint) inflammation has been demonstrated [9, 10]. Therefore care should be taken with this 
approach, as targeting of SOCS3 to improve MSC-based cartilage repair may lead to unwanted 
exacerbation of joint inflammation.
TGF-β restricts IL-6 signaling in chondrocytes via inhibition of IL-6R expression 
Although inflammation-induced SOCS3 did not alter TGF-β signaling in chondrocytes, 
interplay between components of the IL-6 and TGF-β signaling pathway may occur via different 
mechanisms. In chapter three we reveal that in chondrocytes, TGF-β regulates IL-6 signaling on 
multiple levels. We first showed that exposure of human articular chondrocytes to TGF-β rapidly 
induced IL-6 expression and resulted in phosphorylation of STAT3, an IL-6R downstream signaling 
protein. To investigate if the p-STAT3 activation was caused by TGF-β-mediated IL-6 production, 
we stimulated chondrocytes with TGF-β in presence of the IL-6R blocking antibody tocilizumab. 
As expected, induction of p-STAT3 by TGF-β was completely prevented by blockade of the IL-6R, 
suggesting IL-6 dependency. Surprisingly, we observed no effect of TGF-β exposure on gene 
expression of the downstream STAT3-target gene SOCS3, while stimulation with exogenous 
IL-6 significantly increased hSOCS3 expression. As we previously showed that exposure of 
chondrocytes to TGF-β ultimately also leads to IL-6 production, these results suggest that 
TGF-β potentially blocks IL-6-induced regulation of hSOCS3 expression. To unravel the cause 
of this seemingly contradictory finding, we investigated if TGF-β could also block the effects 
of exogenous IL-6. We performed pre-treatment with TGF-β, mimicking the setting where cells 
are first exposed to TGF-β and afterwards to IL-6. Indeed, pre-treatment with TGF-β prevented 
IL-6-mediated induction of p-STAT3 and STAT3 target genes such as hSOCS3, hBCL3, hMMP1 
and hSAA1. These data demonstrate that TGF-β inhibits the IL-6 response in chondrocytes, 
despite upregulating IL-6 itself. In search for the potential underlying mechanism how TGF-β 
inhibits IL-6 signaling, we investigated whether TGF-β could potentially limit IL-6 signaling via 
interference with its receptor. Strikingly, we discovered that TGF-β exposure indeed resulted in a 
strong decrease in hIL6R expression. To confirm that TGF-β-mediated inhibition of IL-6 signaling 
was truly dependent on the IL-6R, we showed that addition of recombinant soluble IL-6R restored 
the TGF-β-mediated reduction of p-STAT3 and IL-6-repsonsive genes. With these experiments 
we uncovered a novel effect of TGF-β, which may play an important role in cartilage homeostasis 
by protecting cartilage via restriction of pro-inflammatory IL-6 effects. As a soluble form of the 
IL-6R is found in OA synovial fluid [11], this may bypass protective TGF-β-mediated inhibition of 
IL-6 signaling, rendering cartilage sensitive again for catabolic IL-6 effects. This highlights soluble 




Ageing negatively affects TGF-β-mediated suppression of IL-6R expression and 
signaling in articular cartilage
After we established that TGF-β regulated IL-6 signaling in cartilage, we hypothesized that ageing 
might affect this regulation as well, as previous studies of our lab showed that TGF-β signaling via 
Smad3 is reduced in ageing cartilage [12-15]. In chapter four, we therefore studied age-related 
changes in TGF-β-mediated regulation of IL-6 signaling. We collected cartilage from bovine MCP 
joints of 80 cows ranging from age 0.5-14 years old, which showed well-known characteristics 
of normal ageing, such as thinning of the cartilage surface, reduced chondrocyte numbers, and 
decreased expression of matrix components such as collagen type 2 and aggrecan [14, 16]. 
As expected, regression analysis showed that expression of bIL6R increased substantially with 
advancing age in articular cartilage (slope: 0.32, 95%CI: 0.20-0.45). In contrast, we observed no 
age-related changes in expression of bGP130 clearly showing that this effect was IL-6R specific. 
To investigate if this change in IL-6R expression translated into the expected enhanced activation 
of intracellular signaling mediator STAT3, we exposed bovine cartilage of different ages to IL-6 ex 
vivo. This revealed that indeed induction of p-STAT3 in response to IL-6 was strongly increased 
upon ageing (slope: 0.14, 95%CI: 0.08 - 0.20). Furthermore, we showed that also IL-6-induced 
gene expression of catabolic target genes like bMMP3, bPTGS2 and bVEGFA was increased in 
aged compared to young cartilage. Together, this confirmed that IL-6R expression and signaling 
was increased in bovine cartilage with advancing age. As we demonstrated in chapter three 
that TGF-β is an important regulator of IL-6R expression in articular cartilage, we hypothesized 
that age-related loss of TGF-β signaling might be the underlying cause for the increase in IL-6R 
levels. Stimulation with TGF-β indeed resulted in suppression of bIL6R in bovine cartilage, which 
was lost upon ageing (slope: 0.21, 95%CI: 0.13-0.30). Concurrently, we observed reduced TGF-
β-mediated suppression of IL-6-induced p-STAT3 and bSOCS3 expression in aged compared to 
young cartilage. Together, these observations provide proof that increased IL-6R expression and 
signaling in ageing cartilage can be explained by loss of TGF-β-mediated IL-6R suppression. 
Due to the catabolic and pro-inflammatory role of IL-6 in OA development, this implies that TGF-
β-mediated loss of IL-6R suppression with age predisposes cartilage to degenerative changes, 
ultimately contributing to age-related OA development. 
The IL-6 signaling pathway as a therapeutic target in OA 
In chapter three and four we established an important role of TGF-β in dampening IL-6 signaling 
in articular cartilage, which might be lost during ageing or inflammation. These implications point 
towards the IL-6 signaling pathway as a potential target in OA. As IL-6 has the unique ability to 
signal via a classic- and trans-signaling pathway, this may have implications for future therapy 
development. In chapter five, we discussed the opposing effects of IL-6 classic versus trans 
signaling in OA pathophysiology and provided future perspective for OA treatment. We reported 
that IL-6 classic signaling mainly results in protective effects in local joint tissues such as cartilage, 
synovium and bone, while trans-signaling leads to pro-inflammatory and catabolic effects. For 
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example, IL-6 trans signaling more strongly activates the expression of cartilage degenerative 
enzymes, while classic signaling has also been linked to protection against matrix degradation. 
Moreover, we described that local regulation of IL-6R levels e.g. by hormones, cytokines and 
epigenetic factors also determines IL-6 outcome to a great extent. Examination of previous 
studies that block IL-6 in experimental OA show that therapeutic targeting of the IL-6 pathway 
could be a promising treatment strategy to reduce cartilage damage, synovial inflammation and 
subchondral bone pathology. However, all of the employed blocking strategies block both the 
classic- and trans signaling pathway. We argue that specific inhibition of IL6 trans signaling in 
OA models might be extremely helpful to dissect detrimental versus protective effects of IL-6 
in the future. In other inflammatory diseases, specific blockade of IL-6 trans signaling using 
soluble gp130 resulted in the blockade of pro-inflammatory events of IL-6 trans signaling, while 
simultaneously allowing homeostatic effects of IL-6 classic signaling. We argue that this approach 
could also be a preferred treatment strategy for OA patients, as several studies demonstrated 
catabolic and proinflammatory effects of IL-6 trans signaling in cartilage and synovial tissue. 
Nonetheless, additional pre-clinical research will first be needed as the significance of IL-6 trans 
signaling in experimental OA has not yet been demonstrated. 
GENERAL DISCUSSION AND FUTURE PERSPECTIVES
In this thesis we have studied two potential crosstalk mechanisms between TGF-β and IL-6 
signaling in articular cartilage. In Figure 1 below, our findings are summarized in a schematic 
representation. Interplay between IL-6 and TGF-β can occur via two routes: 1) regulation of 
TGF-β signaling by IL-6, or 2) regulation of IL-6 signaling by TGF-β. With regard to the first route, 
we showed that SOCS3, as important negative regulator of the IL-6 signaling pathway, does not 
inhibit TGF-β/Smad3 signaling in chondrocytes (chapter two). With regard to the second route, 
we demonstrated that TGF-β has an important role in regulating the IL-6 pathway by suppression 
of IL-6R expression and signaling in chondrocytes (chapter three). Of course this merely 
represents a small selection of the potential mechanisms of interplay between the TGF-β and 
IL-6 signaling pathways. For instance, it still remains to be investigated whether IL-6 regulates 
TGF-β (receptor) expression and signaling or whether Smad3/STAT3 interact in chondrocytes. 
Also, as reviewed in chapter five, it could be important to compare the effects of IL-6 classic- 
versus trans signaling when studying interplay with TGF-β signaling in cartilage. Finally, we show 
that the (patho)physiological context can alter TGF-β and IL-6 crosstalk, such as older age or 
OA-related inflammation as demonstrated in chapter three, four and five of this thesis. 
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Figure 1. Schematic representation of observed interplay between the TGF-β 
and IL-6 signaling pathways as observed in chapter 2, 3 and 4 of this thesis. 
Protective regulation indicated in green, detrimental regulation indicated in red. 
mIL-6R: membrane-bound IL-6R, sIL-6R: soluble IL-6R.
GP130
Figure 1. Schematic representation of observed interplay between the TGF-β and IL-6 signaling 
pathways as observed in chapter 2, 3 and 4 of this thesis. Protective regulation indicated in green, 
detrimental regulation indicated in red. mIL-6R: membrane-bound IL-6R, sIL-6R: soluble IL-6R.
When comparing our findings with published literature, it became clear that crosstalk between 
TGF-β and IL-6 signaling might be strongly cell- or tissue dependent. In T-cell differentiation, for 
example, IL-6 and TGF-β have synergistic effects to stimulate the development of Th17 cells 
[17, 18]. It has been demonstrated that TGF-β increases IL-6R expression in naive T-cells which 
promotes Th17 cell differentiation [17]. Moreover, TGF-β inhibits SOCS3 expression resulting in 
enhanced STAT3 activation which further stimulates Th17 cell development [18]. In the context 
of liver fibrosis on the other hand, TGF-β and IL-6 have an antagonistic relationship. In the liver, 
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IL-6 has an important anti-inflammatory and regenerative role [19], while TGF-β stimulates liver 
fibrosis [20]. Indeed, it has been shown that SOCS3 has a protective role during liver fibrosis 
by inhibiting STAT3-mediated TGF-β production [21]. In articular cartilage, IL-6 and TGF-β are 
thought to have opposite effects, but whether they have a synergistic or antagonistic relationship 
was yet unclear. IL-6 has a detrimental role in cartilage degeneration [22-24], while TGF-β has 
a protective role in cartilage homeostasis [16, 25, 26], which suggests that interplay between 
TGF-β and IL-6 in articular cartilage may result in antagonism. Indeed, in chapter three we 
demonstrate that TGF-β dampens IL-6 signaling via suppression of IL-6R expression in articular 
cartilage, which may be important for the maintenance of cartilage homeostasis. Altogether, 
this suggests that the result of interplay between TGF-β and IL-6 is cell- and context dependent, 
and may depend on the role of these factors in the respective tissue. Indeed, this is a likely 
conclusion as studies show that TGF-β and IL-6 signaling have different roles and impressive 
versatility during context-specific cellular behavior, and that this largely depends on crosstalk 
with other signaling pathways [27-29]. Below we discuss the implications of our mechanistic 
findings in relation to cartilage biology and the development of therapeutic strategies for OA 
patients.
Although we demonstrated in chapter two that SOCS3, as negative regulator of IL-6 signaling 
does not affect TGF-β/Smad3 signaling in articular chondrocytes, a detrimental role for SOCS3 
during MSC-based cartilage formation was identified. This suggests that targeting of SOCS3 
could be a therapeutic strategy to improve cartilage repair in OA. However, SOCS3 is crucial for 
restriction of pro-inflammatory cytokine signaling  [9, 30], suggesting that targeting of SOCS3 in 
OA patients may lead to exacerbated inflammation and cartilage damage, instead of improved 
cartilage repair. Indeed, deletion of SOCS3 in murine articular cartilage resulted in increased 
cartilage degradation, increased joint inflammation and enhanced expression of catabolic 
mediators after intra-articular injection of the IL-6/sIL-6R complex [10]. Furthermore, at present 
there are no inhibitors in the clinic that specifically target SOCS3. Potentially, it would be easier 
to directly target IL-6 itself to prevent upregulation of SOCS3. However, there are several other 
cytokines present in the OA environment which also induce SOCS3 expression via gp130-JAK/
STAT signaling, such as Oncostatin M (OSM), Leukemia Inhibitory Factor (LIF) and IL-11 [1, 
31, 32]. Moreover it may even be disadvantageous to inhibit IL-6 to promote cartilage repair 
as there are some indications that IL-6 signaling may stimulate cartilage regeneration [4, 5]. 
In an in vitro cartilage regeneration model, addition of IL-6 resulted in increased proteoglycan 
production by healthy chondrocytes and decreased proteoglycan release by OA chondrocytes 
[5]. Moreover, chondrogenic differentiation was positively stimulated after addition of IL-6 and 
sIL-6R, resulting in increased matrix generation and cartilage marker gene expression [4]. Thus, 
in vivo targeting of IL-6 or SOCS3 to improve MSC-based cartilage repair is not yet desirable. 
First, it is important to eliminate the possibility that targeting of SOCS3 in the OA joint leads to 
exacerbated inflammation or damage.
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In this thesis, we uncovered a novel function of TGF-β in articular cartilage. We showed that 
TGF-β was able to dampen IL-6 signaling in cartilage via suppressing IL-6R expression. Cartilage 
contains large amounts of inactive TGF-β, which can be activated upon loading [33, 34]. Via 
this mechanism, TGF-β maintains cartilage homeostasis in physiological circumstances, e.g. 
by preventing hypertrophic differentiation of chondrocytes [33, 35]. Possibly, TGF-β mediated 
down regulation of IL-6R is also important for homeostatic regulation of articular cartilage by 
protecting against catabolic IL-6 signaling [33, 36]. In chapter three and four, we identified 
two possible mechanisms how this protective TGF-β effect might be dysregulated during OA. 
First, we showed that soluble IL-6R can bypass TGF-β-mediated IL-6R suppression, rendering 
cartilage sensitive again for catabolic IL-6 signaling. Secondly, we demonstrated that ageing 
negatively affects TGF-β-mediated IL-6R suppression in cartilage, resulting in increased IL-6 
signaling with advancing age (illustrated in Fig 2. of this chapter). These mechanisms shed new 
light on how changes in chondrocyte signaling during ageing or inflammation can contribute to 
IL-6-mediated cartilage degeneration and OA progression. 
As mentioned earlier, soluble IL-6R may be able to bypass TGF-β-mediated IL-6R suppression, 
rendering cartilage sensitive again for catabolic IL-6 signaling. This mechanism is dependent 
on the levels and availability of sIL-6R in OA patients. As described in chapter five, sIL-6R has 
already been detected in OA serum and synovial fluid [37-39], and may even be enhanced in 
a subset of OA patients. Production of sIL-6R is regulated by shedding of membrane-bound 
IL-6R or via differential splicing of IL-6R mRNA [40-42]. Shedding of membrane IL-6R is largely 
regulated by the ADAM class of metzincin proteases, of which ADAM17 (or TACE) and ADAM10 
are identified as important proteases for cleavage of the IL-6R [43, 44]. However, whether 
these proteases are also involved in generation of sIL-6R in OA patients is unknown. It has 
been suggested that ADAM17 activity may be enhanced in OA patients in relation to a rare 
variant of secreted Frizzled-related protein 3 (sFRP3) [45]. As ADAM17 mediates IL-6R shedding, 
this mechanism may contribute to sIL-6R production in OA. sFRP3 acts as an antagonist of 
Wnt signaling, by delaying hypertrophic chondrocyte differentiation and rare variants of sFRP3 
have been associated with OA development [46, 47]. sFRP3 was also identified as a novel 
suppressor of ADAM17 activity, which resulted in inhibition of ADAM17-mediated IL-6R shedding 
[45]. Unfortunately, this study did not confirm whether ADAM17 activity and subsequent sIL-6R 
production were increased in cartilage of OA patients compared to healthy individuals. Besides 
shedding of membrane IL-6R, differential mRNA splicing also contributes to sIL-6R production 
[42]. Differential mRNA splicing generates two distinct IL-6 mRNA transcripts: one encoding sIL-
6R and the other encoding the cognate membrane-bound IL-6R. The first variant lacks the coding 
sequence for the transmembrane domain, which results in a reading frameshift and the introduction 
of a unique COOH-terminal sequence at the tail of this IL-6R isoform [48]. It is not clear yet whether 





















































































































































































































































































































































































DISCUSSION AND FUTURE PERSPECTIVES
screened synovial fluid of 15 OA patients, using an antibody directed against the COOH-terminal 
sequence of sIL-6R, but found only isoforms of differentially spliced sIL-6R in RA patients [49].
Interestingly, levels of sIL-6R are increased up to three-fold in numerous inflammatory diseases 
[50, 51]. As synovitis is observed in around 50% of the OA patients [52-57], it is possible that 
sIL-6R levels are especially increased in inflammatory OA patients. Unfortunately, studies which 
investigate sIL-6R levels in different subsets of OA patients are lacking. Moreover, it is necessary 
to compare sIL-6R levels in OA patients to healthy individuals, to gather evidence that sIL-6R is 
increased during disease and may be relevant in the disease process. As the availability of sIL-
6R in the joint is also determined by the presence of its natural antagonist sgp130 [58], it will 
be crucial to investigate levels of sgp130 in OA patients as well. Thus, in order to demonstrate 
that sIL-6R mediates cartilage degeneration in OA patients by circumventing TGF-β suppression 
of membrane IL-6R in chondrocytes, future studies first need to confirm that sIL-6R is indeed 
increasingly available in (a subset) of OA patients and contributes to OA pathology. This would 
identify sIL-6R as a potential target in OA patients, which could be achieved using a fusion 
protein consisting of two soluble human gp130 proteins fused with the Fc region of human 
IgG (sgp130Fc) [59]. This fusion protein was already successfully used in treating experimental 
Crohn’s disease, is now in clinical trials for inflammatory bowel disease and active ulcerative 
colitis [60, 61] and may also hold promise for OA treatment. 
The data in chapter three (illustrated in Figure 2) demonstrate that TGF-β inhibits the IL-6 
response in articular chondrocytes, despite upregulating IL-6 itself. However, nowadays OA is 
viewed as a “whole joint” disease, with pathophysiological hallmarks such as subchondral bone 
changes, osteophyte formation, inflammation and synovial fibrosis [62, 63]. It is possible that 
TGF-β-induced IL-6 production does not activate chondrocytes due to decreased IL-6R levels 
(as shown in chapter three), but does activate cells in other joint tissues such as synovium or 
bone. However, as reviewed in chapter five, the exact role of IL-6 in (healthy) synovium and 
bone is still unclear making it difficult to interpret the implications of this hypothesis. Alternatively, 
TGF-β may also regulate IL-6R expression in tissues other than articular cartilage. Therefore, it 
would be interesting to investigate whether TGF-β also suppresses IL-6R expression in other 
(joint) tissues or whether this mechanism is unique for articular cartilage. 
In chapter four we described the identification of a second mechanism which bypasses protective 
TGF-β-mediated suppression of IL-6R in chondrocytes and therefore may contribute to cartilage 
damage in OA (Figure 2). We established that ageing leads to loss of TGF-β-mediated IL-6R 
suppression, thus resulting in increased IL-6 signaling in cartilage. As systemic IL-6 levels highly 
increase in ageing individuals [64], this mechanism may be involved in the development of age-
related OA due to detrimental IL-6 effects in cartilage. We expect that the observed loss in TGF-
β-mediated IL-6R expression is caused by decreased expression of ALK5 in aged cartilage. Our 
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lab has previously demonstrated that ALK5 expression strongly decreases with advancing age 
in bovine articular cartilage, while ALK1 expression is unaffected [14]. Moreover, we observed an 
increase in the ratio of ALK1/ALK5 expression in murine cartilage upon ageing, which correlates 
with OA development [13]. In addition, ageing also results in reduced signaling via the protective 
Smad2/3 pathway [12, 14, 16, 65], a pathway which is activated via the ALK5 receptor [66, 67]. 
Interestingly, Smad2 directly regulates IL-6R expression in T-cells [68], supporting our hypothesis 
that TGF-β suppresses IL-6R expression in chondrocytes via the ALK5-Smad2/3 signaling route. 
We did not investigate whether TGF-β-induced IL-6 production by chondrocytes, as observed 
in chapter three, was affected upon ageing. As TGF-β signaling decreases with ageing, 
diminished TGF-β-induced IL-6 production is expected with older age. However, systemic IL-6 
levels are increased with older age [64] and IL-6 is spontaneously produced by senescent 
chondrocytes [64]. It is therefore likely that sufficient IL-6 is present to activate IL-6 signaling in 
articular chondrocytes. Furthermore, it is plausible that miRNA’s are involved as well in TGF-β-
mediated suppression of IL-6R, as epigenetic changes are a hallmark of human ageing, and 
the expression of several miRNA’s is altered in aged cartilage [69, 70]. For example, expression 
of miR-34 is related to cell senescence and mitochondrial dysfunction which also plays a role 
in age-related cartilage degeneration [64, 71-73]. Moreover, TGF-β can modulate expression 
of miR-34a [73], which suggests that altered expression of miR-34a in ageing cartilage may 
contribute to loss of TGF-β-mediated IL-6R suppression and the development of chondrocyte 
senescence and mitochondrial dysfunction. Our observations indicate that reverting or inhibiting 
the age-related increase in IL-6R expression in chondrocytes will be a future challenge to combat 
age-related OA development, for instance by restoring the ALK5-Smad2/3 signaling balance. 
Alternatively, therapies for OA could focus on neutralizing the increase in IL-6 levels observed 
with ageing [64] or upon joint injury [5, 74], in order to prevent activation of highly expressed IL-
6R in aged cartilage. It could be very relevant to study gender-related differences in this context 
as well, as IL-6 has been found to have different effects in males compared to females in relation 
to cartilage damage and OA development [75].
IL-6 has the unique ability two signal via two distinct signaling pathways which is determined by 
activation of either membrane-bound IL-6R (classic signaling) or soluble IL-6R (trans signaling). 
In chapter three we identified a novel mechanism via which TGF-β restricts IL-6 classic signaling 
by suppressing membrane-bound IL-6R expression. Moreover, in chapter four we showed that 
ageing results in increased IL-6 classic signaling in cartilage, which is probably caused by an 
age-related increase in membrane-bound IL-6R expression. Although our results show that IL-6 
classic signaling increases the expression of catabolic mediators in chondrocytes (e.g. MMP-1, 
MMP-3, COX-2, VEGF-A) we did not extensively investigate the long-term effects on cartilage 
matrix synthesis or degeneration. As also protective effects of IL-6 classic signaling in cartilage 
have been demonstrated [5, 76, 77], additional studies are needed that investigate the long-term 
effects of TGF-β-mediated regulation of IL-6 classic signaling on cartilage homeostasis to truly 
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conclude whether this mechanisms is protective. As so far the role of IL-6 in direct modulation 
of proteoglycan synthesis or degeneration is modest [5, 78-81], detrimental IL-6 signaling may 
additionally play a role in other pathological processes in OA. Interestingly, there are indications 
that IL-6 signaling is involved in the development of chondrocyte hypertrophy [82, 83], pre-mature 
senescence [84, 85] or the dysregulation of chondrocyte energy metabolism [86, 87]. It may be 
crucial to study the role of IL-6 in these processes in the future, in order to completely define IL-6 
function in cartilage. Furthermore, we suggest in chapter five that functional differences in IL-6 
classic- versus trans signaling may account for some of the protective and degenerative effects 
of IL-6 in cartilage. This may be of particular importance, as we demonstrate in chapter three 
that the presence of soluble IL-6R can bypass TGF-β-mediated suppression of mIL-6R, leading 
to activation of the IL-6 trans signaling pathway. Several in vitro studies indeed demonstrated 
catabolic and pro-inflammatory effects of IL-6 trans signaling in chondrocytes [22, 88-90], while 
classic signaling has been linked to protective effects such as induction of anti-catabolic TIMPs 
[76, 77]. However, this distinction is not black and white as, for example, IL-6 trans signaling has 
also been reported to increase the production of TIMPs [76]. Moreover, up until now there is no 
direct proof that implicates IL-6 trans signaling in OA development. Therefore, specific inhibition 
of IL-6 trans signaling in OA models is needed to dissect functional differences between IL-6 
classic- versus trans signaling in OA development. Possibly, both the activation of IL-6 trans 
signaling in OA, as well as disturbed expression of mIL-6R levels on chondrocytes contributes to 
IL-6-mediated cartilage degeneration in OA patients.
In this thesis we describe novel interactions between IL-6 and TGF-β signaling in articular cartilage, 
which may be very relevant for cartilage homeostasis and OA development. We provide a strong 
foundation for future fundamental and clinical studies to inhibit IL-6 signaling in OA, and identify 
sIL-6R as a potential therapeutic target. 
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Artrose is de meest voorkomende aandoening aan het bewegingsapparaat. Meer dan 1 
miljoen mensen in Nederland lijden op dit moment aan deze chronische gewrichtsaandoening, 
en er wordt verwacht dat dit aantal aanzienlijk toe zal nemen in de toekomst onder andere 
door verdere vergrijzing van de bevolking. Er is niet één duidelijke oorzaak te benoemen voor 
artrose, maar meerdere risicofactoren verhogen de kans op ontwikkeling van deze ziekte. 
Belangrijke risicofactoren zijn erfelijke aanleg, ouderdom, het vrouwelijke geslacht, overgewicht 
en gewrichtstrauma. Een belangrijk kenmerk van artrose is dat de kwaliteit van de kraakbeen 
laag op de gewrichtsuiteinden zodanig verminderd dat dit resulteert in functieverlies. Het 
gladde oppervlak zorgt ervoor dat de gewrichtsuiteinden soepel langs elkaar heen kunnen 
bewegen. Tevens heeft het kraakbeen een essentiële functie in het gewricht door middel van 
het dempen van belasting die ontstaat door beweging.  Bij afbraak van het kraakbeen, zoals 
tijdens artrose, ontstaat er uiteindelijk direct bot op bot contact wat gepaard gaat met pijn en 
bewegingsbeperking. Naast schade aan het kraakbeen, ontstaan er andere veranderingen 
in het gewricht. Zo neemt de dichtheid van het onderliggende (subchondrale) bot toe, en 
daarnaast ontwikkelen er abnormale botknobbels aan de rand van het gewricht. Artrose 
kan in één gewricht voorkomen zoals alleen in de knie, heup of duim, maar ook in meerdere 
gewrichten tegelijkertijd. Veel voorkomende klachten zijn stijfheid en pijn. Huidige therapieën 
richten zich op symptoombestrijding, zoals het bestrijden van pijn en verbetering van levensstijl 
door meer beweging en gewichtsverlies. Tevens kan bij vergevorderde artrose een gewricht 
worden vervangen door een kunstgewricht. Pijnklachten zijn echter niet altijd verholpen door een 
gewrichtsvervanging, en de kunstgewrichten hebben een beperkte levensduur van gemiddeld 
15 jaar. Op dit moment kan artrose niet worden genezen en hierdoor is er een grote behoefte aan 
een therapie die het ziekteproces remt. Voor de ontwikkeling van deze therapieën is het uiterst 
belangrijk om te begrijpen hoe kraakbeen zich gedraagt in een gezond gewricht en waarom er 
schade ontstaat tijdens de ontwikkeling van artrose. 
Artrose en gewrichtskraakbeen
Gewrichtskraakbeen, ook wel articulair kraakbeen genoemd, bestaat uit kraakbeencellen omringd 
door extracellulaire matrix die stevigheid en structuur biedt. Matrixmoleculen aanwezig in de 
extracellulaire matrix, zoals aggrecan en collageen type II, zijn belangrijk voor de functie van het 
kraakbeen als schokdemper. Kraakbeencellen zijn essentieel voor onderhoud van een gezonde 
kraakbeenmatrix. Onder andere door een balans te onderhouden tussen afbraak van kraakbeen 
middels kraakbeenafbrekende enzymen, en de aanmaak van nieuwe matrixmoleculen. In gezond 
kraakbeen, is er een balans tussen de opbouwende (= anabole) en afbrekende (= katabole) 
processen. Tijdens artrose is deze balans echter verstoord, resulterend in een verschuiving 
naar kraakbeenafbraak. Katabole processen tijdens artrose worden onder andere gereguleerd 
CHAPTER 7
162
door ontstekingsmediatoren. Zelfs bij milde artrose speelt een lichte, chronische ontsteking in 
het gewricht een belangrijke rol. Artrose is niet te vergelijken met ontstekingsreuma; een auto-
immuunziekte waarbij hevige, chronische ontsteking optreedt in meerdere gewrichten. Bij 
artrose wordt met name ontsteking in de slijmvlieslaag (synovium) van het gewricht vastgesteld 
in zeker 50% van de artrose patiënten. Het remmen van ontstekingsfactoren tijdens artrose is 
dus mogelijk een belangrijk aangrijpingspunt voor de ontwikkeling van toekomstige therapieën. 
De rol van groeifactor TGF-β in gezond en verouderd kraakbeen 
Zoals eerdergenoemd, is er in een balans tussen de opbouwende (= anabole) en afbrekende (= 
katabole) functies van kraakbeencellen in gezond kraakbeen. Deze balans wordt onder andere 
gereguleerd door signaalmoleculen buiten de cel, die kraakbeenopbouw of afbraak stimuleren. 
Een belangrijke signaalmolecuul die kraakbeen gezond houdt, is de groeifactor TGF-β (= 
transforming growth factor-β).  TGF-β stimuleert bijvoorbeeld de productie van extracellulaire 
kraakbeen matrix en heeft een belangrijke ontstekingsremmende werking in kraakbeen. Echter 
is deze beschermende werking van TGF-β verstoord tijdens artrose, en kan TGF-β hier zelfs 
een schadelijke rol hebben in het gewricht. TGF-β kan via twee verschillende signaalroutes 
kraakbeencellen activeren, die gebruik maken van een andere receptor genaamd ALK5 en 
ALK1. Binding van TGF-β aan deze receptoren resulteert in de activatie van intracellulaire Smad-
moleculen. Eerder onderzoek heeft aangetoond dat binding van TGF-β aan de ALK5 receptor 
voornamelijk leidt tot activatie van de Smad2/3 signaalroute. Binding van TGF-β aan de ALK1 
receptor leidt tot activatie van de Smad1/5/9 route. In gezond kraakbeen wordt voornamelijk de 
ALK5-Smad2/3 signaalroute geactiveerd, welke kraakbeenopbouwende processen stimuleert 
en een beschermende werking heeft op kraakbeen. Tijdens artrose is de hoeveelheid ALK5 
echter verlaagd op de kraakbeencellen, wat leidt tot verminderde activatie van de Smad2/3 
signaal route waardoor de ALK1-Smad1/5/9 signaalroute de overhand heeft. De ALK1-
Smad1/5/9 route is echter betrokken bij kraakbeenafbrekende processen zoals de productie 
van kraakbeenafbrekende enzymen. Eerder onderzoek heeft aangetoond dat ook tijdens 
veroudering de beschermende ALK5-Smad2/3 signaalroute van TGF-β verminderd werkzaam 
is in kraakbeen, wat mogelijk bijdraagt aan het ontstaan van leeftijdgerelateerde artrose. Door 
te onderzoeken wat de oorzaak is van de verstoorde werking van TGF-β tijdens veroudering 
en artrose kunnen mogelijk in de beschermende en schadelijke effecten van TGF-β van elkaar 
gescheiden worden in de toekomst.  Deze kennis zou kunnen leiden tot de ontwikkeling van 
therapieën die kraakbeenschade remmen of voorkomen. Zoals eerdergenoemd speelt ontsteking 
een belangrijke rol in het ontstaan van kraakbeenschade en artrose. In kraakbeen leidt de 
aanwezigheid van ontstekingsmediatoren bijvoorbeeld tot stimulatie van kraakbeenafbrekende 
processen. Er zijn aanwijzingen dat de aanwezigheid van ontstekingsmediatoren tijdens artrose 
de signaalroute van TGF-β kunnen verstoren. In dit proefschrift onderzoeken we de interactie 





IL-6 is een ontstekingsmediator die in hoge spiegels aanwezig is in de gewrichtsvloeistof van 
patiënten met artrose. Tevens zijn verhoogde waarden van IL-6 in het bloed geassocieerd met 
een verhoogde kans op artrose. Dit suggereert dat IL-6 een belangrijke speler kan zijn in het 
ontstaan van artrose. De IL-6 signaalroute wordt geactiveerd door binding van IL-6 aan de IL-6 
receptor (IL-6R) op de cel, waarna de intracellulaire mediator STAT3 wordt geactiveerd. Deze IL-
6R is echter niet aanwezig op elk celtype, waardoor gevoeligheid voor IL-6 lokaal gereguleerd kan 
worden. Eerder onderzoek laat zien dat de IL-6R in lage niveaus aanwezig is op kraakbeencellen, 
maar dat het expressieniveau verhoogd wordt door onder andere epi genetische regulatie of 
door ontsteking. Een belangrijke remmer van de IL-6 signaalroute is het eiwit suppressor of 
cytokine signaling 3 (SOCS3). SOCS3 wordt snel geactiveerd door IL-6, en zorgt voor negatieve 
terugkoppeling via de remming van intracellulaire mediator STAT3. In het kraakbeen van artrose 
patiënten is SOCS3 verhoogd aanwezig, wat mogelijk duidt op sterke activatie van de IL-6 
signaalroute. IL-6 heeft een schadelijke rol in kraakbeen en stimuleert kraakbeenafbrekende 
processen. In vitro experimenten laten zien dat stimulatie van kraakbeencellen met IL-6 resulteert 
in verhoogde productie van kraakbeenafbrekende enzymen, zoals matrix metalloproteinases 
(MMPs) en A Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS) 
enzymen. In vivo studies bevestigen deze schadelijke rol van IL-6 in kraakbeen. Injectie van IL-6 
in het kniegewricht van de muis resulteert in kraakbeenschade en verhoogde MM-3 en MMP-13 
expressie. Therapeutische remming van IL-6 tijdens experimentele artrose in muismodellen 
vermindert kraakbeenschade en synoviale ontsteking. Dit suggereert dat IL-6 mogelijk een 
belangrijke rol speelt in het ontstaan van kraakbeenschade tijdens artrose.
Doel van dit proefschrift
Ondanks dat zowel TGF-β als IL-6 cruciale processen reguleren in articulair kraakbeen, is het 
nog onbekend of deze twee signaalmoleculen elkaar beïnvloeden. IL-6 heeft een schadelijke rol 
in kraakbeen terwijl TGF-β juist beschermend werkt. Het is mogelijk dat interactie tussen TGF-β 
en IL-6 deze rollen beïnvloedt, resulterend in minder of juist meer kraakbeenschade. TGF-β heeft 
bijvoorbeeld een belangrijke ontstekingsremmende functie in kraakbeen, en eerdere studies 
hebben aangetoond dat schadelijke effecten van ontstekingsmediatoren zoals TNF-α en IL-1β 
geremd worden door TGF-β. Het is echter nog niet onderzocht of TGF-β ook de schadelijke 
effecten van IL-6 in kraakbeen kan remmen. Daarnaast is het bekend dat ontsteking kan leiden 
tot verstoring van de beschermende werking van TGF-β in kraakbeen, maar of IL-6 betrokken 
is bij verstoring van de TGF-β signaalroute tijdens artrose is nog onbekend. Een eerdere studie 
laat zien dat het eiwit SOCS3 de signaalroute van TGF-β verstoort in afweercellen, via remming 
van Smad3. Aangezien SOCS3 sterk wordt geactiveerd door IL-6, en beide IL-6 en SOCS3 
verhoogd aanwezig zijn tijdens artrose, is het mogelijk dat SOCS3 de TGF-β signaalroute 
verstoort in kraakbeen van artrose patiënten. In dit proefschrift hebben we deze potentiële 
interacties tussen de signaalroutes van TGF-β en IL-6 bestudeerd in articulair kraakbeen, en 
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de implicaties hiervan bestudeerd tijdens veroudering en artrose. Door te onderzoeken welk 
samenspel van factoren kraakbeen gezond houdt, en hoe dit verstoord is tijdens artrose, kunnen 
er nieuwe aangrijpingspunten voor therapie worden ontwikkeld met als doel het remmen of zelfs 
voorkomen van kraakbeenschade. 
SOCS3 heeft geen remmend effect op TGF-β signaalroute in kraakbeen maar verstoort 
mogelijk kraakbeenherstel
Zoals vermeld kunnen ontstekingsfactoren de werking van TGF-β verstoren wat mogelijk 
bijdraagt aan de ontwikkeling van kraakbeenschade. Een centrale factor die aanwezig is tijdens 
ontstekingsprocessen is het eiwit SOCS3 dat sterk geactiveerd wordt door aanwezigheid van 
IL-6. Het is eerder aangetoond dat SOCS3 de TGF-β signaalroute verstoord in andere celtypen 
(macrofagen), door de belangrijkste signaalmolecuul van de TGF-β signaalroute, Smad3 te 
remmen. Het is eerder bewezen dat SOCS3 verhoogd aanwezig is in kraakbeen en synovium 
tijdens artrose. In hoofdstuk 1 hebben we onderzocht of deze verhoogde expressie van 
SOCS3 tijdens gewrichtsontsteking kan leiden tot verstoring van TGF-β signaalroute en functie 
in articulair kraakbeen. Dit zou een mogelijke verklaring zou kunnen zijn voor ontwikkeling van 
kraakbeenschade tijdens artrose. We hebben dit onderzocht door de eiwitproductie van SOCS3 
artificieel te verhogen in kraakbeencellen, en vervolgens meerdere componenten van de TGF-β 
signaalroute te onderzoeken zoals de expressie van de TGF-β receptoren en de activatie van 
Smad-moleculen in de cel. In tegenstelling tot de eerdere bevindingen, zoals die in macrofagen, 
laten onze resultaten geen effect zien van SOCS3 op de TGF-β signaalroute in kraakbeen. Dit 
suggereert dat het effect van SOCS3 op de TGF-β signaalroute mogelijk verschilt per celtype. 
Naast het effect van SOCS3 op de signaalroute van TGF-β, hebben we ook de rol van 
SOCS3 in kraakbeenvorming getest. Om het beschadigde kraakbeen van artrose patiënten te 
herstellen kan gebruik gemaakt worden van mesenchymale stamcellen. Deze stamcellen zijn 
in staat om nieuw kraakbeen te vormen onder bepaalde omstandigheden, bijvoorbeeld door 
de toevoeging van de groeifactor TGF-β. De ontstekingsomgeving van een artrotisch gewricht 
heeft echter een remmende werking op deze nieuwe kraakbeenvorming, wat de toepassing van 
deze techniek belemmert. In theorie zou verhoogde expressie van SOCS3 tijdens artrose de 
vorming van nieuw kraakbeen dus kunnen remmen. Om dit aan te tonen hebben we de SOCS3 
eiwitproductie verhoogd in mesenchymale stamcellen en vervolgens deze cellen geweekt 
in een driedimensionaal (3D)-pellet model. Dit is een geschikt model om kraakbeenvorming 
te bestuderen onder invloed van de groeifactoren TGF-β en BMP-2, gedurende een periode 
van 7 dagen. Verhoogde expressie van SOCS3 resulteerde in een sterke remming van de 
kraakbeenvorming. Stamcelpellets met verhoogde SOCS3 niveaus waren duidelijk kleiner 
en vertoonde significant minder extracellulaire kraakbeen matrix dan stamcelpellets met het 
controle eiwit. De activatie van het TGF-β signaalmolecuul Smad3 in de stamcellen was echter 




onafhankelijk is van TGF-β, maar voortkomt uit een ander mechanisme. Een mogelijke kandidaat 
is de signaalmolecuul IGF-1. IGF-1 is cruciaal voor de aanmaak van kraakbeenbouwstenen zoals 
glycosaminoglycanen. Tevens is het bekend dat SOCS3 de IGF-1 signaalroute remt in articulair 
kraakbeen. Mogelijke vervolgstudies moeten uitwijzen of verminderde kraakbeenvorming 
door SOCS3 verklaard kan worden door remming van de IGF-1 signaalroute. Deze resultaten 
suggereren dat de remming van SOCS3 in een artrotisch gewricht zou kunnen leiden tot beter 
herstel van kraakbeenschade tijdens stamceltherapie. Echter heeft SOCS3 ook een potentiële 
beschermende rol in het artrotisch gewricht, als negatieve regulator van ontstekingscytokines 
zoals IL-6. Mogelijk is het therapeutisch remmen van SOCS3 daardoor niet wenselijk, omdat het 
kan leiden tot verergerde gewrichtsontsteking en schade. 
TGF-β remt IL-6 signaalroute in kraakbeen via het verlagen van de IL-6 receptor
Interactie tussen de TGF-β en IL-6 signaalroutes kan plaatsvinden via verschillende mechanismen. 
In andere celtypen is beschreven dat TGF-β effecten van IL-6 kan remmen, maar of dit ook 
plaatsvindt in kraakbeen is nog onbekend. Aangezien IL-6 een schadelijk effect heeft in kraakbeen, 
zou dit een mogelijk beschermend mechanisme kunnen zijn. In hoofdstuk 3 beschrijven we 
dat TGF-β de IL-6 signaalroute op meerdere manieren beïnvloedt in humane kraakbeencellen. 
Ten eerste hebben we aangetoond dat het toevoegen van TGF-β aan kraakbeencellen leidt tot 
productie van IL-6 en activatie van de intracellulaire mediator STAT3. Dit suggereert dat TGF-β 
de IL-6 signaalroute mogelijk stimuleert in kraakbeencellen. Dit was een verrassende bevinding, 
omdat TGF-β juist een aangetoonde ontstekingsremmende werking heeft in kraakbeen. Om te 
onderzoeken of activatie van STAT3 ook leidde tot de activatie van genexpressie, hebben we de 
expressie van het STAT3-afhankelijke gen SOCS3 gemeten. Echter werd de expressie van SOCS3 
enkel verhoogd na stimulatie met recombinant IL-6 en niet door TGF-β, terwijl we eerder hadden 
aangetoond dat er na TGF-β stimulatie ook IL-6 werd geproduceerd. Deze resultaten suggereren 
dat TGF-β mogelijk de verdere IL-6 signaalroute remt. Gebaseerd op deze hypothese hebben we 
onderzocht of TGF-β de effecten van recombinant IL-6 kan remmen. Inderdaad, in aanwezigheid 
van TGF-β werd de activatie van STAT3 na IL-6 stimulatie sterk geremd. Ook de expressie van 
STAT3-afhankelijke genen zoals SOCS3, BCL3, MMP1 en SAA1 werd minder sterk geactiveerd 
door IL-6 als TGF-β aanwezig was. Deze resultaten demonstreren dat TGF-β de signaalroute van 
IL-6 remt in kraakbeen, ondanks dat er IL-6 wordt geproduceerd door de cellen zelf. Een mogelijk 
mechanisme hoe TGF-β de IL-6 signaalroute zou kunnen remmen is als het de aanwezigheid 
van de IL-6 receptor (IL-6R) op celmembranen zou kunnen beïnvloeden. Het bleek inderdaad dat 
na stimulatie met TGF-β de expressie van de IL-6R in kraakbeen sterk verlaagd was. We hebben 
dit effect in kraakbeen van meerdere artrose patiënten vastgesteld, wat laat zien dat dit een 
algemeen mechanisme is. Om te bevestigen dat de verlaging van de IL-6R de onderliggende 
reden is voor de remming van de IL-6 signaalroute door TGF-β hebben we gebruik gemaakt van 
een oplosbare variant van de IL-6R (= sIL-6R) die niet aan het membraan van cel gekoppeld zit. 
Na het toevoegen van sIL-6R, wat de verlaging van de IL-6R op de kraakbeencellen omzeilt, was 
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het remmende effect van TGF-β op de IL-6 signaalroute verdwenen. Deze resultaten onthullen 
een nieuwe rol van TGF-β in kraakbeen. In de gewrichtsvloeistof van artrose patiënten is de 
oplosbare variant van de IL-6R aanwezig, wat mogelijk het beschermende effect van TGF-β 
omzeilt en bijdraagt aan kraakbeenschade tijdens artrose. Op basis van deze bevindingen zou 
de oplosbare IL-6R een potentieel therapeutisch target kunnen zijn in artrosepatiënten.  
Remming van de IL-6 receptor en signaalroute door TGF-β gaat verloren in verouderd 
kraakbeen
Nadat we hadden vastgesteld dat TGF-β een beschermende rol heeft in kraakbeen via remmen 
van de IL-6 signaalroute, vroegen we ons af of dit mechanisme mogelijk beïnvloed wordt door 
veroudering van het kraakbeen. Een hoge leeftijd is de belangrijkste risicofactor voor artrose. Ons 
laboratorium heeft reeds aangetoond dat de beschermende TGF-β signaalroute via Smad2/3 
minder geactiveerd wordt in verouderd kraakbeen, wat mogelijk het kraakbeen kwetsbaarder 
maakt voor de ontwikkeling van schade en artrose. In hoofdstuk vier hebben we daarom 
onderzocht of door het verlies van de Smad2/3 signaalroute in verouderd kraakbeen ook de 
remmende invloed van TGF-β op de IL-6R verloren gaat. Helaas is gezond humaan kraakbeen 
zeer moeilijk te verkrijgen. Om veroudering in kraakbeen te bestuderen is daarom gebruik 
gemaakt van runderkraakbeen, aangezien dit sterk lijkt op humaan kraakbeen en beschikbaar 
is in een brede leeftijdreeks. Alle veranderingen die in verouderd menselijk kraakbeen worden 
waargenomen zijn ook zichtbaar in verouderd runderkraakbeen, zoals het dunner worden van 
het kraakbeen, het verlies van kraakbeencellen, en het verlies van kraakbeenbouwstenen zoals 
aggrecan. Door het gebruik van runderkraakbeen kan bovendien artrotisch kraakbeen worden 
uitgesloten door middel van visuele inspectie, waardoor artrose en veroudering los van elkaar 
bestudeerd kunnen worden. Om het effect van veroudering op TGF-β-gemedieerde regulatie 
van de IL-6 signaalroute te onderzoeken hebben we kraakbeen van het metacarpofalangeale 
gewricht van 80 koeien verzamelt met een leeftijd van 0.5 -14 jaar oud. We hebben aangetoond 
dat de genexpressie van de IL-6R sterk toeneemt in verouderd runderkraakbeen. Daarentegen 
vonden we geen leeftijdsafhankelijke effecten in de genexpressie van IL-6 receptor β (GP130), 
die belangrijk is voor de signaaltransductie van andere ontstekingsmediatoren van de IL-6 
familie zoals oncostatin M en leukemia inhibitory factor. Dit suggereert dat de toename in IL-6R 
expressie met leeftijd specifiek is voor de IL-6 route. Vervolgens hebben we onderzocht of de 
verhoogde IL-6R expressie met leeftijd ook resulteert in een verhoogde reactie op IL-6. Inderdaad, 
na stimulatie met IL-6 werd het intracellulaire signaaleiwit STAT3 sterker geactiveerd met een 
toenemende leeftijd. Ook de activatie van IL-6 afhankelijke genexpressie die een rol spelen 
in kraakbeenschade, zoals bMMP3, bPTGS2 en bVEGFA, was sterk verhoogd in verouderd 
kraakbeen ten opzichte van jong kraakbeen. Deze resultaten bevestigen dat de IL-6R expressie 
en de IL-6 signaalroute verhoogd zijn in verouderd koeienkraakbeen. Aangezien we in hoofdstuk 
drie hebben laten zien dat TGF-β een belangrijke rol speelt in het remmen van IL-6R expressie, 




oorzaak is voor de verhoogde IL-6R expressie met leeftijd. Om dit te onderzoeken hebben we 
runderkraakbeen van koeien van verschillende leeftijden gestimuleerd met TGF-β, en gekeken 
naar het effect op de expressie van IL-6R. Zoals verwacht was IL-6R expressie sterk verlaagd na 
TGF-β stimulatie in jong kraakbeen, maar ging dit effect verloren in verouderd kraakbeen. Tevens 
hebben we onderzocht of het remmend effect van TGF-β op de IL-6 signaalroute verandert in 
jong ten opzichte van oud koeienkraakbeen. Stimulatie met TGF-β resulteerde in remming van 
IL-6-gemedieerde activatie van STAT3 en genexpressie van SOCS3 in jong kraakbeen, terwijl 
in verouderd kraakbeen deze remming van TGF-β sterk verminderd was. Samengenomen 
laten deze waarnemingen zien dat de verhoging in IL-6R expressie en de IL-6 signaalroute in 
verouderd kraakbeen verklaard kan worden door verlies van TGF-β-gemedieerde verlaging 
van de IL-6R, hetgeen in jong kraakbeen nog volop actief is. Aangezien IL-6 een schadelijke 
rol heeft tijdens artrose ontwikkeling, impliceren deze bevindingen dat het verlies van TGF-β-
gemedieerde verlaging van de IL-6R in verouderd kraakbeen zorgt voor verhoogde gevoeligheid 
voor IL-6 gemedieerde schade, wat mogelijk bijdraagt aan de ontwikkeling van artrose. 
De IL-6 signaalroute als therapeutisch doelwit in artrose
In hoofdstuk drie en vier hebben we een beschermende rol aangetoond voor TGF-β als 
remmer van de IL-6 signaalroute in kraakbeen, welke mogelijk is verstoord tijdens veroudering 
of tijdens artrose. Aangezien IL-6 een schadelijke rol heeft in kraakbeen, draagt verstoring van 
dit beschermende TGF-β mechanisme mogelijk bij aan de ontwikkeling van artrose. Deze 
bevindingen impliceren dat de IL-6 signaalroute een mogelijk therapeutisch doelwit zou kunnen 
zijn voor artrose patiënten. De IL-6 signaalroute is uitermate complex, onder andere omdat het 
op twee verschillende manieren geactiveerd kan worden: via de klassieke en trans-signaalroute. 
De klassieke route wordt geactiveerd via de IL-6R op het celmembraan, terwijl de trans-
signaalroute wordt geactiveerd via de eerdergenoemde oplosbare variant van de IL-6R (sIL-6R). 
Eerder onderzoek wijst uit dat activatie van de deze routes kan leiden tot andere effecten in 
gewrichtweefsels, zoals kraakbeen, waarbij de klassieke route vaak beschermend is en de trans-
signaalroute juist schadelijk. Aan de hand van literatuuronderzoek, beschrijven we in hoofdstuk 
vijf de verschillende rol van de klassieke en trans-signaalroute van IL-6 in het gewricht en tijdens 
de ontwikkeling van artrose, en geven we een toekomst perspectief voor therapie ontwikkeling. 
De onderzochte literatuur wijst uit dat de klassieke IL-6 signaalroute voornamelijk betrokken is bij 
beschermende effecten binnen het gewricht, zoals in kraakbeen en synovium, door het remmen 
van kraakbeenafbraak via de productie van beschermende stoffen zoals TIMP-eiwitten. De trans-
signaalroute daarentegen, draagt bij aan de productie van kraakbeen afbrekende enzymen, zoals 
MMP en ADAMTS-eiwitten, en de verhoging van ontsteking in kraakbeen en synovium. Echter 
plaatsen we ook de kanttekening dat deze scheiding niet altijd zwart-wit is, maar er bijvoorbeeld 
ook schadelijke effecten worden gevonden van de klassieke IL-6 signaalroute. Mogelijk wordt 
het uiteindelijke effect van de IL-6 route tevens beïnvloed door het lokale milieu, zoals de 
aanwezigheid van ontsteking- of groeifactoren. We beschrijven dat lokale regulatie van IL-6R 
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expressie, bijvoorbeeld door hormonen, cytokines en epigenetische factoren, de functie van IL-6 
in het gewricht kan beïnvloeden. Lokale verhoging van de IL-6R, bijvoorbeeld door ontsteking, 
kan bijdragen aan verhoogde activatie van de klassieke IL-6 signaalroute. Verscheidene in vivo 
studies laten zien dat het remmen van IL-6 tijdens experimentele artrose opgewerkt in muizen een 
beschermend effect heeft en leidt tot verminderde kraakbeenschade, subchondrale botschade 
en synoviale ontsteking. Echter maken deze studies geen onderscheid tussen de remming van 
de klassieke en trans-signaalroute van IL-6. Op basis van de onderzochte literatuur suggereren 
wij dat dat het specifiek blokkeren van de trans-signaalroute in vivo een slimme strategie zou 
zijn om de beschermende versus de schadelijke effecten van IL-6 te onderscheiden in de 
toekomst. Voorgaande studies toonden aan dat IL-6 trans-signaalroute geremd kan worden 
door toevoeging van ‘soluble gp130’, wat resulteerde in de remming van schadelijke effecten 
terwijl de beschermende effecten van de klassieke route intact bleven. Wij suggereren dat deze 
strategie mogelijk ook interessant is voor de behandeling van artrose patiënten, echter is er 
eerst aanvullend preklinisch onderzoek nodig die de significantie van IL-6 trans signaalroute in 
muismodellen met experimentele artrose aantoont.    
Conclusie
In dit proefschrift beschrijven we interacties tussen de IL-6 en TGF-β signaalroutes in articulair 
kraakbeen, die mogelijk zeer relevant zijn tijdens kraakbeen homeostase en artroseontwikkeling. 
We beschrijven een nieuwe, beschermende rol van TGF-β via het remmen van de IL-6 signaalroute 
door het verlagen van de IL-6R. Tevens laten we zien dat dit beschermende mechanisme mogelijk 
omzeilt wordt tijdens artrose door de aanwezigheid van soluble IL-6R, of tijdens veroudering 
door het verlies van TGF-β-gemedieerde IL-6R suppressie. De resultaten gepresenteerd in dit 
proefschrift bieden een goede basis voor toekomstige fundamentele en klinische studies om te 
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veel geleerd over mijn eigen talenten, valkuilen en wensen in mijn persoonlijke leven en carrière. 
Ik heb geen moment spijt gehad van de keuze om te promoveren en kijk er met veel plezier op 
terug, ondanks dat het wetenschappelijke hoofdstuk nu voor mij is afgesloten. Het einde van 
dit traject is door COVID-19 helaas anders verlopen dan verwacht. Het gedwongen huisarrest 
heeft me echter wel de kans geboden om (op tijd) te beginnen met schrijven en dit proefschrift 
af te ronden. Dit omschrijft dan ook goed mijn instelling; ik zie het glas graag halfvol, en niet 
halfleeg. Er hebben heel veel mensen bijgedragen aan dit proefschrift, en ik wil graag enkele in 
het bijzonder bedanken. 
Allereest mijn promotie team; Esmeralda, jij hebt mij de kans geboden om te starten aan 
het SOCS3-project, na mijn MSc stage op de afdeling. Dit was de start van een hele fijne 
samenwerking, waarin ik veel heb geleerd van je onophoudelijke enthousiasme en creativiteit 
binnen het onderzoek, het onderwijs en het maken van presentaties en figuren. Bedankt voor al 
je vertrouwen en je betrokkenheid. Samen met Fons waren jullie een goed op elkaar ingespeeld 
duo, die mij continu uitdaagden om kritisch te blijven nadenken, mijn eigen onderzoekslijn te 
sturen en mij buiten de gebaande paden te begeven. Het begin van het project liep initieel 
niet zoals verwacht (wat dan misschien wel weer te verwachten is), en zonder jullie duidelijke 
aansporing om het project over een andere boeg te gooien had dit boekje er geheel anders 
uitgezien. Fons, hoewel je me soms van mijn stuk bracht met je volstrekt uiteenlopende ideeën, 
is dit ontzettend leerzaam geweest voor mij. In de wetenschap raak je snel verstrikt in een vorm 
van tunnel-denken, en jij kan als geen ander iemand hieruit sturen. Dankzij jullie beide heb ik 
het project naar mij eigen hand kunnen zetten, waar ik heel erg trots op ben. Ik hoop dat jullie 
een duo kunnen blijven in de toekomst, en dat de combinatie projecten tussen werkgroepen op 
de afdeling worden doorgezet, want: samen sta je sterker! Peter, als echte TGF-β man werd jij 
toenemend enthousiast toen SOCS3 uit de picture verdween en TGF-β steeds meer verscheen. 
Jouw kennis over kraakbeen en TGF-β hebben een grote bijdrage geleverd aan dit proefschrift. 
Bedankt dat ik op jouw afdeling mocht promoveren! 
De manuscriptcommissie, bestaande uit Prof. Dr. I. Joosten, Prof. Dr. G.J.V.M van Osch en 
Dr. M.J.W. Adjobo-Hermans, wil ik bedanken voor de tijd en moeite die ze hebben gestoken in 
het beoordelen van dit proefschrift en hun aanwezigheid bij mijn verdediging.
Bovendien wil ik ook graag het Reuma Nederland bedanken voor de
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financiering van het project. Ook wil ik graag mijn patiënten partner Wilma bedanken. Ik ben je 
dankbaar voor alle dingen die je mij hebt geleerd over het hebben van artrose, en de input die je 
hebt geleverd tijdens onze samenwerking.
Tijdens een promotietraject deel je lief en leed, en het fijnste is om dit te bespreken met collega’s 
die snappen waar je het over hebt. Ellen, Nathalie en Trisha, jullie hebben mijn tijd op lab 
Reuma zoveel leuker gemaakt. Hoe leuk is het als je collega’s ook vriendinnen worden! Ons 
geklets over experimenten, PhD stress, de nieuwste lab-roddels, maar ook over persoonlijke 
onderwerpen heeft voor veel steun en plezier gezorgd de afgelopen jaren. Ellen, jouw vrolijkheid 
en eerlijkheid is ontwapenend en door jou voelde ik me gelijk op mijn plek in werkgroep drie. Ik 
ben heel trots dat ik je mocht bijstaan als paranimf. Trisha, ik heb ontzettend veel bewondering 
voor jouw lef, je Nederlandse talenknobbel en je social skills. Ik hoop dat je nog lang bij mij om 
de hoek woont, en we samen van lekker eten kunnen genieten! Nathalie, mijn mede cowgirl. Je 
bent een mega lieve, en attente vriendin en ik mis ons dagelijks contact op het lab. Ik ben heel 
blij dat je mijn paranimf bent vandaag!  
Tijdens mijn promotie had ik het voorrecht om deel uit te maken van twee werkgroepen. De 
kraakbeen kennis in werkgroep drie heeft me veel gebracht. De wekelijkse vergadering was 
ontzettend leuk én leerzaam. Bedankt Henk, Arjen (of was het Arjan?), Elly, Laurie, Margot en 
Natalia voor al jullie support en gezelligheid! Arjan en Guus, als postdoc in werkgroep 3 waren 
jullie een belangrijke vraagbaken op de werkvloer. Onderschat niet hoe belangrijk dit is voor 
promovendi, veel dank hiervoor! Arjan, jouw onderzoek, inzichten en “koeienkennis” waren een 
grote bijdrage aan dit proefschrift. Ik hoop dat het je is gegund om in de wetenschap te blijven, 
want dat is je op het lijf geschreven. De onderwerpen binnen werkgroep 2 waren wat meer 
gevarieerd, maar dat maakte het juist zo leuk! De discussies over EVs, TAM-receptoren, SOCS3 
en gentherapie, hebben mijn kijk sterk verbreed en ik vond het ontzettend leerzaam om met jullie 
projecten mee te denken: Onno, Bartijn, Claire, Mathijs, en Silke. Miranda, bedankt voor het 
opstarten van het SOCS3 onderzoek; zonder jou was dit project er niet geweest! 
Ik heb niet voor niets het aanbod om te promoveren bij lab Reuma met open armen ontvangen: 
wat een leuke afdeling zijn jullie! Peter van Lent, als werkgroep leider van groepje vier krijg je 
het toch steeds weer voor elkaar om projecten binnen te slepen op basis van al je creativiteit 
en enthousiasme. In jouw groep heb ik kennis mogen maken met lab Reuma, onder leiding 
van Edwin, wat de basis heeft gevormd voor mijn promotietraject, bedankt hiervoor! Martijn, 
hopelijk vorm jij de nieuwe basis voor groepje vier in de toekomst. Je hebt een scherpe blik 
en denkt graag mee met andere projecten. Bedankt voor al je gezelligheid, maar ook de 
wetenschappelijke discussies. Jij komt er wel! Marije, bedankt voor je frisse inzichten, en je 
vriendelijke sturing. Je mag heel trots zijn op jouw begeleiding- en management kwaliteiten, daar 




Liduine, Elly en Monique, jullie vormen de basis van de afdeling, zowel qua kennis als sociaal. 
Ik hoop dat jullie dit kunnen behouden in de toekomst. Bedankt voor al jullie hulp! Monique, 
ik vond het heel gezellig om je U-genootje te zijn. Ik heb veel gehad aan je adviezen over 
verbouwen, nieuwe restaurantjes, maar ook aan ons dagelijks geklets. Marianne en Thea, jullie 
zijn onmisbaar voor de afdeling en niet alleen voor de administratieve zaken. Ook wil ik alle mede 
(oud) PhD studenten en postdocs bedanken voor alle wetenschappelijk discussies, PhD-retreats, 
spelletjesavonden, aesculaafborrels, vierdaagsefeesten, pubquiz avonden, labuitjes, Radboud 
sport deelnames, lablympics en nog veel meer: Claire, Rebecca, Debbie, Stephanie, Joyce, 
Daphne, Giuliana, Irene, Yvonne Bartels, Yvonne van Gemert, Nienke, Stephanie, Nik, 
Rik, Edwin, Wouter, Marieke en Niels, bedankt!
Daarnaast mocht ik een aantal stagiaires begeleiden tijdens mijn PhD traject. Dankjewel
voor al jullie hulp, inzet en gezelligheid Vera, Rasharda en Marissa. Ik vond het heel leerzaam, 
hopelijk jullie ook. Vera en Marissa jullie resultaten zijn de basis geweest voor hoofdstuk 2 en 4 
in dit proefschrift, heel erg bedankt daarvoor. 
Naast collega’s zijn mijn familie en vrienden ook belangrijk geweest in dit traject. Misschien is 
jullie aandeel in mijn proefschrift minder direct, maar die is er zeker. 
Majke, Paulien, Lysanne, Mirre, Jochem, Bas, en Sjoerd we hebben elkaar leren kennen 
tijdens de opleiding Biomedische Wetenschappen en het is prachtig om te zien hoe iedereen 
toch zijn eigen weg vindt. We zijn inmiddels veranderd naar Alumni, maar weten elkaar gelukkig 
nog regelmatig te vinden. Bedankt voor al jullie interesse en gezelligheid! Evi, jij was al snel 
mijn BMW-maatje. Van samen studeren (of power-nappen) tijdens onze vrije studie uurtjes, tot 
het afronden van een biomedisch promotietraject binnen hetzelfde instituut. Ik heb veel gehad 
aan je steun al die jaren en het uitwisselen van onze ervaringen; Nu op naar jouw verdediging! 
Mijn lieve clubje, DJC Passie; Romy, Evi, Niki, Sjacky, Sofie, Kim en Robin. We zijn nu 
al bijna 10 jaar vriendinnen, en hebben al heel veel samen meegemaakt. Bedankt voor jullie 
onvoorwaardelijke support, en vooral voor alle lieve complimentjes en jullie trots. Ik kan niet 
wachten op wat ons de komende 10 jaar te wachten staat!
Mijn vriendinnen van DG LIEF, waaronder mijn mede bestuur-genootjes Eline en Djoeke, 
jullie konden me heel goed uit mijn wetenschappelijke bubbel trekken. Bedankt voor jullie 
herhaaldelijke herinnering dat promoveren best bijzonder is. Ik hoop dat we snel weer met zijn 
allen kunnen proosten! 
Mijn (hockey)vriendinnetjes, Jet, Fieke en Iris bedankt voor jullie support binnen en buiten het 
veld! We hebben misschien weinig gehockeyd dit jaar, maar dat stond ons plezier gelukkig niet 
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in de weg. Iris, als trouwe vrijmibo-thuiswerk-buddy heb je het laatste jaar een stuk vrolijker 
gemaakt (met en zonder discolamp), dank je wel voor al je lieve steun! 
Floor en Tjits, jullie enthousiasme is ongekend. Bedankt voor de slurp-avonden, vier-momentjes 
en gezelligheid, en Tjits bedankt voor je thuiskantoor! 
Ook wil ik mijn dank uitspreken naar mijn (schoon)familie. André, Anne May en Bernhard. 
Na zeven jaar zijn jullie echt deel van mijn familie geworden, en ik geniet van de discussies en 
onuitputtelijke nieuwsgierigheid bij jullie thuis. Bedankt voor al jullie oprechte interesse in mijn 
proefschrift, en hopelijk is het na vandaag nog duidelijker wat ik heb gedaan de afgelopen jaren.
Lieve oma Jal en oma Caravan, dit is niet de eerste promotie die jullie mogen meemaken, 
maar dat maakt het misschien nog wel extra bijzonder. Wie weet wordt deze traditie nog verder 
voortgezet. Ik ben blij dat ik deze mijlpaal met jullie kan delen vandaag.
Het kan niet anders dat ik een onderzoeks-gen heb geërfd van jullie mam en pap. Zonder 
aandringen ben ik toch terecht gekomen in de wetenschap, dat kan geen toeval zijn! Met twee 
hoogleraren als ouders zou je zeggen dat de druk hoog ligt, maar niks is minder waar. Jullie zijn 
altijd op de eerste plek ouder geweest, en dat was super fijn. Ik kan me geen beter voorbeeld 
wensen. Bedankt voor de onvoorwaardelijke steun, het begrip, maar vooral voor jullie liefde. 
Paul en Maria, ik kan me geen betere bonus-ouders bedenken. Ik ben heel blij dat jullie hier 
vandaag als familie naast mij staan. Jidde, hoe groot je ook wordt je blijft mijn kleine broertje. 
Met je verfrissende, commerciële blik houd je ons gezin scherp. Bedankt voor al je knuffels en 
humor, met jou erbij is het altijd leuker! 
Lieve Kim, jij bent mijn grootste steun geweest. Na het afronden van psychologie (jij) en 
biomedische wetenschappen (ik) kozen we beiden voor een promotietraject. Dat heeft mogelijk 
toch wat met onze tweeling-genen te maken. We hebben veel fases van ons promotietraject 
kunnen delen. De pieken, de dalen, koffie in het Radboud of juist samen werken in huis. Jij voelt 
haarfijn aan wat ik denk en weet precies wat ik nodig heb. Bedankt dat je er altijd voor me bent! 
 
Lieve Joey, ik ben ontzettend gelukkig met jou. Jij maakt elke dag vrolijker, zorgelozer, en vol 
met liefde. Je bent heerlijk nuchter, en kan goed relativeren wat voor mij heel waardevol is 
geweest de afgelopen jaren. Door je biologie achtergrond kan ik goed met je praten over werk, 
maar dat is niet het belangrijkste. Bedankt voor al je rust, trots, knuffels en vooral voor je liefde. 
Ik geniet ervan om te zien hoe ons leven samen zich langzaam vormt. Ik hou van je! Een klein, 
laatste bedankje is gereserveerd voor onze knuffelkat Beli die mijn (thuis)werkdagen flink heeft 
opgevrolijkt. Als er typefouten te ontdekken zijn dan is dat haar (on)bedoelde bijdrage.
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